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ABSTRACT 
Membrane proteins are involved in a wide range of vital cellular processes, 
responsible for relaying signals and cargo across cell membranes. A deeper 
molecular understanding of their function is essential to elucidate the mechanisms of 
numerous diseases and medical conditions. As an example, the carnitine 
palmitoyltransferase 1 (CPT1) enzymes are responsible for the regulation of 
mitochondrial fatty acid oxidation thus are central to cell function. 
Previous work had shown that the transmembrane (TM) domains of the mitochondrial 
outer membrane protein CPT1 have a significant influence on the enzyme’s kinetics, 
which is different in the two catalytically active isoforms, CPT1A and CPT1B. It was 
also shown that TM-domains, and specifically TM2, are involved in driving the 
oligomerisation of the full length CPT1A. For this reason, the study of TM-TM 
oligomerisation and their roles in the function of CPT1 are fundamentally important in 
the design of pharmacological strategies aimed at the modulation of the activities of 
these enzymes in conditions such as diabetes. 
The main focus of this PhD research was to systematically investigate the homo- and 
hetero-oligomerisation of the TM domains to help better understand the structure-
function relationship for CPT1 membrane proteins. In this project, different 
techniques were used from the areas of chemistry, molecular biology, and biophysics 
(in vivo oligomerisation assays, chemical crosslinking, circular dichroism and 
analytical ultracentrifugation), in order to examine these interactions. 
The membrane spanning sequences of rCPT1A and rCPT1B were found to self-
associate, and the order of oligomerisation was also determined. Sequence motifs 
likely to be responsible for the interactions of these TM domains were identified using 
in silico modelling. Mutagenesis analyses confirmed the role of suggested GxxxG(A) 
motifs in the homo-oligomerisation of rCPT1A TM2 domains. The hetero-
oligomerisation of TM1-TM2 domains was also studied, and was found to be 
significant in both isoforms. The work presented in this thesis shows that the 
membrane spanning regions of the CPT1 enzymes are capable of interacting through 
both homo- and hetero-oligomerisation. The results strongly suggest that these 
interactions may play a significant role in the complex formation of the full length 
enzymes and provide further evidence that CPT1 may function as a channel in the 
outer mitochondrial membrane. 
 1 
CHAPTER 1  
 
 
 
1. INTRODUCTION 
 
In this chapter basic concepts are introduced about the membrane protein 
research field, concentrating on α-helical membrane proteins, and the 
current knowledge about carnitine palmitoyltransferase 1 (CPT1) enzymes 
is shortly summarized. 
 
1.1 Membrane proteins 
Membrane proteins regulate the flow of information across biological membranes. 
Information flow is crucial for many essential cellular processes such as 
translocation, respiration, signalling and energy metabolism (Chapman et al., 
1998; Chen and Rost, 2002). The multi-level role of membrane proteins in cell 
function makes them important targets for drug design for many diseases 
(Sanders and Nagy, 2000; Sanders and Myers, 2004). Despite the biological 
importance of membrane proteins, the structure and function of relatively few 
such proteins has been determined to date.  
Determining the three-dimensional structure and identifying the mechanisms by 
which these proteins function is one of the most difficult topics in protein science. 
The expression, purification, solubilisation and structural investigation of these 
proteins are very challenging tasks, confirmed by the fact that to date they 
represent fewer than ~0.5% of the structures in the Protein Data Bank, while they 
account for over a quarter of all existing proteins (Granseth et al., 2007). The 
reason for the very limited structural information for membrane proteins is that, 
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since they exist in their native form in a mostly non-polar environment, the three-
dimensional structure gets disrupted during solubilisation. For this reason, they 
cannot be crystallized in the same way as water soluble proteins. 
The complexity of biological membranes explains well the intricacy of membrane 
protein research. In the fluid-mosaic or Singer-Nicolson model (Singer and 
Nicolson, 1972) of biological membranes, the fluidity of the membrane is the 
result of hydrophobic lipid-protein interactions. Globular membrane proteins are 
considered to be of two different types, extrinsic (peripheral) and intrinsic 
(integral).  
One important subfamily of integral membrane proteins are transmembrane 
proteins. There are two main types of transmembrane proteins: β-barrel proteins 
(Figure 1.1 a), in which the membrane-spanning regions are made up of β-
strands, and α-helical proteins, in which the membrane-spanning regions are 
made up of α-helices (Figure 1.1 b). The current state of understanding of the 
stability and folding of these proteins has been summarised in several reviews 
(White and Wimley, 1999; White, 2003; Wimley, 2003; Tamm et al., 2004). These 
reviews focus on their protein binding and folding in bilayer interfaces, the 
transmembrane helix insertion, helix-helix interactions, as well as on their effects 
on the structure and function of lipid bilayers.  
 
Figure 1.1 - The two types of transmembrane proteins: (a) β-barrel (green fluorescent 
protein, PDB ID 1ema) and (b) α-helical (reaction centre from Rhodobacter sphaeroides, 
PDB ID 2hj6) structures.  
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1.2 α-helical integral membrane proteins 
As the main topic of this thesis is the oligomerisation of the transmembrane 
segments within α-helical membrane proteins, in the following sections the 
concepts about the folding and oligomerisation of helical membrane proteins are 
reviewed. 
1.2.1 The folding of α-helical transmembrane proteins 
Involved in a wide range of essential biological functions, α-helical membrane 
proteins are of great interest in protein science. During the last thirty years, many 
studies have helped our understanding of the structural determinants of the 
stability and folding of these proteins. Central aspects about structural stability, 
folding pathways and association of transmembrane segments in α-helical 
membrane proteins have improved markedly in recent years, and we now know 
over 90 unique structures (von Heijne, 1996; Fleishman and Ben-Tal, 2002; 
Bowie, 2005).  
A simplified model of membrane protein folding and complex formation, the “Two-
Stage Model” proposed by Popot and Engelman (Figure 1.2), hypothesises that 
the final structure in the transmembrane region is assembled from several 
smaller elements (helices). According to this model, membrane proteins fold in 
two thermodynamically distinct stages. In the first stage, hydrophobic sequences 
insert into the bilayer and form stable helices. In the second stage, these helices 
associate laterally to form the final fold of the protein (Popot and Engelman, 
1990). While the extensively studied bacteriorhodopsin was the first example of a 
“split” membrane protein capable of refolding via association of its 
transmembrane domains (Liao et al., 1984; Popot et al., 1987), the above model 
was further supported by several other experimental observations. For example, 
lateral associations of membrane-embedded protein fragments were found to 
regenerate and refold into functional proteins in several other systems such as 
lactose permease (Bibi and Kaback, 1990), rhodopsin (Ridge et al., 1995) or the 
red cell anion exchanger protein (Groves and Tanner, 1995). 
It is possible to apply the two-stage model in order to try to understand the folding 
of other membrane proteins. By focusing our attention on the second stage, we 
can investigate structural factors determining transmembrane helix-helix 
association. However, the complexity of helix-interactions in the membrane 
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bilayer also needs to be taken into account when considering the assembly of the 
whole protein.  
Apart from the actual helix-helix interactions, there are additional complicating 
factors in interactions of transmembrane segments that determine the shape and 
stability of membrane proteins. These are the interaction of helices with water, 
the bilayer hydrocarbon core, bilayer interfaces, and with cofactors as well 
(Lemmon and Engelman, 1994; White and Wimley, 1999).  
The two-stage model (Figure 1.2) has been updated to include a possible third 
stage of membrane protein folding. This third stage takes into account the 
involvement of peripheral domains and ligand binding in the quaternary structure 
forming process (Engelman et al., 2003).  
Based on our current understanding, the helix-helix association within the 
membrane bilayer is most likely driven by non-covalent interactions (van der 
Waals forces, electrostatic interactions or hydrogen bonding). Sequence motifs 
from well-studied membrane proteins (see below) were found to have great 
impact in the association of transmembrane domains. Studies investigating the 
role of these motifs in the folding of membrane proteins were recently 
summarized (Senes et al., 2004), while their structural determinants were also 
studied by in silico and statistical analyses (Walters and DeGrado, 2006; 
Harrington and Ben-Tal, 2009). Typical interaction motifs relevant for this work 
are illustrated in the following section. 
 
Figure 1.2 - The “Two-Stage Model”. Stage 1: Hydrophobic sequences form stable 
transbilayer α-helices (left). Stage 2: Lateral association of transbilayer α-helices (right). 
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1.2.2 Interaction motifs in transmembrane helices 
The transmembrane spanning regions of α-helical membrane proteins are 
approximately 20 amino acids in length. These predominantly hydrophobic side 
chains can contain specific sequence motifs which could support helix 
interactions: Russ and Engelman identified the GxxxG motif, where glycine 
residues are separated by three other amino acids (Russ and Engelman, 2000), 
placing the Gly residues on the same face of the α-helix. The small side chain in 
Gly allows very close packing of the helices, giving rise to stabilising van der 
Waals interactions. The GxxxG motif was identified in more than 100 highly 
dimeric transmembrane domains, while statistical analyses revealed that it is 
over-represented in genomes. These observations suggest that many (but not all) 
GxxxG motifs are involved in forming specific helix-helix interactions.  
The discovery of the GxxxG motif was the result of the extensive study of 
glycophorin A (GpA). GpA is an integral membrane protein in human red blood 
cells, carries several medically important blood group antigens, and its TM 
domain has been shown to mediate non-covalent dimerisation. Mutagenesis 
(Lemmon et al., 1992), computational (Treutlein et al., 1992; Adams et al., 1996) 
and thermodynamic (Fleming et al., 1997; Fisher et al., 1999; Fleming et al., 
2004) characterisation also indicated a central role of GxxxG in GpA dimerisation 
(Figure 1.3 a). The variants of this motif, the “small xxx small” (where small 
denotes residues with small side chains such as Ala, Gly, Ser) motifs were also 
found to mediate transmembrane interactions (Senes et al., 2000), although 
these motifs do not always play a role in forming strong helix-helix interactions 
(Schneider and Engelman, 2004).  
Another example of a structural motif is the heptad repeat, which consists of a 
repeating pattern of amino acids. Repeated heptad motifs of amino acids 
characteristic of soluble leucine zipper coiled-coil interaction domains were also 
found in membrane proteins such as bacteriorhodopsin, the photosynthetic 
reaction center, and cytochrome C oxidase (Langosch and Heringa, 1998). The 
importance of leucine zipper-like motifs in transmembrane domain association 
was investigated by Langosch and colleagues. They have found that leucine 
residues are involved in the oligomerisation of designed (polyleucines) and 
biological (erythropoietin) sequences (Gurezka et al., 1999; Gurezka and 
Langosch, 2001; Ruan et al., 2004). Another example of leucine-isoleucine 
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zipper interaction motifs (based on mutagenesis data) can be found in the 
phospholamban pentamer, shown in Figure 1.3 b (Simmerman et al., 1996). 
Aromatic π-π stacking interactions between pairs of aromatic residues (Phe, Thr, 
Tyr) in a membrane environment have also been shown to significantly enhance 
the strength of oligomerisation of designed transmembrane helices, which 
suggested that similar interactions may also be a significant factor in the folding 
and stability of native membrane proteins (Dougherty, 1996; Johnson et al., 
2007). The mutagenesis and molecular modelling studies of the cholera toxin 
secretion protein EpsM provided further evidence for the involvement of aromatic 
residues in the dimerisation of TM domains (Sal-Man et al., 2007). Figure 1.3 c 
contains an example for aromatic interhelical interactions in bacteriorhodopsin, 
with the aromatic rings oriented perpendicular to each other (Harrington and Ben-
Tal, 2009). 
The presence of interhelical hydrogen bonds between polar residues (Gln, Asn, 
Glu or Asp), which help shielding their polarity in the non-polar core of the bilayer, 
was found to be sufficient to induce strong helix association in model TM helices 
(Zhou et al., 2000; Zhou et al., 2001). Modelling and mutagenesis of single 
asparagines and threonine-serine motifs in membrane proteins highlighted their 
role in creating helical oligomers (Dawson et al., 2002; Dawson et al., 2003; Sal-
Man et al., 2004). The modelling of the interface in the erythropoietin receptor 
transmembrane domain suggests that interhelical hydrogen bonds between Ser 
and Thr residues are involved in self-association (Seubert et al., 2003). A recent 
study of conserved polar residues in human nucleoside triphosphate 
diphosphohydrolase 3 (NTPDase3) transmembrane domain also found that the 
formation of interhelical hydrogen bonds promotes oligomerisation and protein 
folding, and is therefore important for optimal protein expression and enzymatic 
activity (Gaddie and Kirley, 2009).  
Furthermore, the presence of proline residues in transmembrane helices causes 
kinks, as the amide nitrogen of proline cannot form a backbone hydrogen bond. 
Incorporation of proline residues provides a way to make highly curved helixes, 
having a great impact on the TM helix packing, as shown by scanning 
mutagenesis and studies on model TM segments (von Heijne, 1991; Nilsson et 
al., 1998; Nilsson and von Heijne, 1998; Orzaez et al., 2004). In summary, the 
above studies suggest that the presence of a variety of residues and sequence 
motifs can be strong predictors of transmembrane helix-helix interactions. 
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Figure 1.3 - Typical interaction motifs within transmembrane α-helices. (a) GxxxG 
motif in glycophorin A (PDB ID 1afo); (b) leucine zippers in the phospholamban pentamer 
(PDB ID 1xnu); (c) interaction between aromatic residues in bacteriorhodopsin (PDB ID 
1c3w); (d) Hydrogen bonding between two glutamic acid residues in sodium-potassium 
channel (PDB ID 3a3y, hydrogen atoms not shown). 
 
1.2.3 Techniques to study helix-helix association 
Biological assays developed for measuring helix-helix association have made it 
possible to study transmembrane domains in a natural membrane environment. 
The ToxR system (Langosch et al., 1996) was initially created to examine the 
sequence-dependent homo-oligomerisation of the GpA transmembrane domain 
in the inner membrane of E. coli, and this domain was later used as a positive 
control to characterise other TM interactions. Other assays such as the TOXCAT 
assay (Russ and Engelman, 1999) and the POSSYCAT assay (Gurezka and 
Langosch, 2001) were modifications of the ToxR system. For the study of hetero- 
(and homo-) oligomerisation, a similar concept was introduced to create the 
GALLEX assay, having a different transcriptional activator, the asymmetric LexA 
operator and promoter system (Schneider and Engelman, 2003). From the above 
mentioned biological assays, the TOXCAT and GALLEX assays are the most 
relevant for the research presented in this work (for details see § 2.2 and § 2.3). 
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Many biophysical techniques have also been successfully employed in the 
research of membrane protein folding, and many of these were initially developed 
and tested on glycophorin A (MacKenzie and Fleming, 2008). Currently, the 
interactions in vitro between membrane spanning α-helical peptides are usually 
studied in detergent micelles or in synthetic membranes (lipids) by SDS-PAGE 
(Fisher et al., 1999), analytical ultracentrifugation (AUC) (Doura et al., 2004), 
Förster resonance energy transfer (FRET) (Fisher et al., 2003), solution-state 
nuclear magnetic resonance spectroscopy (NMR) (MacKenzie et al., 1997), or 
solid state NMR (Liu et al., 2003). 
1.3 Carnitine palmitoyltransferase 1 (CPT1) 
The main focus of this PhD thesis is the analysis of TM helix-helix interactions in 
an essential enzyme for fatty acid oxidation, namely carnitine palmitoyltrans-
ferase 1 (CPT1). For this reason, in the following paragraphs the existing 
knowledge underlying the significance of transmembrane domains in the 
structure and function of this enzyme is reviewed. 
Fatty acids are an important source of energy and therefore play a major role in 
maintaining cell function in many organisms. In order to take part in reactions, 
fatty acids must first be activated. One such activation process is 
thioesterification by an acyl-CoA synthetase enzyme. The thioesterified fatty acid 
can form acylcarnitine in a reaction catalyzed by carnitine acyltransferases 
(Figure 1.4). The carnitine acyltransferases enzyme family includes carnitine 
palmitoyltransferases (CPT1 and CPT2), carnitine octanoyltransferase (CrOT), 
and carnitine acyltransferase (CAT), which have substrate preference for long-
chain, medium-chain and short-chain acyl groups, respectively. 
OR
O
N
+
HSCoA
O
N
+
OH
O
R
O
SCoA
OO
+ +
 
Figure 1.4 - The reaction catalyzed by carnitine acyltransferases. For CPT1 and 
CPT2: R > 16 C atoms, CrOT: R is between 8-14 C atoms and CAT: R < 8 C atoms. 
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Figure 1.5 - Topology of CPT1 in the outer mitochondrial membrane (OMM). 
 
The CPT1 enzyme exists in three tissue specific isoforms, CPT1A (liver, L-
isoform), CPT1B (muscle, M-isoform), and the CPT1C brain-specific isoform. 
Based on our current knowledge, of the three isoforms, only CPT1A and CPT1B 
are catalytically active in fatty acid oxidation (McGarry and Brown, 1997), while 
CPT1C is believed to be involved in appetite control. 
The CPT1 enzymes are polytopic integral membrane proteins, localised in the 
outer mitochondrial membrane (OMM). To date there is no solved 3D crystal 
structure of CPT1 enzymes. The currently accepted structure is based on 
experimental studies involving partial proteolysis, immobilised malonyl-CoA and 
substrates, anti-peptide antibody binding and immunogold electron microscopy 
(Fraser et al., 1997; van der Leij et al., 1999). The topology of CPT1 includes the 
N-terminus and the C-terminus, which are both exposed on the cytosolic site of 
the membrane, while the loop region is extended into the intermembrane space, 
as shown in Figure 1.5. The isoforms also contain two relatively highly conserved 
hydrophobic transmembrane domains (TM1, TM2: predicted to contain residues 
53-75 and 103-122, respectively) in the N-terminal region.  
1.3.1 CPT1A and CPT1B 
The two catalytically active isoforms, CPT1A and CPT1B (772 aa, 88kDa), have 
a considerable sequence similarity (63%). They share the same catalytic 
function, but they have a different sensitivity towards an inhibitor, malonyl-CoA. 
Their inhibition by malonyl-CoA is crucial because it is the point at which the 
metabolism of fatty acids (Figure 1.6) and glucose come into the most direct 
‘contact’, and can influence each other, and this gives these enzymes a central 
role in cell function. 
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It is known that CPT1A is much less sensitive to inhibition by malonyl-CoA 
(Saggerson, 1982) than CPT1B (Park and Cook, 1998). This kinetic characteristic 
was found to be dependent on the physical properties of the mitochondrial outer 
membrane, especially its lipid composition and molecular order (Grantham and 
Zammit, 1986; Kolodziej and Zammit, 1990; Zammit et al., 1998). These 
properties can be influenced by physiological conditions, such as fasting or the 
onset of certain diseases like diabetes, or by experimental manipulation in vitro. 
The membrane microenvironment significantly influences the kinetic properties of 
the CPT1A isoform, which suggests a high degree of molecular “flexibility” in the 
protein (McGarry and Brown, 2000). By contrast, CPT1B has a permanently high 
malonyl-CoA sensitivity which is not modulated by physiological state and 
suggests that this molecule adopts a more “rigid” structure (Mynatt et al., 1992; 
Saggerson et al., 1992). 
TM2TM1
translocase
fatty acids
fatty acyl-CoA
CoASH
acylcarnitine
CoASH acyl-CoA β-oxidation
Mitochondrial matrix 
Inner mitochondrial
Membrane 
Outer mitochondrial
Membrane acyl-CoA
synthetase
carnitine
CPT 2
CPT1
 
Figure 1.6 - The role of liver and muscle type CPT1 in fatty acid oxidation. 
 
In previous homology modelling studies it was shown that the enzyme inhibitor 
malonyl-CoA binds to the catalytic C-terminal domain of CPT1 (Morillas et al., 
2002). In CPT1A, some specific amino acid residues in the N-terminal segment 
also modulate the inhibitor binding properties (Shi et al., 1999; Jackson et al., 
2000; Jackson et al., 2001). Cross-linking experiments showed that in CPT1A 
there are close intermolecular interactions between the N- and C-terminal 
segments which could potentially be modulated by TM1-TM2 interactions (Faye 
et al., 2005). Consequently, we suggest that the TM1-TM2 interaction is an 
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important characteristic of the CPT1A isoform function. Since CPT1B does not 
show a similar adaptation of its kinetic properties to physiological state (Mynatt et 
al., 1992), it is possible that TM1-TM2 interactions are different in this isoform. A 
recent report has suggested that the N-terminal region of the protein containing 
the TM-domains, and specifically TM2, (residues 1-147 in the rat enzyme, 
rCPT1A) is also involved in driving the oligomerisation of CPT1A (Faye et al., 
2007). Studies by Prof. Victor A. Zammit and his research group (Warwick 
Medical School) have also demonstrated the different oligomerisation properties 
of the full length rCPT1A and rCPT1B (unpublished data) extracted from yeast or 
mitochondria. These observations suggest the possibility of CPT1 oligomerisation 
through the self-association of TM domains, although other structural factors, 
such as the C-terminal segment, may also be involved in enzyme 
oligomerisation. 
1.3.2 CPT1C function 
Recently a third isoform of CPT1, CPT1C been identified in mouse brain (Price et 
al., 2002; Lavrentyev et al., 2004). CPT1C has a high degree of sequence 
similarity to CPT1A and B. However, it also has a 33 amino acid residue 
extension at the C-terminal end of the protein. CPT1C was found in specific 
regions of the brain that are known to be involved in appetite control and it has 
been suggested that its function may relate to control of feeding behaviour. 
CPT1C was studied in a yeast expression system (Pichia pastoris), and the 
membrane fractions contained no detectable activity when assayed using several 
different acyl-CoA esters and carnitine as substrates. Interestingly, it did have a 
high affinity for malonyl-CoA binding, suggesting that it is correctly folded and 
imported into the yeast OMM. CPT1C also binds malonyl-CoA with the same 
affinity as CPT1A (Price et al., 2002), and it is believed to act as a ‘sink’ for 
malonyl-CoA in the cell types in which it occurs. Transgenic mice in which the 
CPT1C gene is disrupted have disturbed energy metabolism, becoming unable to 
regulate body weight when placed on a high-fat diet (Wolfgang et al., 2006). Also, 
its localised over-expression in the hypothalamus protects animals against weight 
gain (Dai et al., 2007). To date this isoform is believed to have a different function 
from that of CPT1A and B, and was not studied during this work.  
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1.4 Objectives of the present study 
At present it is believed that possible interactions between the CPT1 
transmembrane domains are modulated by physicochemical properties of the 
membrane. A change in membrane fluidity or composition would influence the 
interaction between N- and C-terminal segments located on the same side of the 
membrane. The interaction between these segments can therefore alter the 
protein conformation in the vicinity of the substrate- and inhibitor-binding sites, 
with consequent modulation of the kinetic characteristics of the protein. 
Furthermore, a region containing TM2 in CPT1A is thought to control homo-
oligomer formation in the full-length protein, and these oligomerisation properties 
are thought to differ between the muscle and liver forms of the enzyme. In light of 
the above discussed observations, the interaction of TM domains is suggested to 
have a critical role in CPT1 structure and function, and was not studied before in 
detail. Therefore, the present study was designed to investigate the homo- and 
hetero-oligomerisation of the TM domains in CPT1A and CPT1B (Figure 1.7). 
As summarised in Figure 1.7, the overall aims of the present PhD project were: 
 To examine the self-association of the rCPT1A TM domains in order to 
identify the oligomeric states achieved and compare these with the full length 
protein’s known oligomerisation behaviour (CHAPTER 3). 
 Investigation of the role of helix-helix interaction motifs in the possible 
oligomerisation of rCPT1A TM2 (CHAPTER 4). 
 Study the oligomerisation of rCPT1B TM domains, and compare this with 
what has been observed for rCPT1A TM domains (CHAPTER 5). 
 Determine the possible hetero interactions of TM1-TM2 in both isoforms 
(CHAPTER 6). 
 
 
Figure 1.7 - Schematic representation of possible homo and hetero TM interactions 
in CPT1. 
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CHAPTER 2 
 
 
 
2. MATERIALS AND METHODS 
 
In this chapter the biochemical and biophysical experimental techniques 
used are presented, as well as the methods employed in data analysis and 
theoretical modelling of helix-helix interactions. 
2.1 General practice 
2.1.1 Chemicals 
Throughout this research, unless otherwise stated, all standard laboratory 
chemicals were purchased from the following companies in analytical reagent or 
the highest grade for microbiology work: Sigma Aldrich (UK), BDH Merck (UK) or 
Fisher Scientific (UK). Enzymes and buffers for DNA work were purchased from 
Fermentas (UK), Invitrogen (UK), New England Biolabs (UK), Promega (UK) or 
Stratagene (UK). 
2.1.2 Reagents and buffers 
All buffers were prepared using distilled water (dH2O, Millipore), and organic 
solvents were of analytical reagent grade or better. Buffers and dH2O for DNA 
work were sterilized by autoclave and/or filtered using 0.22 µM filters (Millipore).  
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2.1.3 Cloning and modifying of DNA 
2.1.3.1 Oligonucleotides  
All oligonucleotides used during this work were purchased from Invitrogen (UK), 
and are listed in Table 2.2 (sequences listed in Appendix 1), Table 2.3 
(sequences listed in Appendix 2), and Table 2.4. The oligonucleotides were 
used in 10 µM concentration either to carry out Polymerase Chain Reaction 
(PCR) (§ 2.1.3.3) or as an insert DNA for ligation reactions (§ 2.1.3.8). The 
oligonucleotides used as an insert DNA were first phosphorylated and annealed 
before being ligated into the target plasmid. For phosphorylation, 5 µL of 
oligonucleotides (10 µM), 2 µL of 10x T4 polynucleotide kinase (PNK) buffer, 
1 µL ATP (10 mM), 2 µL T4 PNK (Fermentas, UK) and 10 µL dH2O were 
incubated at 37°C for 30 min, followed by 56°C for 10 min to stop the reaction. 
For annealing, 4 µL each of the forward and reverse primers, 2 µL annealing 
buffer (200 µL 1 M Tris-HCl (pH=7.5), 20 µL of 1 M MgCl2, 166 µL 3 M NaCl, and 
614 µL dH2O) and 10 µL dH2O were incubated at 95°C for 7 min. Annealed 
oligonucleotides were cooled to room temperature before ligation and stored at 
-20°C. 
2.1.3.2 Plasmids 
The plasmids used to carry out the TOXCAT and GALLEX biological assays were 
provided by Professor Donald M. Engelman (Yale University, USA) and Dr Dirk 
Schneider (Albert-Ludwigs-University, Germany), respectively, and are listed 
below in Table 2.1. 
In this study, modifications of the pCC-KAN plasmid were carried out as follows: 
the KAN cassette was cut out of the vector plasmid (§ 2.1.3.5) and the 
transmembrane domain (TM) sequences of interest were cloned in (§ 2.1.3.8). 
These constructs were used as templates to create shorter and/or point mutant 
TM sequences in the pCC-plasmid by PCR site directed mutagenesis (§ 2.1.3.4). 
The pCC-KAN modified plasmid vectors were used for the TOXCAT experiments 
(§ 2.2). All of the pCC-plasmid constructs created during this work carry ampicillin 
antibiotic resistance and are listed in Table 2.2. 
In the GALLEX study, pALM148, pBLM100 and their modified vectors were used 
(see Table 2.1) and our TM domains of interest incorporated (Table 2.3).
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Table 2.1 - List of previously generated plasmid vectors used in this study. 
Plasmid Details Reference 
pCC-KAN 
New England Biolabs pMAL-c2 and -p2 vectors 
(pBR322 + lacI and Maltose binding protein). 
Carries ampicillin antibiotic resistance. 
 
 
 
(Russ and 
Engelman, 
1999) pCC-GpA 
pCC-KAN with glycophorin A (GpA) transmembrane 
(TM) domain. 
Carries ampicillin antibiotic resistance. 
pCC-G83I 
pCC-GpA with Gly83 to Ile substitution. 
Carries ampicillin antibiotic resistance. 
pALM148 
Described in detail in reference. 
Carries tetracycline antibiotic resistance. 
 
 
(Schneider 
and 
Engelman, 
2003) 
 
pBLM100 
described in detail in reference. 
Carries ampicillin antibiotic resistance. 
pALM-Gpa 
pALM with glycophorin A (GpA) transmembrane (TM) 
domain. 
Carries tetracycline antibiotic resistance. 
pALM-G83I 
pALM-GpA with Gly83 to Ile substitution. 
Carries tetracycline antibiotic resistance. 
pBLM-Gpa 
pBLM with glycophorin A (GpA) transmembrane (TM) 
domain. 
Carries ampicillin antibiotic resistance. 
pBLM-G83I 
pBLM-GpA with Gly83 to Ile substitution. 
Carries ampicillin antibiotic resistance. 
 
Table 2.2 - List of plasmid vectors generated from pcc-KAN throughout this study. 
QC=quick change, T=template plasmid was used in the quick change reaction. “for” 
denotes forward, “rev” denotes reverse primers. 
Plasmid name 
Generating 
Oligonucleotide 
Features 
pcc_rCPT1A TM1(27)1 
rCPT1A_TM1(27)for 
rCPT1A_TM1(27)rev 
Oligonucleotide of 
Lys47 to Met73 
pcc_rCPT1A TM1(24)2 
rCPT1A_TM1(24)for 
rCPT1A_TM1(24)rev 
QC primer, deletion of 
Lys47 -Gly49, T
1 
pcc_rCPT1A TM1(21) 
rCPT1A_TM1(21)for 
rCPT1A_TM1(21)rev 
QC primer, deletion of 
Ser71 -Met73, T
2 
pcc_rCPT1A TM1(18) 
rCPT1A_TM1(18)for 
rCPT1A_TM1(18)rev 
Oligonucleotide of 
Ile50 to Val67 
pcc_rCPT1A TM1(16) 
rCPT1A_TM1(16)for 
rCPT1A_TM1(16)rev 
Oligonucleotide of 
Thr52 to Val67 
pcc_rCPT1A TM2(22)3 
rCPT1A_TM2(22)for 
rCPT1A_TM2(22)rev 
Oligonucleotide of 
Lys102 to Arg123 
pcc_rCPT1A TM2(20)4 
rCPT1A_TM2(20)for 
rCPT1A_TM2(20)rev 
QC primer, deletion of 
Met122 -Arg123, T
3
 
pcc_rCPT1A TM2(18)5 
rCPT1A_TM2(18)for 
rCPT1A_TM2(18)rev 
QC primer, deletion of 
Lys102 -Asn103, T
4 
pcc_rCPT1A TM2(16)6 
rCPT1A_TM2(16)for 
rCPT1A_TM2(16)rev 
QC primer, deletion of 
Met120 -Thr121, T
5 
pcc_rCPT1A TM2(16)_G107I7 
rCPT1A_TM2(16)_G107Ifor 
rCPT1A_TM2(16)_G107Irev 
QC primer, changing 
Gly107 to Ile, T
6 
pcc_rCPT1A TM2(16)_G111I 
rCPT1A_TM2(16)_G111Ifor 
rCPT1A_TM2(16)_G111Irev 
Oligonucleotide of 
Ile104 to Ile119 where 
Gly111 changed to Ile 
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Plasmid name 
Generating 
Oligonucleotide 
Features 
pcc_rCPT1A TM2(16)_G113I8 
rCPT1A_TM2(16)_G113Ifor 
rCPT1A_TM2(16)_G113Irev 
QC primer, changing 
Gly113 to Ile, T
6 
pcc_rCPT1A TM2(16)_A117I 
rCPT1A_TM2(16)_A117Ifor 
rCPT1A_TM2(16)_A117Irev 
QC primer, changing 
Ala117 to Ile, T
6 
pcc_rCPT1A 
TM2(16)_G107IG111I 
rCPT1A TM2(16)_G107IG111Ifor 
rCPT1A TM2(16)_G107IG111Irev 
Oligonucleotide of 
Ile104 to Ile119 where 
Gly107 and Gly111 changed 
to Ile 
pcc_rCPT1A 
TM2(16)_G113IA117I 
rCPT1A TM2(16)_G113IA117Ifor 
rCPT1A TM2(16)_G113IA117Irev 
QC primer, changing 
Ala117 to Ile, T
8 
pcc_rCPT1A 
TM2(16)_G107IG113I9 
rCPT1A TM2(16)_G107IG113Ifor 
rCPT1A TM2(16)_G107IG113Irev 
QC primer, changing 
Gly113 to Ile, T
6 
pcc_rCPT1A TM2(16) 
G107IG111IG113IA117I10 
rCPT1A TM2(16)_ 
G107IG111IG113IA117Ifor 
rCPT1A TM2(16)_ 
G107IG111IG113IA117Irev 
Oligonucleotide of 
Ile104 to Ile119 where 
Gly107, Gly111, Gly113 and 
Ala117 changed to Ile 
pcc_rCPT1A TM2(16) _T112A 
rCPT1A TM2(16) _T112Afor 
rCPT1A TM2(16) _T112Arev 
QC primer, changing 
Thr112 to Ala, T
6 
pcc_rCPT1A 
TM2(16)_G107IG113IT112A 
rCPT1A TM2(16)_ 
G107IG113IT112Afor 
rCPT1A TM2(16)_ 
G107IG113IT112Arev 
QC primer, changing 
Thr112 to Ala, T
9 
pcc_rCPT1A 
TM2(16)_G107IG113I T112V 
rCPT1A TM2(16)_ 
G107IG113IT112Vfor 
rCPT1A TM2(16)_ 
G107IG113IT112Vrev 
QC primer, changing 
Thr112 to Val, T
9 
pcc_rCPT1A TM2(16) 
G107IG111IG113IA117I 
T112A 
rCPT1A TM2(16)_ 
G107IG111IG113IA117IT112Afor 
rCPT1A TM2(16)_ 
G107IG111IG113IA117IT112Arev 
QC primer, changing 
Thr112 to Ala, T
10 
pcc_rCPT1A TM2(16) 
G107IG111IG113IA117I 
T112V 
rCPT1A TM2(16)_ 
G107IG111IG113IA117IT112Vfor 
rCPT1A TM2(16)_ 
G107IG111IG113IA117IT112Vrev 
QC primer, changing 
Thr112 to Val, T
10 
pcc_rCPT1B TM1(25)11 
rCPT1B TM1(25)for 
rCPT1B TM1(25)rev 
Oligonucleotide of 
Arg52 to Lys76 
pcc_rCPT1B TM1(22) 
rCPT1B TM1(22)for 
rCPT1B TM1(22)rev 
QC primer, deletion of 
Arg52 -Val54, T
11 
pcc_rCPT1B TM1(24) 
rCPT1B TM1(24)for 
rCPT1B TM1(24)rev 
QC primer, addition of 
Asn48 –Leu51, T
12 
pcc_rCPT1B TM1(23) 
rCPT1B TM1(23)for 
rCPT1B TM1(23)rev 
QC primer, deletion of 
Cys75 -Lys76, T
11 
pcc_rCPT1B TM1(22*)12 
rCPT1B TM1(22*)for 
rCPT1B TM1(22*)rev 
QC primer, deletion of 
Tyr74 - Lys76, T
11 
pcc_rCPT1B TM1(20*) 
rCPT1B TM1(20*)for 
rCPT1B TM1(20*)rev 
QC primer, deletion of 
Ser72 -Asn73, T
12 
pcc_rCPT1B TM2(22)13 
rCPT1B TM2(22)for 
rCPT1B TM2(22)rev 
Oligonucleotide of 
Glu104 to Arg125 
pcc_rCPT1B TM2(20)14 
rCPT1B TM2(20)for 
rCPT1B TM2(20)rev 
QC primer, deletion of 
Glu104 -Thr105, T
13 
pcc_rCPT1B TM2(19)15 
rCPT1B TM2(19)for 
rCPT1B TM2(19)rev 
QC primer, deletion of 
Arg125, T
14 
pcc_rCPT1B TM2(17) 
rCPT1B TM2(17)for 
rCPT1B TM2(17)rev 
QC primer, deletion of 
Leu123 -Phe124, T
15 
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Table 2.3 - List of plasmid vectors generated from pALM148 and pBLM100 
throughout this study. “for” denotes forward, “rev” denotes reverse primers.  
Plasmid name 
Generating 
Oligonucleotides 
Features 
pBLM_ rCPT1A_iTM1(21) 
rCPT1A_iTM1(21)for 
rCPT1A_iTM1(21)rev 
Oligonucleotide of 
Ile70-Ile50 
pBLM_ rCPT1A_iTM1(18) 
rCPT1A_iTM1(18)for 
rCPT1A_iTM1(18)rev 
Oligonucleotide of 
Val67-Ile50 
pBLM_ rCPT1A_iTM1(16) 
rCPT1A_iTM1(16)for 
rCPT1A_iTM1(16)rev 
Oligonucleotide of 
Ile67-Thr52 
pBLM_ rCPT1A_TM2(16) 
rCPT1A_TM2(16)for 
rCPT1A_TM2(16)rev 
Oligonucleotide of 
Ile104-Ile119 
pALM_ rCPT1A_TM2(16) 
rCPT1A_TM2(16)for 
rCPT1A_TM2(16)rev 
Oligonucleotide of 
Ile104-Ile119 
pBLM_ rCPT1B_iTM1(20) 
rCPT1B_iTM1(20)for 
rCPT1B_iTM1(20)rev 
Oligonucleotide of 
Gly71-Arg52 
pBLM _rCPT1B_TM2(19) 
rCPT1B_TM2(19)for 
rCPT1B_TM2(19)rev 
Oligonucleotide of 
Leu106-Phe124 
pALM_ rCPT1B_TM2(19) 
rCPT1B_TM2(19)for 
rCPT1B_TM2(19)rev 
Oligonucleotide of 
Leu106-Phe124 
 
2.1.3.3 Amplification of DNA by Polymerase Chain Reaction  
We have used the PCR (Polymerase Chain Reaction) technique for amplification 
of DNA fragments and for deletion and single amino acid quick change mutation 
experiments of several plasmids. Oligonucleotide PCR primers specific for the 
regions of DNA of interest were designed following the polymerase enzyme 
manufacturers’ manuals. The list of PCR primers used throughout this study is 
shown in Table 2.2. The reactions were carried out in a Biometra® T-personal 
PCR machine. 
The amplification of DNA fragments was typically performed in 50 µL volumes 
using 38.5 µL filter sterilized dH2O, 1 µL template DNA, 1.5 µL of each (forward, 
reverse) primer (10 µM), 1.5 µL of dNTP mix (contaning 10 mM of each dNTP), 
5 µL of Pfx50TM10x PCR reaction buffer and 1 µL of Pfx50TM DNA polymerase 
(Invitrogen, UK). A typical PCR reaction contained 35 cycles with the following 
three steps in each cycle: denaturation at 94°C for 2 min, annealing at 55°C for 
30 sec, and extension at 68°C for 30 sec, followed by a final extension at 68°C 
for 5 min. PCR reaction mixtures were purified using the Qiaprep PCR 
purification kit (Qiagen, Germany) according to the manufacturers manual. 
2.1.3.4 Site-directed mutagenesis of DNA using PCR  
The PCR methods for creating deletion and single amino acid quick change 
mutations were carried out according to the Stratagene site directed mutagenesis 
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kit manual. The reaction was performed typically in 50 µL volumes using 40 µL 
filter sterilized dH2O, 1 µL wild type template DNA, 1 µL of each quick change 
(forward, reverse) primer (10 µM), 1 µL of dNTP mix (containing 10 mM of each 
dNTP), 5 µL of Hot-Start Pfu-TURBO™ 10x PCR reaction buffer and 1 µL of Hot-
Start Pfu-TURBO™ DNA polymerase (Stratagene, UK). A typical PCR reaction 
contained 18 cycles of the following three steps: denaturation at 95°C for 30 sec, 
annealing at 55°C for 1 min, and extension at 68°C for 2 min.  
2.1.3.5 Digestion of DNA by restriction endonucleases 
The restriction endonuclease digestion reactions were carried out according to 
the enzyme manufacturer’s manual, typically with an incubation period of 3-4 
hours at 37°C in a water bath. The reaction was inactivated by heat (20 min at 
65°C) and products were purified using a PCR purification kit (Qiagen, Germany) 
or agarose gel electrophoresis. The enzymes used in this study are listed below: 
- BamH I, Nhe I were used for double digestion of the pccKAN plasmid. 
- Sac I, Spe I were used for double digestion of the pALM148 and 
pBLM100 plasmids. 
- Dpn I was used to remove the methylated template DNA from the quick 
change PCR mutagenesis reaction mixtures. 
2.1.3.6 Detection of DNA- Agarose Gel Electrophoresis  
Agarose gel electrophoresis was routinely used for detection, concentration 
determination and purification of DNA samples. Typically 1-2% (w/v) agarose 
gels were prepared. The required amount of agarose was dissolved by heating in 
1x TAE buffer (40 mM Tris-acetate, 2 mM EDTA, 0.12% (v/v) acetic acid), and 
finally 3 µL of ethidium bromide was added. DNA samples were mixed with 1 µL 
of 6x Loading Dye sample buffer (Fermentas, UK) and DNA standards were 
prepared using 1 µL of Gene RulerTM 1 kb DNA Ladder (Fermentas UK) or 100 
bp DNA Ladder (Invitogen, UK) mixed with 1 µL of 6x Loading Dye sample buffer 
and 4 µL of dH2O. 
2.1.3.7 Purification of DNA fragments 
Products of restriction endonuclease double digestions reactions were separated 
by using agarose gel electrophoresis. The DNA of interest was cut out from the 
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gel under UV light, and purified by removing the agarose using QIAprep gel 
extraction kit (Qiagen, Germany) according to the manufacturer’s instructions. 
2.1.3.8 Ligation of DNA fragments 
The digested plasmid vector and the insert DNA concentrations were estimated 
by comparison to quantitative molecular weight standards on an agarose gel. For 
ligation reactions, typically a 1:3 vector to insert ratio was used and the ligations 
were set up as follows: 8.5 µL dH2O, 2 µL cut plasmid, 6 µL insert DNA fragment, 
2 µL 10x ligation buffer and 1.5 µL T4 DNA ligase enzyme (Fermentas, UK). The 
ligation reactions were performed at 4°C for 16 hours. The enzyme in the ligation 
reaction samples was then heat inactivated at 65°C for 10 min before 
transforming competent cells. 
2.1.3.9 Plasmid isolation  
For plasmid preparation, QIAprep Spin Miniprep kit was purchased from Qiagen 
(Qiagen, Germany). The DNA plasmid was isolated, purified and concentrated 
according to the manufacturer’s manual.  
2.1.3.10 Plasmid sequencing 
The sequences of all the plasmids obtained by cloning and PCR mutagenesis 
were confirmed using the University of Warwick, Department of Biological 
Sciences Molecular Biology Service or the GATC Biotech Laboratory (Germany). 
Sequencing primers used in this study are listed in Table 2.4. 
Table 2.4 - List of sequencing primers generated and used throughout this study. 
Primer 
Name 
Sequencing 
Target 
Sequence (5’ to 3’) 
pCC_for TM insert in pCC-KAN CCTTCATCAGCCACTGTAGTGAAC 
pCC_rev TM insert in pCC-KAN CAGTTCAGCGAGACCGTTATAG 
pABLM_for TM insert in pALM or pBLM GGGATTCGTCTGTTGCAGGAAGAGGAAGAA 
 
2.1.4 Growth and maintenance of E. coli strains 
2.1.4.1 E. coli bacterial strains 
The bacterial strains of Escherichia coli (E. coli) used throughout this study are 
listed in Table 2.5. All of the cloning was performed in a (laboratory stock) DH5α 
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strain. To perform TOXCAT and GALLEX assays, the NT326 E. coli strain 
(provided by Professor Donald M. Engelman, Yale University) was used. For the 
GALLEX assay, further E. coli strains SU101 and SU202 (provided by Dr Dirk 
Schneider, Albert-Ludwigs-University) were also used. 
Table 2.5 - List of Escherichia coli strains used throughout this study. 
Strain Genotype Reference 
DH5α supE44, ∆lacU169(φ80lacZ∆M15), hsdR17, recA1, 
endA1, gyrA96, thi-1, relA1 
(Sambrook and 
Russel, 2001) 
NT326 
F−(argF-lac)U169, rpsL150, relA1, rbsR, flbB5301, 
ptsF25, thi-1, deoC1, ∆malE444, recA, srlA+ 
Strep25 resistance. 
(Treptow and 
Shuman, 1985) 
SU101* 
lexA71::Tn5(Def)sulA211 
∆(lacIPOZYA)169/F’lacIq lacZ∆M15::Tn9 
CAM20, Km30 resistance. 
(Dmitrova et al., 
1998) 
SU202* 
lexA71::Tn5(Def)sulA211 
∆(lacIPOZYA)169/F’lacIq lacZ∆M15::Tn9 
CAM20, Km30 resistance. 
(Dmitrova et al., 
1998) 
* The strains differ in LexA operator sequence controlling the lacZ expression SU101 
(wt), SU202 (mut) are the lysogen of JL1434 E. coli strain. JL1434 transformed with 
pGC202 bears sulA promoter variant op+/op+ or op408/op+ operon fusion to lacZ gene 
respectively. 
 
2.1.4.2 Media for E. coli culture 
The E. coli cells were grown on agar plates (Luria Broth Miller (LB) liquid medium 
plus agar; Sambrook and Russel, 2001, Appendix A2.5). For liquid culture, E. coli 
cells were cultured in LB liquid medium (Sambrook and Russel, 2001, Appendix 
A2.2). The cultures were grown by inoculating a volume of 5 mL of the 
LB/antibiotic medium with a single colony from an agar plate and incubating for 
16 hrs under aerobic conditions in an incubator shaker at 37°C and 250 rpm. For 
making outgrowth liquid cultures, E. coli cells were typically prepared as 1 in 100 
dilutions of overnight cultures (100 µL overnight culture in 10 mL LB) and were 
grown in the presence of the required antibiotics until their optical density 
measured at 600 nm, OD600, reached a value of 0.6; this corresponds to a mid-
exponential growth phase. 
2.1.4.3 Antibiotics 
For the experiments, where it was necessary, we have used several antibiotics 
with different final concentrations, as detailed below: 
CHAPTER 2- MATERIALS AND METHODS 
21 
• Ampicillin 100 µg/mL (Amp100) or 200 µg/mL (Amp200) 
• Chloramphenicol 5 µg/mL (CAM5) 
• Kanamycin 5 µg/mL (Km5) 
• Tetracycline 12 µg/mL (Tet12) 
2.1.4.4 Preparation of chemically competent E. coli cells 
To generate chemically competent E. coli cells for transformation by our DNA of 
interest, cells were prepared based on the calcium chloride (CaCl2) or rubidium 
chloride (RbCl) methods.  
The calcium chloride method (Sambrook and Russel, 2001) was performed as 
follows: 10 mL mid-exponential phase culture (OD600 reached 0.6) was 
sedimented at 2500 rpm and resuspended in 10 mL of 100 mM filter sterilized 
MgCl2 and incubated at 4°C for 5 min. After sedimentation, cells were 
resuspended in 1 mL of 100 mM filter sterilized CaCl2. The cells were incubated 
at 4°C for 2-24 hours before transformation and stored as 200 µL aliquots at -
80°C.  
The RbCl method was used to generate 'super competent' E. coli cells, to use 
with quick change mutagenesis modified DNA plasmids. For this method, 2.5 mL 
LB media was inoculated with cells grown in liquid media or on plates, and grown 
for 16 h at 37°C, 250 rpm in a shaker incubator. All were transferred to 250 mL of 
LB supplemented with 20 mM MgSO4 and grown until OD600 reached 0.4 – 0.6. 
Cells were sedimented at 2500 rpm and resuspended in 100 mL buffer 1 (30 mM 
CH3COOK, 10 mM CaCl2, 50 mM MnCl2, 100 mM RbCl, 15% glycerol, adjusted 
to pH=5.8 with 0.2 M acetic acid and filter sterilized) and left on ice for 5 min. 
After sedimentation, cells were resuspended in 10 mL buffer 2 (10 mM 
C7H15NO4S (MOPS: 3-(N-morpholino) propanesulfonic acid), 75 mM CaCl2, 10 
mM RbCl, 15% glycerol, adjusted to pH=6.8 with 0.1 M NaOH and filter sterilized) 
and left on ice for 15-30 min. Competent cells were dispensed as 200 µL aliquots 
into pre-chilled 500 µL centrifuge tubes, flash frozen in an ethanol-dry ice bath 
and stored immediately at -80°C. 
2.1.4.5 Bacterial transformation 
The transformation of DH5α with the desired DNA was performed as follows: a 
10 µL aliquot of ligated DNA was added to 100 µL chemically competent DH5α 
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cells, and this was left at 4°C for 30 min. Cells were then heat-shocked at 42°C 
for 45-70 sec, suspended in 500 µL fresh LB, placed in a shaker incubator at 
37°C, 250 rpm for 45 min. The cells were sedimented at 13,000 rpm for 1 min 
using a bench top mini-centrifuge, and 400 µL of supernatant was removed. Cells 
were resuspended and plated out on LB-agar plates containing the required 
antibiotic. The plates were incubated at 37°C for 16 hours.  
A 10 µL aliquot of the DNA obtained from quick change PCR mutagenesis was 
added to 90 µL of filter sterilized TCA buffer (10 mM Tris-HCl (pH=7.5), 10 mM 
CaCl2, 10 mM MgCl2) before DH5α super competent cells were transformed as 
described above. Chemically competent DH5α, NT326, SU101, and SU202 
E. coli cells were transformed as above mentioned, except that 100 µL aliquots of 
cells and 1-2 µL of plasmid DNA were used.  
2.1.5 Detection of proteins 
2.1.5.1 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The separation of the proteins was carried out using Invitrogen X-Cell Sure 
Lock™ vertical electrophoresis system, and the samples were loaded on to 
NuPAGE 12% Bis-Tris ready gels and run in 1x MES-SDS NuPAGE running 
buffer (Invitrogen, UK). The gels were typically run at 120 mA and 200 V for 
35 min at room temperature. However, the electrophoresis conditions for the 
cross-linking experiments were 120 mA, 200 V, 50 min at 4°C. With all gels, 
1-5 µL SeeBlue® Plus2 Pre-Stained Standard (Invitrogen, UK) was loaded. 
The protein samples were prepared by sedimenting 500 µL of OD600=0.6 protein 
culture at 13,400 rpm for 60 sec, adding lysis buffer to normalize the sample 
concentration to OD600=0.1 and breaking up the pellet by pipetting. To 15 µL of 
this sample, 5 µL of 4x LDS sample buffer (Invitrogen, UK) was added and 
samples were heated at 80°C for 10 min before loading on the gel (10 µL).  
The TCA precipitated samples (see in § 2.2.2.4) were resuspended in 80 µL 1x 
LDS sample buffer and heated at 80°C and/or sonicated for 10 min to break up 
pellets. Typically 10-15 µL of the prepared sample was then loaded on the gel.  
The peptide samples from cross-linking experiments were prepared by adding 
2 µL of 4x LDS sample buffer to 8 µL of each peptide-detergent sample, and 8 µL 
of the resulting solution was loaded on the gel. 
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2.1.5.2 Coomassie staining 
After gel-electrophoresis, protein bands were visualized by coomassie staining. 
The coomassie binds through a combination of hydrophobic interactions and 
heteropolar binding of the dye to basic amino acids such as arginine, histidine or 
lysine. This technique is widely used for visualization of peptides bands 5-50 ng 
range detection.  
During the experiments, the gel was first soaked in 50 mL fixing solution 
(50(v/v)% CH3OH, 10(v/v)% CH3COOH) for 15 min and stained in 50 mL 
coomassie stain solution (0.025 (w/v)% coomassie blue G250 or R250, 10(v/v)% 
CH3COOH) for 3-16 h at room temperature. The gels were then destained in 50 
mL 10(v/v)% acetic acid solution for 3 h. The destain solution was changed 
several times until the bands were seen with minimal background. The gel was 
stored in dH2O. 
2.1.5.3 Silver nitrate staining 
The silver staining mechanism for proteins in gels is relatively well understood. 
The protein detection depends on the binding of silver ions to the amino acid side 
chains, primary the sulfhydril and carboxyl groups of proteins (Switzer et al., 
1979; Merril et al., 1981; Merril and Pratt, 1986) followed by reduction to free 
metallic silver (Rabilloud, 1990). The protein bands are visualized as brown-black 
spots where the reduction occurs and, as a result, the image of protein 
distribution within the gel is based on the difference in oxidation-reduction 
potential between the gel’s area occupied by proteins and the free adjacent sites. 
Here, the low concentration protein and peptide bands were visualized by the 
following silver nitrate method. The gels were electrophoresed with 0.2-0.5 µL 
protein standard. Coomassie staining was performed before silver staining to 
help minimise the background discolouration. For silver staining, all solutions 
were freshly prepared using pre-cleaned glassware, and all soaking steps were 
carried out at room temperature with gentle shaking in a fume cupboard. First, 
the gels were soaked in a fixer solution (60 mL 50% acetone, 1.5 mL 50% TCA 
(16.339 g TCA dissolved in 200mL dH2O) and 25 µL 37% formaldehyde) for 15 
minutes, washed quickly three times with dH2O, then soaked in dH2O for 5 
minutes, followed by a final three quick washes with dH2O. Next, the gels were 
soaked in 50% acetone (500 mL acetone (100%) and 500 mL dH2O) for 5 min, 
Na2S2O3 solution (10 mg Na2S2O3 in 60mL dH2O) for 1 min, then washed quickly 
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three times with dH2O. The gels were then soaked in staining solution (160 mg 
silver nitrate, 600 µL 37% formaldehyde in 60 mL dH2O) for 8 minutes and 
washed quickly two times with dH2O. In the developing solution (1.2 g Na2CO3, 
25 µL 37% formaldehyde, 2.5 mg Na2S2O3 in 60ml dH2O), the gels were soaked 
for 10-20 seconds as protein bands appear very quickly. The reaction was 
quenched by soaking gels in 1% acetic acid (990 mL acetone dH2O, 10 mL 
glacial acetic acid) and finally rinsing and storing in dH2O. 
2.1.5.4 Immunoblotting (Western Blot)  
The western blot analyses were used to detect maltose binding protein (MBP) 
and its fusion proteins (see in § 2.2 and § 2.2.2.1-2.2.2.3). After the proteins were 
electrophoresed on 12% NuPAGE gels, they were electro blotted onto a 0.45 µm 
pore size nitrocellulose membrane at 160 mA, 90 V for 1 hour using the transfer 
XCell II™ Blot Module according to the manufacturer’s manual (Invitrogen, UK).  
After the transfer the membrane was blocked in TTBS + 3% milk solution for 
1 hour (or overnight at 4°C), it was washed with TTBS buffer (30 mM Tris-HCl, 
140 mM NaCl, 3 mM KCl, 0.1% Tween-20, pH 7.4) three times at 5 min each. 
The membrane was incubated for 1 hour with the primary antibody anti-MBP 
(Sigma), which was diluted 1 in 4000 with TTBS - 3% milk solution, before the 
washing step was repeated. The secondary antibody, anti-mouse IgG (Sigma), 
was used in a 1 in 10,000 dilution with TTBS + 3% milk solution and incubated for 
1 hour, followed by the washing step. Finally, to detect MBP and its fusion 
proteins, the SigmaFast™ kit was used according to the manufacturer’s 
instructions (Sigma, UK). 
2.2 The TOXCAT assay 
The in vivo oligomerisation of rCPT1 transmembrane domains was studied using 
the TOXCAT biological assay, the details of which have been described 
previously (Russ and Engelman, 1999). TOXCAT employs a chimeric protein, in 
which the α-helical TM domain of interest is inserted between the N-terminal DNA 
binding domain of ToxR, a dimerization-dependent transcriptional activator, and 
maltose binding protein (MBP), a monomeric periplasmic anchor protein. The 
fusion protein is constitutively expressed in E. coli together with a chlorampheni-
col acetyltransferase (CAT) reporter gene under the control of a ToxR-responsive 
cholera toxin (ctx) promoter. Oligomerisation of the TM domains within the 
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bacterial inner membrane results in oligomerisation of the ToxR domain, 
transcriptional activation of the ctx promoter, and CAT expression (Figure 2.1). 
The amount of CAT expressed in this system is proportional to the strength of 
oligomerisation of the TM domains.  
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Figure 2.1 - The principle of the TOXCAT assay.  
 
2.2.1 Constructing protein chimeras 
The expression vectors (pcc-KAN, pcc-GpA and pcc-G83I, see in § 2.1.3.2), and 
E. coli strain NT326 (see in § 2.1.4.1), were kindly provided by Dr Donald M. 
Engelman (Yale University, USA). To create chimeric proteins containing the TM 
domains of interest, oligonucleotides corresponding to the predicted rCPT1A and 
rCPT1B TM domain sequences were ligated into the pcc-KAN plasmid, between 
the Nhe I and BamH I restriction sites, and the resulting plasmids were used to 
transform NT326 E. coli competent cells (detailed in § 2.1.3 and 2.1.4.5). The 
oligonucleotides are listed in Appendix 1, and the resulting plasmids are 
summarised in Table 2.2. 
2.2.1.1 Construction of chimeric protein mutants  
The chimeras used in the length optimization and the sequence mutants (GxxxG, 
GxxxA, Thr) were constructed using quick change PCR as described in § 2.1.3.4. 
The oligonucleotide quick change primers are listed in Appendix 1, the resulting 
plasmids are summarised in § 2.1.3.2, Table 2.2. 
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The assay controls are the wild type glycophorin A (GpA) TM domain, known to 
form a strong dimer and therefore used as a positive control, and its dimerisation 
defective point mutant G83I, used as the negative control. Before performing the 
TOXCAT assay, several tests are performed to ensure that the constructed 
chimeras are correctly inserted into the E. coli membrane and changes to the TM 
sequence do not change the relative amounts of expressed or membrane 
inserted chimera. For further discussion of the concept, see also § 3.3. 
2.2.2 Control assays  
2.2.2.1 Sample preparation for expression level test 
To confirm that different CAT activities were not due to differences in the 
chimeras’ expression level, similar expression levels for all constructs were 
established via Western analysis against the MBP domain prior to performing 
CAT assays. Approximately 200 µL of NT326 cells expressing the chimeric 
proteins (cells harvested from fresh outgrowth culture, volume normalized to 
OD600=0.6) were sedimented at 13,000 rpm for 3 min using a bench top mini-
centrifuge, the supernatant was removed, and the cell pellet was resuspended in 
80 µL of 1x LDS sample buffer (Invitrogen, UK). The proteins were separated by 
SDS-PAGE, and MBP was detected by immunoblotting (see in § 2.1.5.4). 
2.2.2.2 NaOH extraction  
Prior to performing the TOXCAT assay, membrane association of all chimeric 
proteins was confirmed using sodium hydroxide washes (Chen and Kendall, 
1995). In this method, 1 mL of an NT326 outgrowth culture expressing the 
chimeric proteins (normalized to OD600=0.6) was sedimented at 4°C and 
13,000 rpm for 3 min using a bench top mini-centrifuge and the pellet was 
resuspended in 90 µL dH2O, 2.4 µL MgCl2, 5 µL DNase (10 mg/mL), and 5 µL 
lysosyme (10 mg/mL) and incubated at room temperature for 1 hour. To the lysed 
cells, 150 µL of ice cold dH2O was added and 125 µL was taken as a whole cell 
fraction (WC). To the remaining cells, 125 µL of ice cold 0.1 M NaOH was added 
and the solution was vortexed for 1 min and centrifuged at 4°C at 13,000 rpm for 
15 min. The supernatant was separated as the soluble protein fraction (SP) and 
the pellet was taken as the membrane protein fraction (MP). The preparation of 
the whole cell (WC) and soluble protein (SP) samples was continued with the 
TCA precipitation. 
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2.2.2.3 Spheroplast proteolysis assay 
 Membrane association and correct orientation of the TOXCAT chimeras in the 
E. coli membrane was also confirmed through protease sensitivity in a 
spheroplast proteolysis assay. In this assay, 1 mL of NT326 outgrowth culture 
(normalized to OD600=0.6) was sedimented at 4°C and 13,000 rpm for 15 min. 
The pellet was resuspended in 375 µL buffer A (100 mM Tris-acetate, 500 mM 
sucrose, pH=8.2), and 1 µL of 187.5 mM EDTA, 6 µL of 10 mg/mL lysosyme, 
8 µL of 1 M MgSO4 and 375 µL ice cold dH2O was added. The sample was 
incubated at 4°C for 1 hour. After the incubation, the sample was split into 
3x250 µL fractions (whole cell (WC), spheroplast (SPH), broken spheroplast 
(BSP)). To the SPH fraction, 100 µL buffer B (10 mM HEPES, 2 mM EDTA 
pH=7.6) and 15 µL of 3.5 mg/mL proteinase K were added, and the sample was 
incubated at 4°C for 40 min. The BSP fraction was sedimented at 4°C and 
13,000 rpm for 1 min, the supernatant was retained, and the pellet was 
resuspended in 100 µL buffer B. The resuspended pellet was frozen in dry ice 
and then left to defrost (i.e. freeze-thaw). After the freeze-thaw procedure was 
repeated three times and the supernatant was returned to the sample, 15 µL of 
3.5 mg/mL proteinase K was added and the sample was incubated at 4°C for 
30 min. TCA precipitation was then carried out for each of the WC, SPH, and 
BSP samples. 
2.2.2.4 TCA precipitation 
The WC and SP fractions from the NaOH assay, and the WC, SPH and BSP 
fractions from the spheroplast assay were prepared by TCA precipitation 
(trichloroacetic acid, CCl3COOH). 1 mL of 10% TCA was added to each sample, 
followed by incubation at 4°C for 30 min. The samples were centrifuged at 4°C 
and 13,000 rpm for 15 min, and all the supernatant was removed. 1 mL of 
acetone was added to the pellet, and incubated at 4°C for 5 min. Finally, the 
samples were centrifuged at 4°C and 13,000 rpm for 10 min, the acetone was 
removed, the pellet was allowed to dry, and the dry pellets were dissolved in 
80 µL 1x LDS sample buffer to load on an SDS-PAGE gel. The proteins were 
separated on the protein gel and MBP was detected by immunoblotting (see in 
§ 2.1.5.4).  
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2.2.2.5 MalE complementation assay 
The correct orientation of the chimera in the membrane was also confirmed using 
the malE complementation assay. In this assay, maltose minimal media agar 
plates were prepared by sterilizing 50 mL 5xM9 minimal medium (Sambrook and 
Russel 2001, A2.2), 0.5 mL of 1 M MgSO4, 25 µL of 1 M CaCl2 and 5 mL 20% 
maltose solutions and adding these to a sterile, melted agar solution (3.73 g agar 
in 195 mL dH2O). The mixture was poured into Petri dishes and allowed to dry 
and set. Single colonies of NT326 cells were streaked out on these maltose 
plates and were incubated at 37°C for 3 days. 
In this assay the malE deficient (∆malE) NT326 cells are used as negative 
controls, as they do not express MBP and cannot grow on maltose minimal 
media. However, the cells containing the plasmid of the constructed TOXCAT 
chimeras are able to grow, if the chimera is correctly inserted in the membrane 
with the MBP in periplasmic orientation. 
2.2.3 The qualitative and quantitative CAT assay 
To perform the qualitative CAT assay (or disk diffusion assay), NT326 outgrowth 
cultures (OD600 0.6-0.8) were normalized to OD600 0.1 by dilution with LB. 100 µL 
of the diluted cells were plated onto LB/agar/Amp200 plates and allowed to dry for 
1 hour. On a 1 cm diameter Wathman filter paper disk, 42 µL of 90 mg/mL 
chloramphenicol (CAM) was pipetted and allowed to soak through. These CAM 
soaked disks were then placed in the centre of each agar plate. The plates were 
incubated at 37°C for 16 hours. 
The quantitative CAT assays were performed using the FAST CAT Kit (Molecular 
Probes, Invitrogen), where an acetylation reaction yields a fluorescent butyryl-
cloramphenicol (butyryl-CAM) product (see reaction scheme in Figure 2.2) which 
was isolated via liquid-liquid extraction into a xylene phase. The concentration of 
butyryl-CAM was measured using a fluorimeter. 
Samples were prepared from 200µL of NT326 outgrowth culture (OD600 0.6) 
which was sedimented at 4°C and 13,000 rpm for 3 min. The pellet was 
resuspended in 500 µL 100 mM Tris-HCl pH=8.0 and vortexed to mix, then 20 µL 
of lysis solution (100 mM EDTA, 100 mM DTT, 50 mM Tris-HCl (pH=8.0)) and 
one drop of toluene was added. The sample was incubated at 30°C for 30 min. 
The lysed cells were used freshly or after being stored for 1-3 days at -80°C. In 
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the TOXCAT assay, a 10x dilution of lysed cells was used (6 µL of lysed cells, 54 
µL 100 mM Tris-HCl (pH=8.0)). To each sample of diluted cells, 10 µL of 
fluorescent CAM (FAST CAT® kit) was added and incubated at 37°C for 5 min. 
Then 10 µL of 5 mg/mL butyryl-CoA (Amersham) was added to the sample and it 
was returned to incubate at 37°C for 90 min. The reaction was terminated by 
adding 300 µL of xylene and vortexed to mix for 30 sec.  
For solution phase extraction, the samples were centrifuged at 13,000 rpm for 3 
min and the upper, organic phase was collected. To the upper phase (xylene) 
300 µL of 100 mM Tris-HCl (pH=8.0) buffer was added and it was mixed and 
centrifuged as before. Finally, this last wash step was repeated and the CAT 
concentration in the upper phase was measured using a fluorimeter (Jasco, FP-
6500). 
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Figure 2.2 - The reaction scheme of the CAT assay. 
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2.3 GALLEX methods 
The GALLEX assay (Schneider and Engelman, 2003) can measure not only 
homo, but also hetero TM interactions in a natural membrane, and was used to 
investigate the transmembrane domains of rCPT1A and rCPT1B. To perform this 
assay, the expression vectors (pALM148 and pBLM100 furthermore pALM148 or 
pBLM100 GpA and pALM148 or pBLM100 G83I), and E. coli strain SU101 and 
SU202 (see in § 2.1.4.1), were kindly provided by Dr Dirk Schneider (Albert-
Ludwigs-University, Germany). 
The GALLEX assay, similar to TOXCAT (previously described in § 2.2), also 
employs a chimeric protein, in which the α-helical TM domain of interest is 
inserted between an N-terminal DNA binding domain (in this case, the LexA 
dimerisation-dependent transcriptional activator), and maltose binding protein 
(MBP), a monomeric periplasmic anchor protein. The fusion protein is 
constitutively expressed in E. coli together with the lacZ reporter gene under the 
control of the op+ or op408 promoter as shown in Figure 2.3. When studying 
homo-oligomerisation, interaction of TM domains within the bacterial inner 
membrane results in oligomerisation of the wild type LexA domains and 
transcriptional activation of the op+ promoters which causes the repression of the 
β-galactosidase expression of in the E. coli cell (SU101). When measuring 
hetero-oligomerisation, the TM domain interactions results in oligomerisation of 
the wild type and mutant LexA domains, and this in turn results in the 
transcriptional activation of the hybrid op408/op+ promoters. This represses the 
expression of β-galactosidase in E. coli (SU202). The amount of β-galactosidase 
repression in these systems is proportional to the strength of oligomerisation of 
the TM domains (Figure 2.3). 
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Figure 2.3 - The principle of GALLEX in vivo oligomerisation assay. 
 
2.3.1 The construction of chimeric proteins 
To create the GALLEX chimeric proteins, primers were ligated into pALM148 and 
pBLM100 vectors between the Sac I and Spe I restriction sites (see § 2.1.3.5 and 
§ 2.1.3.8).  
To perform the homo-oligomerisation assay, SU101 E. coli competent cells were 
transformed with vectors generated from pBLM100 depending on the TM of 
interest of rCPT1A and rCPT1B domains as well as the GpA and G83I controls. 
These created the wt LexA-TM-MBP protein chimeras. 
To measure hetero-oligomerisation, TM1-TM2 domains were cloned into the 
vector pair pALM148/pBLM100, and used to transform the SU202 E. coli cells, as 
were the pALM148/pBLM100 GpA and G83I controls. These created the wt 
LexA-TM-MBP and mut LexA-TM-MBP protein chimera pairs. SU202 competent 
cells were first transformed with pALM148 plasmids.  
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After transformation, one single colony from the Tet12 selection-plate was cultured 
and the cells were made competent again. This was followed by transformation of 
SU202 (pALM148) with the second pBLM100 plasmid DNA (plasmid vectors 
generated from pALM148 and pBLM100 see in § 2.1.3.2, Table 2.3). 
 
2.3.2 Control assays 
The GALLEX assay uses the same biological control assays to confirm the 
correct topology and similar expression levels of chimeric proteins as the 
TOXCAT assay (see in § 2.2.2).  
The culturing and any differences in performing control assays will be discussed 
below. 
To perform the control assays, the MBP deficient NT326 E. coli strain was used. 
For the GALLEX assay, the SU101 (for homo-oligomerisation) and SU202 (for 
hetero-oligomerisation) strains were used. Overnight cultures of freshly 
transformed cells were grown in the presence of antibiotics Amp100, Tet12, Km5, 
CAM5 (see § 2.1.4.3 for definitions) and 0.01- 0.1 mM IPTG, at 37°C and 250 rpm 
for 16 hours. The following morning, 250 µL of the cells were used  to  innoculate  
10 mL of fresh LB media (1:40 dilution) containing the above mentioned 
antibiotics and IPTG, and the cultures were grown in a 50 mL Erlenmeyer flask 
until OD600 reached 0.6, which were typically 3 hours for SU101 and 5 hours for 
SU202 cells. To confirm the correct topology of chimera protein constructs, 
NT326 E. coli stain were transformed with vectors generated from pALM148 and 
pBLM100 plasmids and the malE complementation and spheroplast proteolysis 
assays were performed. To achive the malE complementation assay, the maltose 
minimal media agar plates (above in § 2.1.4.2) here were prepared to contain 
Amp100 and 0.01 mM IPTG. 
2.3.3 The β-galactosidase assay 
The association capacity of the different GALLEX protein chimeras was 
measured as a function of the repression of β-galactosidase activity. To measure 
the β-galactosidase concentration, an enzymatic reaction was carried out, as 
described below. The synthetic compound o-nitrophenyl-β-D-galactoside (ONPG) 
was added to the lysed cells. In the reaction catalyzed by the β-galactosidase 
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(Figure 2.4), ONPG was cleaved (hydrolysis) to yield galactose and 
o-nitrophenol, which has a yellow colour. The production of o-nitrophenol is 
proportional to the concentration of β-galactosidase; thus the production of the 
yellow colour followed with UV spectroscopy can be used to determine the 
β-galactosidase enzyme concentration. The standardized amount of β-galacto-
sidase was calculated in Miller units:  
600
550420
)mL()min(
)75.1( 1000
  unitsMiller 
ODVt
AbsAbs
⋅⋅
⋅−⋅
=  
where 420Abs  is the absorbance of the yellow o-nitrophenol at 420 nm, 550Abs is 
the scatter from cell debris, which, when multiplied by 1.75 approximates the 
scatter observed at 420 nm, t  is the reaction time in minutes, V  is the volume of 
the culture assayed in millilitres. 600OD  stands for the optical density of the 
cultures at 600 nm. 
Cultures were prepared as described above in § 2.3.2. The OD600 of a 1 mL 
culture was recorded, then 100 µL of the sample was diluted with 900 µL Z-buffer 
with 50 mM 2-mercaptoethanol (1x Z buffer: 60 mM Na2HPO4x7H2O, 40 mM 
NaH2PO4xH2O 10 mM KCl, 1 mM MgSO4x7H2O). Cells were lysed with 10 µL of 
10% SDS and 2 drops of chloroform, and were mixed with a vortex mixer for 10 
seconds. To start the reaction catalysed by β-galactosidase (Figure 2.4), 200 µL 
of ONPG (4 mg/mL in Z buffer), to stop the reaction, 0.5 mL 1M Na2CO3 solution 
was added. The reaction mixture was centrifuged for 10 min and the supernatant 
was transferred into a plastic cuvette. The absorbance was recorded at 420 and 
550 nm for each sample. 
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Figure 2.4 - The β-galactosidase reaction scheme. 
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2.4 Synthetic peptide purification  
Peptides corresponding to the TM domains (Table 2.6) of rCPT1A and rCPT1B 
were synthesized by the Keck Facility at Yale University, using F-moc chemistry. 
Lysine residues were added to the sequences at the N- and C-termini for rCPT1A 
TM2, and only at the C-terminus for rCPT1A TM1, to aid solubility and to reduce 
non-specific aggregation, an approach that has been shown in several previous 
studies not to affect the properties of strongly interacting TM domain peptides 
(Ding et al., 2001; Melnyk et al., 2003; Lazarova et al., 2004). 
Table 2.6 - The amino acid sequences of synthetic peptides used in this study. 
Non-native lysine residues are shown in bold.  
TM domain of 
interest 
Synthetic peptide sequence 
Molecular 
weight (Da) 
rCPT1A TM1 COCH3-KNGIITGVFPANPSSWLIVVVGVISSMK-CONH2 2957 
rCPT1A TM2 wt COCH3-KKNIVSGVLFGTGLWVAVIMTMRK-CONH2 2689 
rCPT1A TM2 G107I COCH3-KKNIVSIVLFGTGLWVAVIMTMRK-CONH2 2745 
rCPT1A TM2 
G107G113I 
COCH3-KKNIVSIVLFGTILWVAVIMTMRK-CONH2 2804 
rCPT1B TM1 COCH3-KILRGVYPGSPTSWLVVVMATVGSNYK-CONH2 2963 
rCPT1B TM2 COCH3-KETLLSMVIFSTGVWATGIFLFRK-CONH2 2785 
 
These hydrophobic peptides were purified by reversed-phase high performance 
liquid chromatography (RP-HPLC) using a Phenomenex C4 or phenylhexyl semi-
preparative column. The peptides were solubilised adding a solution containing 
200 µL trifluoroacetic acid (TFA), 200 µL 2,2,2-trifluoroethanol (TFE) then 400 µL 
acetonitrile (ACN) to the dried peptide, and injecting this solution onto the HPLC 
column. For separation, a 30% to 100% linear ACN gradient containing 0.1% 
TFA was used. The eluent was monitored at 280 nm (Figure 2.5). The fractions 
comprising the major peaks were collected and analyzed by mass spectrometry. 
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Figure 2.5 - Reverse phase liquid chromatography purification of rCPT1A TM2 
peptide on Phenomenex C4 column. The solid purple line represents the 
chromatogram and the broken line shows the ACN gradient.  
 
2.4.1 Lyophilisation of purified peptides 
The pooled HPLC fractions containing peptide were frozen on dry ice to form a 
thin layer in a round bottomed flask. The flask was placed in liquid nitrogen 
before being attached to vacuum (Schlenk line) and left under vacuum until all 
the solvent had been removed. Lyophilised peptide was dissolved in TFE, 
aliquoted, dried under nitrogen to remove the organic phase and then stored at -
20ºC until required. Peptides were stored as dry powders until use. 
2.4.2 Determination of peptide concentration 
Peptide concentration was determined by measuring UV absorbance. Peptides 
were dissolved in organic solvent or buffer and their absorbance was measured 
using a spectrophotometer (Biomate, Thermo Scientific). The extinction 
coefficients at 280 nm of all studied peptides were ε280 = 5500 M
-1 cm-1 and for 
rCPT1B TM1 peptide it was 8480 M-1 cm-1. These values were calculated using 
ProtParam (http://www.expasy.org), and the peptide concentration was 
calculated using the Beer-Lambert law:  
cAbs ⋅⋅= bε , 
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where Abs  is the absorbance, ε  is the extinction coefficient (M-1cm-1), b is the 
optical path length (cm), and c  is the concentration (M). 
2.5 Analysis of synthetic peptides  
2.5.1 Mass spectrometry 
The HPLC peak fractions were analyzed by electro spray ionization time-of-flight 
mass spectrometry (ESI-TOF-MS micrOTOF, Bruker). Samples were prepared 
by adding 10 µL 10% formic acid to 90 µL of the HPLC fraction. During analysis, 
the positive ionisation mode was used and detection was between 50 and 3000 
m/z. Spectra were typically recorded for 2 minutes, averaged and deconvoluted 
to determine the mass of the main species (for spectra see § 3.4.1 Figure 3.8 
and Figure 3.9).  
For detection and characterization of peptides, matrix-assisted laser 
desorption/ionisation-time-of-flight mass spectrometry (MALDI-TOF-MS) was also 
used, mainly to check the purity of the lyophilised peptide samples (for spectra 
see § 5.4.1, Figure 5.7 and Figure 5.8). Samples were prepared by mixing 5 µL 
of peptide sample with 5 µL of matrix solution (10 mg/mL α-cyano-4-hydroxy 
cinnamic acid in 50% ACN, 50% H2O and 0.1 % TFA). 1 µL of the sample/matrix 
solution was spotted onto a MALDI target plate and allowed to air dry for 30 mins. 
MALDI-MS spectra were acquired in the positive ion and linear modes. The mass 
range from m/z 2000 to 5000 was externally calibrated with polyethyleneglycol 
2000.  
2.5.2 Solubilisation of synthetic peptides in detergent micelles 
The synthetic peptides were dissolved in detergent micelles prior to structural or 
oligomerisation experiments. During this research, the detergents used were 
purchased from Avanti Polar Lipids (Alabaster AL, USA) and included: 
dodecylphosphocholine (DPC), octylglucoside (OG) and lyso-palmitoyl 
phosphatidylglycerol (LPPG). Sodium dodecylsulfate (SDS) was also used, but 
was purchased from Sigma Aldrich (UK). 
The concentration of detergent micelles in a detergent solution (Table 2.7) was 
calculated using the following equation:  
CHAPTER 2- MATERIALS AND METHODS 
37 
AgrNcc /)cmc( detergentmicelle −= , 
where micellec  is the micelle concentration (M), detergentc  is the detergent 
concentration (M), cmc  is the critical micelle concentration (M), and AgrN  is the 
aggregation number. The aggregation number is the number of detergent 
molecules present in a micelle once the critical micelle concentration ( cmc ) has 
been reached, and the critical micelle concentration is the concentration of 
detergent at which micelles are spontaneously formed. 
Table 2.7 - List and properties of biological detergents were used in this study 
(Sanders and Sonnichsen, 2006). 
Detergent 
Molecular 
weight 
(MW) 
Critical Micelle 
Concentration 
(mM) (cmc ) 
Aggregation 
Number 
( AgrN ) 
Dodecylphosphocholine (DPC) 352 1.5 
50-60 
(here used 56) 
Octylglucoside (OG) 292 19-25 90 
Lyso-palmitoyl 
phosphatidylglycerol (LPPG) 
506 0.02-0.6 125 
Sodium dodecylsulfate (SDS) 288 1-7 62-101 
 
2.5.3 Circular Dichroism (CD) 
Circular Dichroism (CD) is a widely used spectroscopic technique used for 
studying the structure of any optically active biomolecule (e.g. DNA, proteins). It 
measures differences in the absorption of left-handed versus right-handed 
polarized light which occur due to structural asymmetry in the molecule. 
The CD spectra were measured using Jasco J715 and J815 spectropolarimeters 
(Jasco UK, Great Dunmow, UK) with 1.0 mm path-length quartz cuvettes (Starna, 
Optiglass Ltd, Hainault, UK). All spectra were recorded in the far UV spectral 
region, from 190 to 260 nm using a 2.0 nm spectral bandwidth, 0.2 nm step 
resolution, 100 nm min-1 scanning speed, and 1 sec response time.  
All peptide samples were prepared in 50 mM sodium phosphate buffer (pH 7) and 
100 mM NaCl, containing either 10 mM SDS, 3.74-91.1 mM DPC, 97-385 mM 
OG, or 25-50 mM LPPG. The final peptide concentrations were 40 µM in each 
sample. CD spectra were collected at room temperature. Data were averaged 
from 4 individual spectra and measurement of the buffer without peptide was 
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subtracted to obtain the final spectra. The secondary structure composition of the 
peptides was estimated from the CD spectra using CDSSTR (Johnson, 1999), for 
details see § 2.6.3. 
2.5.4 Cross-linking  
To determine the oligomeric state of TM peptides, SDS-PAGE analyses were 
carried out. Since SDS is a denaturing detergent, it breaks up non-covalent 
interactions, such as the TM-TM oligomerisation. For this reason, to be able to 
detect the higher order oligomeric species, TM peptides were chemically cross-
linked.  
It is known that the concentration of detergent can affect the dissociation 
constant (kd) and thus the oligomeric states of transmembrane interactions 
(Fisher et al., 1999). For this reason the cross-linking reactions were carried out 
for 20 µM solutions of the rCPT1 TM peptides dissolved in DPC micelles at 
micelle to peptide ratios ranging from 1:3 to 20:1 (M:P=1/3-20) (corresponding 
concentrations ranging from 1.89 to 23.9 mM, see in Table 2.8), LPPG micelles 
at M:P=2-10 (corresponding to LPPG concentrations ranging from 5 to 25 mM), 
OG micelles M:P=10-40 corresponding to OG concentrations ranging from 43 to 
97 mM) and 15 mM SDS at M:P=4. All samples were prepared in 20 mM sodium 
phosphate and 150 mM NaCl buffer (pH 8). Bis[sulfosuccinimidyl]suberate (BS3, 
Pierce (Thermo Scientific, UK)) was used to cross-link peptides in solution via 
primary amine groups according to the manufacturers protocol (for the BS3 
reaction mechanism, see Figure 2.6). The cross-linking reaction was terminated 
after 30 min by the addition of 1M Tris-HCl (pH 8) to a 50 mM final concentration. 
Un-crosslinked and SDS cross-linked samples were prepared as controls. All 
samples were analyzed by gel electrophoresis (see in § 2.1.5.1), and peptides 
were visualized on gels by staining either with coomassie blue and silver nitrate 
(see in § 2.1.5.2-2.1.5.3). 
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Figure 2.6 - The general reaction scheme of amine-reactive NHS ester crosslinkers. 
The bis[sulfosuccinimidyl]suberate, BS3, also NHS ester, where spacer arm length is 
(CH2)6, 11.4 Å. 
 
Table 2.8 - The concentrations of the peptide and DPC detergent used in cross-
linking experiments at different micelle to peptide ratios. 
Micelle to Peptide ratio 
(M:P) 
C peptide 
(µM) 
C micelle 
(µM) 
C DPC detergent 
(mM) 
1:3 20 7 1.89 
1:2 20 10 2.06 
1:1 20 20 2.62 
2:1 20 40 3.74 
3:1 20 60 4.86 
5:1 20 100 7.1 
10:1 20 200 12.7 
15:1 20 300 18.3 
20:1 20 400 23.9 
2.5.5 Analytical Ultracentrifugation (AUC) 
A classical method, analytical ultracentrifugation became a very useful research 
technique in modern biochemistry and other (e.g. polymer science) fields for 
studying the solution-state behaviour of macromolecules (Laue and Stafford, 
1999). It can provide information on the size and shape of biomolecules, and the 
stoichiometry of complex formation (assembly, disassembly), as well as 
equilibrium constants and thermodynamic parameters for self- and hetero-
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associating systems. In an AUC experiment, UV optical spectroscopy is used to 
record absorption and interference data. There are two types of commonly used 
AUC experiments: sedimentation velocity (SV) and sedimentation 
equilibrium (SE). 
2.5.5.1 Sedimentation velocity (SV) 
Sedimentation velocity (SV) experiments were employed in this study as they 
provide information about the shape and size of peptides in solution. Due to the 
high rate of back diffusion expected from low molecular weight peptides, high 
speeds are sometimes required to obtain reliable SV data. In the present study, 
measurements were made at speeds of 40,000 rpm and/or 55,000 rpm to 
generate data with the required mass resolution. 
To determine the size distribution of peptide samples, absorbance data collected 
during an SV experiment was analyzed with the SEDFIT software (§ 2.6.3) using 
the c(S) method (Schuck et al., 2002). The size distribution profiles were then 
converted to a molecular mass distribution using the molecular mass of the 
peptide monomer. 
The sedimentation velocity measurements were carried out on a Beckman XL-
1/A analytical ultracentrifuge (Beckman Coulter, Fullerton CA, USA) housed in 
the Department of Biological Sciences, University of Birmingham (Birmingham, 
UK) and in the Biochemistry Department, University of Oxford (Oxford, UK). 
Peptide samples were prepared in 50 mM Tris-HCl (pH 7.5), containing 15 mM 
DPC 100 mM NaCl, and 52.2% D2O (Sigma) to match the buoyant density of the 
detergent. Density matching is needed so that the solvent density matches the 
buoyant density of the detergent micelles, and the only contribution to the 
buoyant molecular weight is from the peptide (Kochendoerfer et al., 1999; Salom 
et al., 2000). Data were collected using absorbance optics set to 280 nm.  
Data were collected at one or two peptide concentrations (see in Table 2.9) using 
a two chamber centerpiece at a speed of 40,000 rpm and a temperature of 25°C 
or 55,000 rpm and a temperature of 20°C. The AUC cells were set up and filled 
according to the manufacturer’s instructions (Figure 2.7). 400 scans were 
recorded for each sample, with 50 seconds between each scan. The moving 
boundary was monitored by repetitive radial scanning at a constant step size of 
0.003 cm at 280 nm using a UV absorption optical system.  
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The peptides’ monomeric molecular masses are shown in Table 2.9. The buffer 
density was 1.0608 g mL-1, the buffer viscosity was 1.186 cP, (values were 
measured by Dr Andrew Beevers). The partial specific volumes (Table 2.9) were 
calculated using SEDNTERP software (see in § 2.6.3).  
 
Table 2.9 - Peptide parameters used for AUC-SV data analysis. PSV stands for partial 
specific volume. 
TM domain of 
interest 
Molecular 
weight (Da) 
Peptide 
concentration 
(µM) 
PSV 
(mLg
-1
) at  
25 °C 
PSV  
(mLg
-1
) at  
20 °C 
rCPT1A TM1 2957 40 0.7722 0.7701 
rCPT1A TM2 wt 2689 62, 142 0.7792 0.7771 
rCPT1A TM2 
G107I 
2745 49, 98 0.7872 0.7851 
rCPT1A TM2 
G107G113I 
2804 112 0.7949 0.7928 
rCPT1B TM1 2963 83 0.7592 0.7571 
rCPT1B TM2 2785 107 0.7730 0.7709 
 
 
Figure 2.7 - Experimental setup of an analytical ultracentrifugation sedimentation 
velocity (AUC-SV) two chamber centre piece. The left panel shows a two-chamber cell 
during a SV experiment with the typical absorbance data. The loading setup of centre 
piece chambers is shown on the right hand side of the figure, where sample is loaded into 
the right chamber, and the reference solution (buffer) is loaded into the left chamber. 
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2.6 Software 
2.6.1 Analysis of DNA sequences 
SeqScanner: the sequencing data of all plasmids DNA was analysed using the 
free version of the Sequence Scanner program version 1.0 (downloadable from 
http://www.appliedbiosystems.com). 
Clone Manager: For the design of cloning strategy and alignment of DNA 
sequences the Clone Manager version 5.02 software was used. 
2.6.2 Analysis of protein sequences 
ProtParam: Allows the computation of various physical and chemical parameters 
for a user entered sequence. The computed parameters include molecular 
weight, amino acid composition, atomic composition, extinction coefficient, 
aliphatic index and grand average of hydrophobicity (downloadable from 
http://www.expasy.ch/tools/protparam.html). 
TMSTAT: Analysis of TM domains to identify helix-helix interaction motifs (Senes 
et al., 2000). http://bioinfo.mbb.yale.edu/tmstat/. 
ClustalW: Multiple sequence alignment of CPT1A and CPT1B proteins was 
carried out using Biology Workbench, http://workbench.sdsc.edu/. 
2.6.3 Analysis of biophysical data 
SEDNTERP: was used to estimate physical parameters are required for AUC 
data analysis, for example buffer density, buffer viscosity and the partial specific 
volume of peptides from their amino acid composition. The software developed 
by J. Philo, D. Hayes, and T. Laue, University of New Hampshire, USA, available 
at www.jphilo.mailway.com (Laue, 1992). 
SEDFIT: was used for AUC-SV data analysis. The software is available at 
https://sedfitsedphat.nibib.nih.gov, (Schuck, 2000). 
Dichroweb: Calculation of protein secondary structure from CD spectra 
(Whitmore and Wallace, 2008). The CDSSTR algorithm (Johnson, 1999; 
Sreerama and Woody, 2000) was used with the SP175 reference set (Lees et al., 
2006); see also http://dichroweb.cryst.bbk.ac.uk/html/home.shtml. 
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2.6.4 Molecular modelling  
CHI: Structural calculations were performed using the CHI program (CNS 
searching of helix interactions), the details of which have been described 
previously (Adams et al., 1995; Adams et al., 1996; Brunger et al., 1998). The 
calculations were performed using an 8 node dual 2.66 GHz Xenon processor 
Linux cluster (Streamline Computing, Warwick).  
CHI was used to create molecular models of all rCPT1A and rCPT1B TM domain 
homo- and hetero-oligomer structures. Using CHI, either two (for dimer), three 
(for trimer), or six (for hexamer) canonical α-helices containing TM domain 
sequence of interest were built. The starting geometries incorporated both right-
handed (-25°) and left-handed (25°) crossing angles and an axis-to-axis distance 
between the helices of 10.4 Å. In a search of approximately symmetrical 
interactions, the helices were simultaneously rotated about their central axis in 
45° increments from 0°-360°. After each rotation, molecular dynamics (MD) 
simulations were performed using simulated annealing of atomic coordinates. 
Four different MD simulations were performed for each starting geometry, and 
energy minimization of structures was carried out both before and after MD 
simulations. Groups of structures with a backbone RMSD of ≤1 Å were placed in 
clusters of 10 or more members, followed by a calculation of an average structure 
for each cluster and energy minimization. (The RMSD and cluster size was 
changed between 1.0-1.6 and 10-6, respectively, if the simulation did not produce 
meaningful results). 
PyMOL: All peptide sequences present in this thesis were visualised and the 
figures produced using the PyMOL software (DeLano, 2002) (freely available 
from http://www.pymol.org). 
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CHAPTER 3 
 
 
 
3. HOMO-OLIGOMERISATION OF 
CPT1A TRANSMEMBRANE DOMAINS 
 
This chapter presents the results from biological assays and studies on 
synthetic peptides constituting the transmembrane domains of CPT1A. The 
self-association of both studied TM domains is observed, and the 
stoichiometry of assembly is determined in detergent micelles in vitro. 
Possible interacting sites between these helical peptides are proposed 
from in silico models. 
 
3.1 Introduction 
The kinetic characteristics of the two catalytically active isoforms of carnitine 
palmitoyltransferases, CPT1A and B, have been extensively studied since the 
late 1970s. Although they share a high degree of sequence similarity, CPT1A 
and B have been found to have significant differences in their substrate and 
inhibitor (carnitine and malonyl-CoA) binding sensitivity (Saggerson, 1982; 
Paulson et al., 1984; Park and Cook, 1998). Furthermore, only the CPT1A 
isoform is found to alter its inhibitor binding sensitivity in different physiological 
states, where significant changes in membrane fluidity and composition are 
observed (Kolodziej and Zammit, 1990; Zammit et al., 1998). These results 
highlighted the potential importance of transmembrane helix interactions in the 
enzyme’s kinetics and folding of CPT1A, and that differences in transmembrane 
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helix-helix interactions may contribute to the differences in kinetics of the two 
CPT1 isoforms. Recently it has also been reported that CPT1A exists as an 
oligomeric complex in the OMM and that the N-terminal region of the protein 
containing TM1 and TM2 (residues 1-147 in the rat enzyme, rCPT1A) is involved 
in driving the oligomerisation of CPT1A (Faye et al., 2007). Therefore, a closer 
study of the homo- and hetero-interactions of the TM domains in CPT1A could 
provide new understanding of the role of TM domains in enzyme folding and 
function.  
The present chapter summarises the investigation of oligomerisation of each of 
the TM domains in CPT1A in isolation, carried out to identify what regions of the 
protein drive the oligomerisation and kinetics of the full-length enzyme. Here the 
self-association of each individual TM domain of rat CPT1A (rCPT1A) was 
studied in natural E. coli membranes using the TOXCAT (Russ and Engelman, 
1999) and GALLEX (Schneider and Engelman, 2003) assays. Synthetic peptides 
corresponding to the TM sequences were used to obtain quantitative biophysical 
evidence of TM1 and TM2 oligomerisation, including the stoichiometry of 
assembly in detergent micelles. The results have enabled us to construct 
molecular models that highlight potential points of contact between TM helices 
and suggest that oligomer formation is favoured by the relative positioning of 
helix-helix interaction motifs within the predicted transmembrane domain helices.  
3.2 Sequence analysis of CPT1A TM domains 
The prediction of membrane spanning regions in CPT1A proteins was first carried 
out using the Uniprot online database (http://www.expasy.org), where TM1 and 
TM2 are indicated in the protein sequence of different species (highlighted in 
white in Figure 3.1). Additionally, the transmembrane hidden Markov model 
(TMHMM) software (Sonnhammer et al., 1998) was used to predict the location 
of the transmembrane helices from the sequences, and these results are 
highlighted in colour in Figure 3.1. 
3.2.1 Sequence conservation and helix-helix interaction motifs 
The sequences of CPT1A TM domains (as predicted by the bioinformatics tool 
TMHMM) were further analysed to look for sequence conservation between 
species as well as known helix-helix interaction motifs. Multiple sequence 
alignments of the predicted TM sequences from a variety of species are shown in 
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Figure 3.2, where the sequence similarity across different species is 73.3% for 
CPT1A TM1 and 81.8% for TM2. TM domains of membrane proteins frequently 
contain sequence motifs that are known to both stabilise the proteins and provide 
structural plasticity by promoting TM helix-helix interactions. Moreover, different 
motifs within the same TM may separately promote hetero- or homo-interhelical 
associations (Gerber et al., 2004).  
 
 
Figure 3.1 - Prediction of TM domain regions in CPT1A proteins from different 
species. Transmembrane domain regions defined by UniProt are in white brackets, 
highlighted with yellow and green, while residues highlighted with light yellow or light 
green were also predicted as part of TM domains by TMHMM. The UniProt codes of the 
analysed CPT1A proteins are shown on the left hand side. 
 
 
Figure 3.2 - Analysis of conserved residues and helix-helix interaction motifs in 
CPT1A TM1 and TM2. The sequence analyses of conserved residues were carried out 
using Biology Workbench http://workbench.sdsc.edu/. Completely conserved residues 
are labelled green, identical residues are labelled with yellow, similar residues with blue, 
and different residues with white. The sequence motifs are highlighted according to 
TMSTAT analysis. 
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3.3 In vivo oligomerisation of rCPT1A TM domains 
Although previously reported data suggests that the TM2 domain plays a key role 
in oligomer formation of rCPT1A (Faye et al., 2007), no direct measurements of 
self-association for either TM of rCPT1A had been reported at the start of the 
present work. To address this, we have examined the homo-oligomerisation of 
rCPT1A TM1 and TM2 in natural E. coli membranes using in vivo oligomerisation 
assays. 
Studying lateral helix-helix interactions between transmembrane α-helices in a 
natural membrane environment has been made possible by several biological 
assays such as the ToxR system (Langosch et al., 1996), TOXCAT (Russ and 
Engelman, 1999), POSSYCAT (Gurezka and Langosch, 2001) and GALLEX 
(Schneider and Engelman, 2003).  
Previously, TOXCAT and GALLEX assays were successfully applied to the 
examination of several different TM homo- and hetero-interactions (Li et al., 
2004; Escher et al., 2009). For this reason, in the present study both assays were 
initially used to measure homo-association of rCPT1A TM domains, providing 
complementary data. Here both TOXCAT and GALLEX assays were used to 
examine CPT1A TM domain oligomerisation and also to compare the two 
techniques. The GALLEX assay was further employed to measure hetero-
association between TM1 and TM2 domains (see CHAPTER 6). 
The TOXCAT assay is a ToxR-based transcriptional assay linked to 
chloramphenicol acetyltransferase (CAT) expression. The degree of TM 
association can be measured in terms of the CAT activity generated as a result of 
the homo-oligomerisation of TM domains in ToxR-TM-MBP chimera (where ToxR 
is a dimerisation-dependent DNA binding domain from Vibrio cholerae and MBP 
is maltose binding protein, for schematic figure and detailed description see 
Materials and Methods § 2.2). The sequence of the investigated TM domains was 
based on analyses of the full-length sequence of rat CPT1A (rCPT1A) using the 
bioinformatics program TMHMM to predict the location of TM domains (as 
described in § 3.2.1). Initial measurement of self-association of rCPT1A TM 
domains in TOXCAT chimera suggested that none of these sequences self-
associate. However, previous studies suggest that the length of the TM cloned 
into the TOXCAT chimera can affect ToxR-based transcriptional activity 
(Langosch et al., 1996; Li et al., 2004). We undertook therefore a more extensive 
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investigation of how the length of the TM insert affected the association 
measured, and attempted to optimize the CAT activity by decreasing the length of 
the TM sequence in the chimera. The shorter rCPT1A TM sequences were 
designed taking into consideration the position of GxxxG motifs in the 
transmembrane segments.  
In the GALLEX assay, the fundamental concepts of measuring TM homo-
association are similar to those in the TOXCAT assay, but here a different LexA-
TM-MBP chimera (where LexA is transcription factor) is expressed and the 
oligomerisation of the TM domain within the chimera results in the repression of 
β-galactosidase synthesis in E. coli cells. TM domain oligomerisation was 
characterized by the quantitative measurement of β-galactosidase (for schematic 
figure and detailed description see Materials and Methods § 2.3). The TM 
sequences cloned into GALLEX chimeras were originally designed with shorter 
TM lengths in agreement with the TOXCAT assay results mentioned above. 
Before the quantitative measurement of CAT activity (in TOXCAT assay) or β-
galactosidase repression (in GALLEX assays), correct insertion of all chimeras 
was confirmed using NaOH extraction, malE complementation and spheroplast 
proteolysis assays as described in detail in § 2.2.2.  
The above mentioned biological assays were performed using the TM domain of 
glycophorin A (GpA), a very well-characterized and strongly-dimerising TM 
domain, as a positive control and a dimerisation-defective point mutant (G83I) as 
a negative control.  
3.3.1 Homo-oligomerisation of transmembrane domain 1 (TM1) 
The oligomerisation of rCPT1A TM1 was first measured using the TOXCAT 
assay. The initial sequence cloned into the TOXCAT chimera contained 27 
residues (Lys47-Met73) from the TM domain (as predicted using TMHMM) and 
showed little or no ability to self-associate. When shortened to 24 and 21 
residues (Ile50-Val73, Ile50-Val73 respectively), the CAT activities of resulting 
chimeras were lower than that obtained for the negative control (Figure 3.3). The 
chimera containing the 21 residue TM1 insert also failed to grow on maltose 
minimal media plates when analysed using the malE complementation assay, but 
we could confirm the correct orientation of the chimera in the E. coli membrane 
using the spheroplast proteolysis assay (Figure 3.4). 
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Figure 3.3 - Oligomerisation of rCPT1A TM1 (27, 24, 21, 18, 16) TOXCAT chimeras in 
E. coli membranes. (a) Transmembrane domain sequences of rCPT1A TM1 were 
cloned and analyzed using the TOXCAT assay. (b) CAT activities obtained for the 
different length rCPT1A TM1 inserts, and expression levels of each chimera detected by 
western blot analysis (using antibodies directed against MBP). All CAT activities are 
reported relative to the value obtained for wt GpA (positive control). Values are means 
(+/- standard deviation) for three or more independent measurements. (c) malE 
complementation to test the ToxR-TM1-MBP chimera's correct insertion and orientation. 
 
The sequence of TM1 was further shortened to 18 and 16 residues (Ile50-Val67, 
Thr52-Val67 respectively) and the resulting chimeras showed higher propensity to 
self-associate, yielding CAT activities of 35% and 53% of GpA levels, 
respectively. The self-association of rCPT1A TM1 studied using the TOXCAT 
assay suggests that shorter constructs of this sequence have the ability to form 
homo-oligomers (Figure 3.3). 
Self-association of the rCPT1A TM1 domain was also studied using the GALLEX 
assay. In wt LexA-TM-MBP chimeras, different lengths of TM1 sequences were 
also tested. Reassuringly, TM1 inserts show the same length-dependent 
oligomerisation observed using the TOXCAT assay. However, the GALLEX 
assay suggests much stronger oligomerisation of the 21 residue construct as well 
as for the 18 and 16 residue sequences, which yielded results very similar to 
those obtained for wt GpA (Figure 3.5). The correct insertion and orientation of 
chimeras containing 21, 18 and 16 residues was confirmed by the spheroplast 
proteolysis assay (data not shown). 
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Figure 3.4 - Immunoblots of spheroplast proteolysis assay to investigate the 
topology of the ToxR-TM1(21)-MBP chimera. Chimeras were expressed in NT326 
cells. The immunoblotting was carried out using antibodies directed against MBP. The 
correctly inserted chimeras were detected at 66 kDa (the full length chimera protein 
molecular weight) in W: whole cell fractions, and at 43 kDa (molecular weight of MBP) in 
S*: spheroplast treated with proteinase K and B*: lysed spheroplast treated with 
proteinase K fractions.  
 
 
Figure 3.5 - Oligomerisation of rCPT1A TM1 (21, 18, and 16 amino acids in length) 
in GALLEX homo-oligomerisation assay. (a) The inverse sequences of rCPT1A TM1 
were cloned into the pBLM vector to form the wt LexA-TM-MBP chimera. Chimeras were 
expressed in SU101 using 0.01 mM IPTG when analyzed using the GALLEX homo-
oligomerisation assay. (b) The resulting β-galactosidase activities of GpA and rCPT1A 
TM1 chimeras. All activities are reported relative to the value obtained for GpA G83I 
(negative control). Values are means (+/- standard deviation) for three independent 
measurements. The expression levels of each chimera detected by western blot analysis.  
 
In summary, results from both TOXCAT and GALLEX assays support the self-
association of the rCPT1A TM1 domain in the E. coli membrane. 
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3.3.2 Homo-oligomerisation of transmembrane domain 2 (TM2) 
In a similar manner as that described above, the TOXCAT assay was also used 
to measure self-association of rCPT1A TM2. The initial sequences of rCPT1A 
TM2 inserts containing 22 or 20 residues indicate no significant interaction, 
however after further optimization of the length of the TM domain insert, chimeras 
showed a much greater propensity to form homo-oligomers in the membrane. 
The CAT activity of a 16 amino acid TM2 insert (Ile104-Ile119) was approximately 
47% of that observed for the positive control wt GpA (Figure 3.6).  
 
Figure 3.6 - Oligomerisation of rCPT1A TM2 (22, 20, 18, and 16 amino acids in 
length) TOXCAT chimeras in E.coli membranes. (a) Transmembrane domain 
sequences of rCPT1A TM2 were cloned and analyzed using the TOXCAT assay. (b) CAT 
activities obtained for the different length TM2 constructs, and expression levels of 
chimeras detected by western blot analysis. All CAT activities are reported relative to the 
value obtained for wt GpA (positive control). Values are means (+/- standard deviation) 
for three or more independent measurements. (c) malE complementation to confirm the 
ToxR-TM2-MBP chimeras correct insertion. 
 
The 16 amino acid TM2 sequence, which yielded the strongest signal in the 
TOXCAT assay, was also cloned into the GALLEX wt LexA-TM-MBP chimera 
and the homo-oligomerisation assay was performed. The resulting 
wt LexA-TM2(16)-MBP chimera yielded β-galactosidase repression similar to that 
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observed for the positive control (GpA), which further validates the results 
obtained using TOXCAT (Figure 3.7). 
 
 
Figure 3.7 - Oligomerisation of rCPT1A TM2 (16 amino acids in length) in GALLEX 
homo-oligomerisation assay. (a) The sequence of rCPT1A TM2 was cloned into the 
pBLM vector to form the MBP-TM-wtLexA chimera. Chimeras were expressed in SU101 
using 0.01 mM IPTG when analyzed by the GALLEX homo-oligomerisation assay. (b) 
The resulting β-galactosidase activities of GpA and rCPT1A TM2 chimera. All activities 
are reported relative to the value obtained for GpAG83I (negative control). Values are 
means (+/- standard deviation) for three independent measurements. The expression 
levels of chimeras detected by western blot analysis. (c) malE complementation assay 
results to confirm the correct insertion of the LexA-TM2-MBP chimera. 
 
The correct insertion and orientation of all of the above-mentioned TM2 chimeras, 
analyzed using either the TOXCAT or GALLEX assays, was confirmed by growth 
on maltose minimal media plates in the malE complementation assay.  
In summary, similarly to TM1, both homo-oligomerisation assays also suggest 
significant homo-oligomerisation of rCPT1A TM2. 
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3.4 In vitro oligomerisation of rCPT1A TM peptides  
While the above presented oligomerisation studies provide a strong indication 
that the rCPT1A TM sequences can support self-association of these domains, 
the TOXCAT or GALLEX assay cannot report on the order of the oligomeric state 
achieved. Therefore, in order to validate the results of in vivo assays and 
characterise the oligomeric state(s) of the rCPT1A TM domains, in vitro 
approaches were used. 
Synthetic peptides corresponding to the rCPT1A TM domains were investigated 
to establish whether the oligomeric states attained in vitro correspond to those 
observed for full-length rCPT1A (i.e. trimer and hexamer; (Faye et al., 2007)). 
The secondary structures of the synthetic peptides were first characterised in a 
number of detergents using circular dichroism (CD). To investigate the oligomeric 
state(s) of rCPT1A TM peptides, chemical cross-linking and analytical 
ultracentrifugation sedimentation velocity (AUC-SV) experiments were carried out 
(§ 2.4 and Table 2.6). 
3.4.1 Purification of synthetic TM peptides 
The crude synthetic peptides were purified by reversed-phase high performance 
liquid chromatography (RP-HPLC). Further details and peptide sequences can be 
found in § 2.4. The purity of the peptide fractions was confirmed by electrospray 
ionization time-of-flight mass spectroscopy (ESI-TOF-MS micrOTOF, Bruker). 
The deconvoluted mass spectra of rCPT1A TM1 and TM2 peptides are shown in 
Figure 3.8 and Figure 3.9, respectively. 
Table 3.1 - The amino acid sequences of rCPT1A TM1 and TM2 synthetic peptides 
used in this study. Non-native lysine residues are shown in bold. 
TM domain of 
interest 
Synthetic peptide sequence 
Molecular 
weight (Da) 
rCPT1A TM1 COCH3-KNGIITGVFPANPSSWLIVVVGVISSMK-CONH2 2957 
rCPT1A TM2 wt COCH3-KKNIVSGVLFGTGLWVAVIMTMRK-CONH2 2689 
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Figure 3.8 - Analysis of purified rCPT1A TM1 peptide by electrospray ionisation 
mass spectrometry (ESI-MS). The HPLC fractions containing the desired peptide were 
pooled and analyzed using ESI-MS. In the deconvoluted spectrum, the major peak 
corresponds to the rCPT1A TM1 peptide (2954 Da), and additional peaks correspond to 
sodium and solvent adducts. 
 
 
Figure 3.9 - Analysis of purified rCPT1A TM2 peptide by electrospray ionisation 
mass spectrometry (ESI-MS). The HPLC fractions containing the pure peptide were 
pooled and analyzed using ESI-MS. In the deconvoluted spectrum, the major peak 
corresponds to the rCPT1A TM2 peptide (2689 Da), and additional peaks correspond to 
sodium and solvent adducts. 
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3.4.2 Secondary structure of TM peptides 
Before characterizing the oligomeric state, the secondary structure of the rCPT1A 
TM peptides was determined using circular dichroism (CD) spectroscopy (details 
in § 2.5.3). The analyses of secondary structure composition from the collected 
CD spectra were carried out by fitting of the data using the CDSSTR software 
(Johnson, 1999). 
CD spectra were collected for the CPT1A TM1 peptide, and visual inspection of 
the spectra suggested that the peptide adopts mainly an α-helical secondary 
structure in the anionic and denaturing detergent sodium dodecylsulphate (SDS) 
at a 3:1 micelle to peptide ratio and in zwitterionic detergent, dodecyl-
phosphocholine (DPC) micelles at 10:1 and 20:1 ratios. DPC was selected 
because it is a less denaturing detergent than SDS, and is amenable to a large 
range of biophysical methods (including analytical ultracentrifugation) (Li et al., 
2001; Oates et al., 2008). However, at lower DPC micelle to peptide ratios (4:1 
and 2:1), the peptide adopted a primarily β-sheet secondary structure, which we 
suggest arises from insoluble aggregates. Fitting of CD data using CDSSTR 
software confirmed that the rCPT1A TM1 peptide secondary structure 
composition in DPC is dependent on the micelle concentration (Figure 3.10). 
Secondary structure composition was calculated by fitting of the CD data 
between 200-260 nm. Data collected at lower wavelengths (190-200 nm) was not 
included in the fit due to the increased effects of light scattering of detergent 
micelles in this range, as evidenced by high tension (HT) values greater than 
600 mV.  
Despite the fact that results for TM1 have been presented here first, our initial CD 
experiments were actually carried out on the rCPT1A TM2 peptide, and in these 
initial experiments we screened a number of different detergent micelles to 
determine which were optimal for solubilisation of the TM peptides. Spectra were 
collected for the solubilised TM2 peptide in trifluoroethanol (TFE), SDS, 
octylglucoside (OG), a neutral and non-denaturing detergent, lyso-palmitoyl 
phosphatidylglycerol (LPPG), an anionic detergent, as well as in DPC. Apart from 
the spectra collected for the OG-solubilised peptide, all of the resulting spectra 
(Figure 3.11) displayed a characteristic α-helical profile, with negative absorption 
maxima at 208 and 222 nm, demonstrating that the peptides adopt an α-helical 
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secondary structure in TFE, SDS, LPPG and DPC micelles. In the case of OG, 
the spectra suggest more β-sheet content.  
 
Figure 3.10 - The effect of DPC micelle concentration on the secondary structure of 
rCPT1A TM1 peptide. (a) CD spectra measured at different detergent micelle to peptide 
ratios, plotted in units of mean residue ellipticity (MRE). (b) High tension (HT) over the 
wavelength region specified in (a). (c) The secondary structure composition of the 
rCPT1A TM1 peptide estimated from the CD spectra shown in (a) using the CDSSTR 
software (Johnson, 1999). 
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Figure 3.11 - The effect of TFE solvent and different detergent micelles (SDS, LPPG. 
OG, DPC) on the secondary structure of rCPT1A TM2 peptide. (a) CD spectra 
measured in different detergent micelles, plotted in units of mean residue ellipticity 
(MRE). (b) High tension (HT) over the wavelength region specified in (a). (c) The 
secondary structure composition of the rCPT1A TM2 peptide estimated from the CD 
spectra shown in (a) using the CDSSTR software (Johnson, 1999). 
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Figure 3.12 - The effect of DPC micelle concentration on the secondary structure of 
the rCPT1A TM2 peptide. (a) CD spectra measured at different detergent micelle to 
peptide ratios, plotted in units of mean residue ellipticity (MRE). (b) High tension (HT) 
over the wavelength region specified in (a). (c) The secondary structure composition of 
the rCPT1A TM2 peptide estimated from the CD spectra (190-260 nm) shown in (a) using 
the CDSSTR software (Johnson, 1999). 
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Fitting of CD data using CDSSTR software confirms that the CPT1A TM2 peptide 
is predominantly α-helical in TFE, SDS and LPPG, while it is primarily β-sheet in 
OG (Figure 3.11). Further investigation also revealed that, as observed for the 
CPT1A TM1 peptide, the helical character of the TM2 peptide is also dependent 
on the micelle concentration in DPC (Figure 3.12). Since the HT values were 
lower than 600, here the secondary structure of the rCPT1A TM2 peptide was 
calculated using the 190-260 nm data set as shown in Figure 3.12. 
 
3.4.3 Determination of rCPT1A TM1 peptide oligomeric state 
Synthetic peptides corresponding to rCPT1A TM1 and TM2 were solubilised in 
DPC micelles and then treated with the water-soluble chemical cross-linker 
bis[sulfosuccinimidyl] suberate (BS3). BS3 reacts specifically with the terminal 
-NH2 of the peptide as well as the -NH2 groups on lysine side chains, provided 
that the reactive groups are within 11.4 Å of one another (Staros, 1982). Cross-
linking reactions were carried out at increasing DPC micelle to peptide (M:P) 
concentration ratios to investigate the effect of detergent concentrations on 
oligomeric state of TM peptides (Fisher et al., 1999). Cross-linked species were 
analyzed using SDS-PAGE and visualized by staining with silver nitrate (for 
details see § 2.1.5.3). 
The rCPT1 TM1 peptide (K47-M73, 2954 Da) was electrophoresed under 
denaturing conditions (SDS-PAGE) before and after treatment with a chemical 
crosslinker. When dissolved in SDS detergent, the TM1 peptide migrated as a 
monomeric species at ~3 kDa (Figure 3.13 a and b, cross-linked and un-cross-
linked in the last two lanes), as expected from the ability of SDS to destabilize the 
non-covalent interactions involved in transmembrane oligomer formation (Fisher 
et al., 2003). In order to investigate its oligomeric state in a less denaturing 
detergent, the peptide was dissolved in DPC detergent micelles followed by 
chemical cross-linking with BS3 to covalently stabilize rCPT1A TM1 peptide 
oligomers in DPC micelles. Cross-linked species were visualized by SDS-PAGE 
analysis. The TM1 peptide produced a number of bands between the 6 and 14 
kDa molecular weight markers, which corresponds to oligomeric states between 
trimer and pentamer. A broad band between 28-38 kDa was observed at the 
lowest detergent concentrations (M:P=1/3–2), suggesting the presence of higher 
order aggregates. As the detergent concentration was increased (M:P=3–5), only 
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trimer and tetramer species were observed, and at the highest detergent 
concentrations (M:P=10–20) only trimer species were detected (Figure 3.13 b). It 
is well-established that increasing detergent concentration can destabilize TM 
helix oligomers (Fisher et al., 1999), and this behaviour is reconfirmed in this 
study of the CPT1A TM1 peptide. These results also suggest that the most stable 
oligomeric state for the TM1 peptide at all detergent concentrations is that of a 
trimer.  
To confirm the specificity of the cross-linking reaction and investigate the strength 
of helix-helix interactions in SDS micelles, samples were also analysed in the 
absence of a cross-linker on SDS-PAGE. Although the bulk of the peptide 
migrated at the molecular weight of the monomer, we were surprised to find that 
the trimer species was also present on the gel, especially at the lowest detergent 
concentrations (Figure 3.13 c). According to the cross-linking experiments, the 
CPT1A TM1 peptide forms predominantly trimers when dissolved in DPC 
micelles.  
 
 
Figure 3.13 - SDS-PAGE analysis of chemically cross-linked rCPT1A TM1 peptide 
oligomerisation. (a) The molecular weight marker is shown in the left-hand lane. Peptide 
dissolved in SDS and visualised by coomassie staining. (b) BS3-mediated cross-linking of 
peptides dissolved in DPC micelles. Cross-linking reactions were carried out in DPC 
detergent micelles at various micelle to peptide concentration ratios as indicated below 
each lane. Protein bands were visualized by staining with silver nitrate. Oligomeric states 
(e.g. trimer indicated by n=3) are indicated at the far right of the gels. (c) rCPT1A TM1 
peptide in the absence of crosslinker migrates mainly as monomer, but bands 
corresponding to trimer were also detected at different DPC micelle concentrations, as 
visualized by silver nitrate staining. 
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In order to directly and more quantitatively study the oligomerisation behaviour of 
rCPT1A TM peptides, they were also studied in the absence of a cross-linker 
using analytical ultracentrifugation (AUC). For investigating the oligomeric state of 
the TM1 peptide, sedimentation velocity (SV) experiments were carried out at 
25°C at a speed of 40,000 rpm (Department of Biochemistry, Birmingham 
University) and at 20°C at a speed of 55,000 rpm, (Department of Biochemistry, 
University of Oxford) using Beckman Optima XL-1/A ultracentrifuges (as 
described in § 2.5.5). 
The data collected during the lower speed AUC-SV experiments (40,000 rpm) 
were analyzed. When the data were fit using the programme SEDFIT (Schuck, 
2000), the sedimentation coefficient profile showed hexamer or higher order 
sedimenting species (aggregation) in rCPT1A TM1 samples (data not shown). 
Since the sizes of the sedimenting species were estimated to be ~ 3-15 kDa 
(based on what we learnt from our cross-linking experiments, Figure 3.13 and 
§ 3.4.3,), it was hoped that we could resolve any small molecular weight 
sedimenting species by carrying out further experiments at a higher speed 
(55,000 rpm). AUC-SV data were collected at 55,000 rpm at two different peptide 
concentrations, but only the lower concentration sample yielded a sedimentation 
profile of sufficient quality to be analyzed. The peptide concentration of this 
sample was 40 µM (M:P ratio ~ 6). The partial specific volume was 0.7701 mL g-1 
(at 20°C). Sedimentation profiles were again fit using SEDFIT (Schuck, 2000) 
and the resulting sedimentation coefficient profile and fitting residuals are shown 
in Figure 3.14. The sedimenting species in the rCPT1A TM1 peptide sample 
were typically hexamers, centered at S=0.68. Upon conversion of this 
sedimentation coefficient to molecular mass, the peak mass value was 16.75 
kDa, corresponding to hexamers. When compared with the calculated molecular 
weights for the TM1 hexamer (17.72 kDa), the experimental value agreed to 
within 5.5% of the theoretical values.  
Although the higher speed AUC-SV data was in agreement with our results 
collected at lower speed, AUC did not detect the smaller species (trimer), which 
was observed previously by SDS-PAGE analysis (Figure 3.13). However, the 
absence of hexameric or higher order species on the cross-linking SDS-PAGE 
and the presence of SDS-stable trimers in the uncross-linked samples suggest 
that the hexamers detected with AUC-SV analyses are most likely dimers of 
trimers. 
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Figure 3.14 - Analytical ultracentrifugation analysis of rCPT1A TM1 synthetic 
peptide in DPC detergent solution. Sedimentation velocity data were obtained for TM1 
peptide dissolved in buffer containing 15 mM DPC and 52.5% D2O. (a) Residuals of the 
fitting process for samples containing 63 µM peptide. (b) Sedimentation coefficient 
distribution profiles for the peptide as calculated using the SEDFIT program.  
 
3.4.4 The order of rCPT1A TM2 peptide oligomerisation 
Similar to rCPT1A TM1, after significant homo-oligomerisation behaviour was 
observed for the rCPT1A TM2 domain using in vivo assays (see in § 3.3.2), 
further experiments were carried out to identify the order of TM2 oligomerisation. 
As before, cross-linking with BS3 was initially used to assess the oligomeric state 
of the rCPT1A TM2 synthetic peptide (K102-R123, 2689 Da) dissolved in DPC 
micelles, and cross-linked species were visualized by SDS-PAGE analysis.  
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Figure 3.15 - SDS-PAGE analysis of chemically cross-linked rCPT1A TM2 peptide 
oligomerisation in different detergent micelles (DPC, OG, LPPG). Molecular weight 
marker is shown in the first left-hand lane. BS3-mediated cross-linking of peptides were 
dissolved in DPC, OG and LPPG micelles. Cross-linking reactions were carried out in 
each detergent micelles at various micelle to peptide concentration ratios as indicated 
below each lane. Protein bands were visualized by staining with silver nitrate. Oligomeric 
states (e.g. trimer indicated by n=3) are shown at the far right of the gels.  
 
The data shown in Figure 3.15 indicates that the TM2 peptide migrates primarily 
as monomers (2.69 kDa), and hexamers (16.1 kDa) after cross-linking. In 
addition to these species, small concentrations of dimer, trimer and dodecamer 
species are also observed. In OG micelles, the peptide forms aggregates which 
sit in the wells, explaining the high β-sheet content (Figure 3.11) of the peptide 
CD spectra in this detergent. In LPPG micelles, the peptide is found to form 
predominantly monomers. For this reason, in further experiments throughout this 
work peptides were dissolved in DPC micelles when studied with the different 
techniques. 
To test the reproducibility of the above results, and to investigate the effect of 
detergent concentration on the rCPT1A TM2 oligomeric states, the cross-linking 
reactions were carried out using M:P=1/3-20, DPC micelle to peptide ratios and 
M:P=4 SDS micelle to peptide ratio.  
The cross-linking reaction samples (Figure 3.16 b) at 1/2 and 1/3 M:P ratios 
were overloaded on the gel however bands correspond to hexamer and 
dodecamer were detected as well as in M:P=1. No bands corresponding to lower-
order oligomeric states (e.g. trimer) or monomer were evident in these lanes. As 
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the M:P ratio was increased to a value of 2, a monomer band could be observed 
(2.69 kDa) as well as weak bands corresponding to dimer (5.38 kDa) and trimer 
(8.07 kDa). Further increases in the M:P ratio resulted in increasing amounts of 
monomeric, dimeric and trimeric species, accompanied by decreasing 
populations of hexamers and dodecamers. The results shown in Figure 3.16 b 
demonstrate that the oligomeric states of the TM2 peptide differ with increasing 
detergent concentrations. The rapid loss of the dodecamer of TM2 with 
increasing M:P ratios suggests that this is the least stable species. The hexamer 
is evidently more stable, as its presence can be detected at all M:P ratios studied, 
although the concentration of hexamer is greatly reduced at M:P > 5. The 
oligomeric species that are most stable at the highest M:P ratios are the dimer 
and trimer. These two species (together with the monomer) steadily increased in 
concentration at high M:P ratios.  
As a negative control, cross-linking was carried out with the peptide dissolved in 
SDS; as expected (Fisher et al., 2003), only a band corresponding to the 
monomer was observed (Figure 3.16 b). TM2 peptide samples were also 
analysed in the absence of cross-linker on SDS-PAGE. At the lowest M:P ratios, 
SDS-stable hexamers and dodecamers are clearly detected (Figure 3.16 c). 
However, as the micelle concentration is increased, the high-order oligomers are 
rapidly destabilized and cannot be detected at M:P ratios above 3 (as shown in 
Figure 3.16 c). These results suggest an SDS-stable interaction (at least at low 
M:P ratios), and validate specificity of BS3 cross-linking reaction. 
To confirm the oligomeric state(s) of the rCPT1A TM2 peptide in the absence of a 
cross-linker, analytical ultracentrifugation studies were carried out. Here a speed 
of 40,000 rpm was sufficient to generate data with the required mass resolution 
for the analysis of the oligomeric state of the TM2 peptide. Two peptide 
concentrations were analyzed, 62 µM (M:P ~ 4) and 142 µM (M:P ~ 1), in 
buffered DPC solution. The fitting residuals for both concentrations are shown in 
Figure 3.17 a-b (sedimentation profiles not shown), corresponding to fits with 
RMSD values of 4.9×10-3 and 6.5×10-3, respectively. The sedimentation 
coefficient profile for the higher of the two concentrations (Figure 3.17 c) 
contained two species centered at S=0.747 and S=1.15.  
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Figure 3.16 - SDS-PAGE analysis of chemically cross-linked rCPT1A TM2 peptide 
oligomerisation in DPC. (a) Molecular weight marker is shown in the first left-hand lane. 
Peptide dissolved in SDS and visualised by comassie staining. (b) BS3-mediated 
cross-linking of peptides were dissolved in DPC micelles. Cross-linking reactions were 
carried out in DPC detergent micelles at various micelle to peptide concentration ratios as 
indicated below each lane. Protein bands were visualized by staining with silver nitrate. 
Oligomeric states (e.g. trimer indicated by n=3) are indicated at the far right of the gels. 
(c) rCPT1A TM2 peptide in the absence of a crosslinker. 
 
Conversion of sedimentation coefficients to molecular mass yielded one peak at 
low peptide concentration, with a mass value of 16.3 kDa (hexamer), and two 
peaks at high peptide concentration, with mass values of 16.13 kDa and 30.85 
kDa (corresponding to hexamer and dodecamer, respectively). When compared 
with the calculated molecular weights for the TM2 hexamer (16.1 kDa) and 
dodecamer (32.2 kDa), the experimental values agreed to within 4% of the 
theoretical values. This result agrees with the cross-linking results shown in 
Figure 3.16 where, at M:P=1, only hexamers and dodecamers were present. At 
the lower concentration of peptide (M:P ratio ~ 4), the resulting sedimentation 
coefficient profile contained a single species centered at S=0.787, corresponding 
to a molecular mass for the TM2 peptide of 16.3 kDa, i.e. within 2% of the 
theoretical molecular weight of the hexamer (16.1 kDa). These data are in 
accordance with the results obtained after cross-linking at M:P ratios of 3 and 5. 
Within the range of these M:P ratios, the concentration of cross-linked 
dodecamer decreased significantly, while the hexamer remained detectable. 
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Figure 3.17 - Analytical ultracentrifugation analysis of rCPT1A TM2 derived peptide 
in DPC detergent solution. Sedimentation velocity data were obtained for TM2 peptide 
dissolved in buffer containing 15 mM DPC and 52.5% D2O. Residuals of the fitting 
process for samples containing (a) 62 µM peptide and (b) 142 µM TM2 peptide. (c) 
Sedimentation coefficient distribution profiles for the peptide at concentrations of 62 µM 
(open circles) and 142 µM (closed circles) as calculated using the SEDFIT program.  
 
Fitting of the data described above produced a frictional ratio of 1.88, suggesting 
a slightly elongated ellipsoidal shape for the hexamer as would be expected for a 
bundle of TM α-helices. Therefore, the SV data suggest that the TM2 peptide in 
DPC detergent solution exists as an equilibrium mixture of hexamers and 
dodecamers at the concentrations studied. The dodecamer species, which was 
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also detected in the cross-linking experiments, is present only at low M:P 
concentration ratios. 
3.5 In silico models of rCPT1A TM oligomerisation 
For further insight into the structural features of rCPT1A TM domains that may 
have a role in stabilising the observed oligomers, computational models were 
produced using the program ‘CNS searching of helix interactions’ (CHI), 
described in detail in § 2.6.4. 
3.5.1 Modelling TM1 homo-oligomerisation 
As previously discussed, the rCPT1A TM1 sequence contains several conserved 
motifs (Figure 3.2) that could support inter helical interactions. The helical wheel 
representation of the TM domain sequence (K47-M73) in Figure 3.18 a-b also 
indicates that GxxxG, Ser and Leu-Val-Ile motifs are present on the same helical 
interface. 
Chemical cross-linking and AUC suggest that the 27 residue TM1 peptide 
primarily forms trimers in DPC and SDS micelles, while TOXCAT data also 
suggest that a shorter sequence of TM1, composed of only 16 amino acids, can 
also support strong self-association. Therefore, both the 27 (K47-M73) and 16 (T52-
V67) TM1 residues were initially used to create dimer models in the program CHI 
to explore helix-helix interactions in the simplest possible model.  
Full dimer searches were performed using the TM1 (K47-M73) sequence, and the 
results were clustered into 15 clusters with RMSD < 1.4 Å and a cluster size > 7, 
yielding two symmetric left-handed structures and one right-handed structure. In 
Figure 3.18 c, a model of a left-handed TM1 homo-dimer is shown where well-
known helix interaction motifs pack at the helix-helix interface of the dimer. The 
G49 and G53 residues make up a GxxxG motif, bringing the top (N-termini) of the 
helices into close contact. The two Pro residues (P56 and P59), known to disrupt 
the α-helical structure and form kinks (von Heijne, 1991; Nilsson et al., 1998; 
Orzaez et al., 2004), could explain the high β-sheet content of the TM1 peptide 
as indicated by the CD spectra (Figure 3.10). The Ser residues form interhelical 
hydrogen bonds (assigned in this case since the donor and acceptor were within 
2.1 Å of one another) in the middle of the TM sequence. Finally, Leu63-Val67-Ile70 
residues were also found to support the self association of the modelled TM1 
CHAPTER 3 – HOMO-OLIGOMERISATION OF CPT1A TM DOMAINS 
68 
helices by close packing at the bottom (C-termini) of the sequence. In addition, 
the CHI model of TM1 16 (T52-V67) proposed the possible role of an interhelical 
Ser hydrogen bond in the 16 residue chimera observed in vivo (see in § 3.3.2). 
As before, full dimer searches were performed using the TM1 (T52-V67) sequence, 
and the results were clustered into 18 clusters with RMSD < 1.2 Å and cluster 
size > 8, yielding two symmetric left-handed structures and one right-handed 
structure. 
The 27 amino acid TM1 (K47-M73) sequence was also used to initiate a 
symmetrical trimer search to study the synthetic peptide oligomerisation 
behaviour observed using cross-linking and AUC (see in § 3.4.3) in silico. The 
symmetric trimer searches were performed using the TM1 (K47-M73) sequence, 
and the results were clustered into 6 clusters with RMSD < 1.5 Å and cluster size 
> 4, yielding two symmetric left-handed structures and four symmetric right-
handed structures. The trimer model (cluster 1, left-handed, Figure 3.18 e), was 
selected because it contains well-known interaction motifs packing on the 
interface of the sequence. The structure suggests that the motifs packing against 
neighbouring helices are similar to those observed in the dimer model, promoting 
formation of a plausible left-handed helical bundle. In the trimer model, the Ser 
residues also form interhelical hydrogen bonds, in this case the donor and 
acceptor distances were within 2.2-4.1 Å of one another. 
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Figure 3.18 - Molecular models of rCPT1A TM1 oligomerisation.  
(a) Amino acid sequence of rCPT1A TM1 domain (Lys47-Met73). (b) Helical wheel 
representation of the TM1 domain, where colour coded residues found on the same 
interface of the helix suggest well known helix interaction motifs. (c) CHI model of a 27 
amino acid (K47-M73) left-handed, symmetrical dimer. (d) CHI model of 16 amino acid 
(T52-V67) left-handed, symmetrical dimer. (e) CHI model of the K47-M73 trimer sequence 
(left-handed, symmetrical helical structure). In (c)-(e), individual helices are represented 
as grey ribbon cartoons and residues are labelled as follows: G49 and G53, highlighted as 
blue spheres, S60 as stick coloured by elements, L63 in grey, V67 in green, and I70 in yellow 
spheres. 
 
3.5.2 Modelling TM2 homo-oligomerisation 
CHI searches were performed on either three or six parallel α-helices containing 
the predicted sequence of TM2 to gain insight into the structural features that 
may have a role in stabilizing both the trimeric and hexameric forms of the 
synthetic peptide (see § 3.4.4). The trimer models suggest that the TM domain 
can form chemically plausible right- and left-handed coiled-coils. However, in the 
all of the trimer models obtained (Figure 3.19), the interaction interface contains 
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either a GxxxG motif (G107, G111) or a GxxxA motif (G113, A117), respectively. Both 
of these motifs are highly conserved in TM2 domains of the CPT1A isoform 
across all mammalian species (Figure 3.2), and are known to stabilize TM helix-
helix interactions in several other membrane proteins (see § 3.2.1). The in silico 
models of the trimer of rCPT1A TM2 also suggest that this oligomer is capable of 
being stabilized by the interhelical hydrogen bonding of Thr112 (Figure 3.19 c). In 
the present analyses, hydrogen bonds were assigned whenever a hydrogen 
bond donor and acceptor were within 3 Å of one another. 
 
Figure 3.19 - Molecular models of rCPT1A TM2 trimers and hexamers. 
(a) The amino acid sequence of rCPT1A TM2 (Lys102-Arg123) (b) Orientation of the GxxxG 
and GxxxA motifs relative to each other on a helical wheel (left panel) and in a canonical 
α-helix (built using CHI) containing residues K102-R123 of TM2. Both models predict that 
the relative angle between the two motifs corresponds closely to the apex angles of a 
hexamer (120°). Also highlighted is the apex angle in a trimer (60°), which cannot 
accommodate both motifs. (c) Side view of a right-handed TM2 trimer, in which individual 
helices are represented as ribbons. In this model, the trimer is stabilized by packing of the 
GxxxG motifs (G107, G111, shown in yellow) against sidechains from an adjacent helix, as 
well as interhelical hydrogen bonding of Thr112 (shown in red, bond representation) at the 
centre of the bundle. (d) Model of a left-handed trimer in which the GxxxA motif (G113, 
A117, shown in dark blue) packs against the adjacent helix; while the GxxxG motif is 
predicted to be on the outside of the bundle. (e) Top-down view of the left-handed TM2 
hexamer. (f) Side view of the left-handed TM2 hexamer, showing the simultaneous 
packing of both the GxxxG (yellow) and GxxxA (dark blue) motifs against adjacent TM 
helices. The hexamer is the only observed oligomeric state for which it is predicted that 
both of these oligomer-favouring TM-domain motifs are used to stabilise the quaternary 
structure of the peptide. 
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The modelling of the TM2 hexamer (Figure 3.19 e-f) suggests that TM2 can form 
a plausible left-handed helical bundle (no right-handed solutions were found) in 
which both the GxxxG and the GxxxA motifs pack against neighbouring helices. 
In this way, the stabilizing effects of both motifs can be exploited simultaneously 
through interactions with adjacent helices. This is possible only in a hexameric 
arrangement, which has apex angles of 120° - the predicted angle between the 
two motifs (G107xxxG111 and G113xxxA117) in the α-helical model of TM2 (depicted 
in Figure 3.19 b). Such simultaneous packing of the two motifs is not possible in 
the trimer, as the angle between the two motifs is such that they can never both 
pack at once (apex angles = 60o), resulting in exclusion of one motif from 
interfacial interactions with the other two helices.  
3.6 Summary 
The lack of a detailed crystal structure for CPT1A proteins and the unknown role 
of the TM domains in the observed kinetic characteristics and protein complex 
formation has meant that this system provides an interesting problem to study. 
Therefore, within this project one of the main aims was to characterise and 
quantify the oligomerisation propensities of TM1 and TM2 in isolation. Using the 
TOXCAT and GALLEX biological assays, we have explored their oligomerisation 
in vivo (§ 3.3). Furthermore in vitro biophysical analyses (§ 3.4) performed on TM 
synthetic peptides corresponding to TM1 and TM2 not only quantified the order of 
oligomerisation, but also indicated the possible correspondence between the 
oligomerisation behaviour of rCPT1A in vivo (Faye et al., 2007). Finally, in silico 
modelling of TM segments highlighted the GxxxG motif (and variants) and other 
well-known interaction motifs may be important in stabilizing the observed 
oligomers of CPT1A TM domains as shown in Figure 3.2, Figure 3.18 and 
Figure 3.19 (§ 3.5). 
By studying different lengths of rCPT1A TM domain sequences, we further 
validate the previously observed behaviour of the TOXCAT and GALLEX assays, 
in which the association of chimeras could depend on the length of the TM 
sequence. The results of the quantitative CAT assays with the shorter length of 
ToxR-rCPT1A TM-MBP or wtLexA-rCPT1A TM-MBP chimeras strongly indicates 
that the length of the TM spanning region needs to be optimised when using 
these assays. Changes in CAT and β-galactosidase activities, measured for 
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rCPT1A TM chimeras suggest significant homo-oligomerisation of both rCPT1A 
TM1 and TM2 domains. 
For the first time this work quantified the homo-oligomerisation of both rCPT1A 
TM domains. The synthetic peptide of TM1 was found to form trimer species in 
DPC micelles when cross-linked and hexamers (possibly dimer of trimers) when 
analyzed by AUC-SV. When the TM2 peptide was dissolved in DPC micelles and 
cross-linked with BS3, oligomers corresponding to the hexamer were observed, 
suggesting that the TM2 sequence has inherent primary and secondary structural 
properties that favour hexamerisation. These results were supported by the AUC-
SV experiments, when the TM2 peptide was found to sediment according to the 
size of the hexamer in the absence of cross-linker. The fact that the hexamer also 
appears to be a favoured oligomeric state in vivo (Faye et al., 2007), suggests 
that these interactions are also important in the context of the full-length protein 
when this is stabilised within a lipid bilayer. This finding points to an interesting 
correlation between the oligomerisation behaviour of rCPT1A TM2 and that of the 
full-length protein and further, possibly supporting the hypothesis that rCPT1A 
oligomerisation may be initiated and/or regulated by its TM domain. The 
molecular modelling results also support the trimer and hexamer formation of 
TM2 and suggest the GxxxG(A) motifs role in developing these oligomeric 
structures. 
Although the observed homo-oligomerisation described above suggests the 
possibility of a potential role of both rCPT1A TM domains in assembly of the full-
length protein, the results obtained for TM2 were most consistent between the 
various techniques used. This consistency provided a strong foundation to further 
study the sequence dependent oligomerisation CPT1A TM2, as presented in the 
following CHAPTER 4. 
Finally, it is important to note the reason for discrepancy between data presented 
in this chapter and in (Jenei et al., 2009) about rCPT1A TM1 oligomerisation 
(paper attached at the end of this thesis). The chimeras of 18 and 16 residues 
long TM1 peptides were re-cloned and re-measured in TOXCAT assay after 
further CPT1A TM1 peptide studies raised the possibility of oligomerisation. Also, 
when the homo-oligomerisation of TM1 was measured using the GALLEX assay, 
the results also indicated the ability of TM1 oligomerisation. 
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CHAPTER 4 
 
 
 
4. THE ROLE OF SEQUENCE MOTIFS 
IN CPT1A TM2 OLIGOMERISATION 
 
Here the implications of mutagenesis strategies coupled with in vivo and in 
vitro biophysical methods are discussed on investigating sequence-
dependent homo-oligomerisation of rCPT1A TM2. The results suggest a key 
role of GxxxG(A) motifs in stabilizing TM2 hexamers.  
 
 
4.1 Introduction 
Carnitine palmitoyltransferase 1A (CPT1A) is the key regulatory enzyme of fatty 
acid metabolism, since it catalyses the conversion of long chain acyl-CoA to 
acylcarnitine, and transports acyl-CoA from the cytosol into the mitochondrial 
matrix (§ 1.3.1, Figure 1.6). Its sensitivity to its inhibitor, malonyl-CoA, is 
modulated by intramolecular interactions, which depend on the properties of the 
mitochondrial outer membrane, such as fluidity (Kolodziej and Zammit, 1990) and 
lipid composition when altered by dietary lipids, fasting, and diabetes (Zammit et 
al., 1998). The modulation of CPT1A sensitivity to malonyl-CoA is crucial in the 
hepatic response to dietary fat intake, obesity, fasting and diabetes (Zammit, 
1999), and implies that CPT1A has a high degree of molecular plasticity (adopts 
a “flexible” structure). From these observations, it has been proposed that 
membrane-sensitive TM-TM interactions are central to CPT1A function. 
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Furthermore, a recent study suggests that the TM-domains, and specifically TM2, 
also drive the oligomerisation of CPT1A (Faye et al., 2007). Thus, it was shown 
that full-length rCPT1A forms oligomeric complexes and the fundamental 
oligomeric unit was suggested to be a trimer, which associates into a dimer of 
trimers to yield hexamers. The protein-protein interactions that stabilize these 
complexes were narrowed down to a 51 amino acid stretch of CPT1A (residues 
97-147) that includes TM2. When expressed as a fusion protein with 
dihydrofolate reductase (DHFR), this region induced the formation of hexamers 
(Faye et al., 2007).  
As discussed in CHAPTER 3, the formation of trimers and hexamers by rCPT1A 
was further traced to a group of 22 residues thought to comprise TM2 (Lys102-
Arg123), which also form stable trimers and hexamers when studied in vivo and in 
vitro (Jenei et al., 2009). In this same study, molecular modelling results 
suggested that interaction of GxxxG(A) sequence motifs (see in § 3.5.2), might 
play a role in stabilizing hexamer and trimer formation. TM2 contains two such 
motifs (Gly107xxxGly111 and Gly113xxxAla117), which are highly conserved among 
species (see in § 3.2.1, Figure 3.2). Molecular models also suggested that the 
polar Thr112, located in the transmembrane domain, may also play a role in 
stabilizing rCPT1A TM2 homo-trimers by interhelical hydrogen bonding. Motifs 
containing Thr residues have been discussed previously in (§ 1.2.2). These 
observations point toward an important role for the TM2 domain in the oligomeric 
assembly of rCPT1A, and raise the question of whether there is any sequence 
specificity in TM2 oligomer formation. 
Hence, the aim of the work presented in the current chapter is to examine the 
role of GxxxG(A) motifs and a Thr residue in the oligomerisation of rCPT1A TM2 
using mutagenesis strategies coupled with in vivo and in vitro biophysical 
methods. In order to investigate sequence-dependent self-association, we 
designed single and double mutants of the conserved GxxxG and GxxxA motifs, 
as well as of the Thr112 residue, and measured TM helix-helix interactions using 
the TOXCAT assay. These data were compared to TOXCAT data collected 
previously for the wild-type rCPT1A TM2 domain. Synthetic peptides 
corresponding to highly disruptive single (G107I) and double (G107IG113I) point 
mutants were also studied, and confirmed the key role of GxxxG(A) motifs in 
stabilizing TM2 hexamers.  
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4.2 Sequence specific self-association in vivo 
In order to experimentally validate our previously reported model (obtained from 
molecular dynamics simulations) predicting that GxxxG and GxxxA motifs work 
together to stabilize the rCPT1A TM2 hexamer, systematic mutation of these 
motifs was carried out. The self-association of point mutant TM domains was 
measured using the TOXCAT assay, described in detail in § 2.2. Single and 
double point mutations of Gly or Ala to Ile were introduced in place of Gly107, 
Gly111, Gly113 and Ala117 within the rCPT1A TM2 sequence (as detailed in 
§ 2.1.3.4). The resulting CAT activity for each mutant is shown in Figure 4.1, 
alongside the value obtained for the 16 amino acid sequence of wild-type 
rCPT1A TM2 (wt TM2).  
 
 
Figure 4.1 - Oligomerisation of rCPT1A TM2 (16 amino acids in length) and various 
GxxxG(A) mutants in TOXCAT chimeras in E. coli membranes. (a) Sequences of wt 
and point mutants rCPT1A TM2 analyzed using the TOXCAT assay. (b) CAT activities 
obtained in TOXCAT relative to wt rCPT1A TM2. Values are means (+/- standard 
deviation) for three or more independent measurements. (c) malE complementation to 
test the wild type and mutant ToxR-TM2-MBP chimera's correct insertion and orientation. 
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Here the positive (GpA) and negative (G83I) controls are absent in order to 
compare the self-association of the various mutants more directly with that 
observed for wt TM2 (which were previously compared to these controls in 
§ 3.3.2, Figure 3.6). 
All of the single point mutants showed a marked decrease in self-association (as 
indicated by CAT activity) from wild-type levels. These single point mutants were 
found to have the most destabilizing effect on rCPT1A TM2 oligomerisation, with 
the G107I, G113I and A117I mutants producing an approximately 60% reduction in 
CAT activity relative to the wild-type sequence. Surprisingly, the double mutants 
(G107IG111I and G107IG113I) had a less significant effect on homo-oligomerisation, 
producing at most a ~20-30% reduction in CAT relative to the wild-type levels 
(Figure 4.1). This at first seems counter-intuitive, however previous experimental 
and computational results suggest that TM2 trimers may be stabilised by a single 
GxxxG(A) motif, whereas hexamers may require both motifs (§ 3.5.2) (Jenei et 
al., 2009). Therefore, one explanation may be that the single mutants tested here 
may represent destabilized hexamers while the G107I G111I and G113I A117I 
mutants may form stable trimers which interact via the remaining unmutated 
GxxxG or GxxxA motifs (for visual clarification see Figure 4.13).  
In addition, the complete substitution of all four residues in the GxxxG(A) motifs 
with Ile was also carried out, to create the G107I G111I G113I A117I (4xI) mutant. 
Surprisingly, this mutant produces CAT activities similar to that obtained for wild-
type rCPT1A TM2. It is important to note that creation of the 4×I mutant resulted 
in a TM domain sequence where over 50% of the residues are Ile, Leu, or Val, 
residues that can stabilize helix-helix interactions by packing in a “leucine zipper” 
or heptad repeat motif (Gurezka et al., 1999). Specifically, a potential heptad 
motif is created in the sequence by residues IxxIxxxIxILxxIxI, placing Ile and Leu 
residues at the a and d positions of the heptad motif (see in § 1.2.2). Because we 
have created this motif by extensive mutation of the sequence, the resulting CAT 
activities are difficult to interpret in comparison with wt TM2 interaction. 
We also could not rule out the possibility that, as well as changes in oligomeric 
state (which are undetectable in TOXCAT), other motifs may also participate in 
helix-helix interactions. One residue of interest in TM2 was Thr112, especially in 
the interpretation of the G107I G113I mutant where both GxxxG(A) motifs were 
disturbed, yet significant self-association was observed. To test whether the Thr 
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residue could stabilise TM2 self-association through formation of interhelical H-
bonds, further TOXCAT experiments were carried out. 
 
 
Figure 4.2 - Oligomerisation of rCPT1A TM2 (16 amino acids in length) and its 
GxxxG(A)-Thr mutants using the TOXCAT assay in E. coli membranes. (a) 
Sequences of wt and point mutants of rCPT1A TM2 analyzed in TOXCAT assay. (b) CAT 
activities obtained in TOXCAT relative to wt rCPT1A TM2. Values are means (+/- 
standard deviation) for three or more independent measurements. (c) malE 
complementation to test the wild type and mutant ToxR-TM2-MBP chimera's correct 
insertion and orientation.  
 
To study the possible role of Thr in rCPT1A TM2 oligomerisation, Thr112 was 
mutated to Ala in the wild-type TM2 domain (T112A) and self-association was 
again measured using the TOXCAT assay. The resulting CAT activity of this 
mutant is shown in Figure 4.2, and demonstrates that this residue on its own 
does not have a large effect on oligomerisation when both GxxxG(A) motifs are 
intact. However, when both GxxxG(A) motifs are disrupted, as they are in the 
G107IG113I mutant, further mutation of Thr to Ala (to create the G107I G113I T112A 
mutant) results in a considerable decrease in self-association to ~30% of wild-
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type levels. This suggests that, in the context of the G107IG113I mutant sequence, 
Thr now contributes considerably to self-association. However, this contribution is 
unlikely to be entirely due to H-bond formation as replacing T112 with Val (G107I 
G113I T112V, (Figure 4.2)) restores some CAT activity relative to the G107I G113I 
T112A mutant.  
As discussed above, with the 4xI sequence mutation heptad repeat motif was 
created. The observed homo-oligomerisation of this sequence can also be 
stabilised by H-bond formation of the Thr112 residue. The data given in Figure 4.2 
also summarises mutagenesis strategies designed to test the effect of Thr112 
mutation in the 4xI sequence. It is again important to see that mutation of 5 
residues in a 16 amino acid sequence resulted a 31% different sequence and the 
CAT activities are difficult to interpret in comparison with wt TM2 interaction. 
However, it is interesting to note when 4xI was mutated jointly with Thr112, the 
4xIT112A, 4xIT112V mutants yielded signals 90% smaller than wt TM2 or 4xI.  
From the TOXCAT data presented in Figure 4.1 and Figure 4.2, we can see that 
mutation of the GxxxG and GxxxA motifs in rCPT1A TM2 can result in a reduced 
self-association of this sequence. Furthermore, in certain sequence contexts (but 
not independently), mutation of Thr112 can also destabilise helix-helix interactions, 
suggesting this residue may also play a role in TM2 oligomer formation. These 
results are complicated by the fact that the TOXCAT assay cannot report on 
changes in oligomeric state, and an understanding of the oligomeric state is 
critical to elucidation of the role of key motifs. For this reason, further research 
was focused on the GxxxG(A) motifs role in wt TM2 oligomerisation by selecting 
mutants that not only have a minimal change in the sequence while yielding large 
effects on self-association in the TOXCAT assay, but also can be employed to 
systematically study the effect of both GxxxG and GxxxA motifs on 
oligomerisation. Therefore, the G107I and G107IG113I mutants were further studied 
in vitro in order to quantitatively determine their oligomeric state.  
4.3 GxxxG(A) driven oligomerisation of rCPT1A TM2  
The in vivo oligomerisation study suggested that mutation of conserved 
GxxxG(A) motifs destabilises homo-oligomerisation of the second 
transmembrane domain in rCPT1A. In light of this result, synthetic peptides were 
used to more directly examine the possible differences in oligomerisation caused 
by mutation of these motifs. As described in CHAPTER 3, the oligomerisation of 
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the purified mutant peptides was studied by cross-linking and AUC. Molecular 
modelling was also used to help interpret the oligomerisation behaviour. 
4.3.1 Purification of mutant peptides 
The crude peptides were purified by RP-HPLC using a linear acetonitrile gradient 
with 0.1% trifluoroacetic acid as detailed in § 2.4. The HPLC fractions were 
analysed for the presence of pure peptide using ESI-MS, and fractions containing 
the pure peptide of interest were pooled for further analysis. The major species 
detected by ESI-MS are shown in Figure 4.3 and Figure 4.4. In Figure 4.3, the 
major peak corresponded to pure G107I peptide (2745 Da), with an additional 
peak corresponding to sodium adducts (2790 Da). The G107IG113I peptide was 
detected at 2802 Da, with an additional peak corresponding to sodium adducts 
(2847 Da) as shown in Figure 4.4. Sodium adducts have previously been 
observed in the purification of TM peptides (Rijkers et al., 2005). The minor peak 
at ~2700 Da in this spectrum is likely a truncated peptide that co-purified with the 
major product.  
4.3.2 Secondary structure of mutant peptides  
To determine the secondary structure of the G107I and G107IG113I peptides in 
detergent micelles, CD spectra were collected. The spectra were recorded for 
peptides solubilised in buffer containing SDS (at a M:P ratio of 3:1) and DPC 
detergent at different M:P ratios ranging from 2:1 to 20:1 (for details see § 2.5.3). 
Fitting of the data between 190 nm and 260 nm using the CDSSTR software 
(Johnson, 1999) indicates that the G107I peptide is predominantly α-helical in DPC 
at a 20:1 M:P ratio and in SDS at a 3:1 ratio. Similar to the previously discussed 
peptides (§ 3.4.2), here the α-helical content of the peptide also depends on the 
micelle to peptide ratio. In the samples with M:P=2:1, 4:1 and 10:1, aggregation 
of the hydrophobic peptide decreases the α-helical content. This is especially true 
in samples with M:P=2:1 and 4:1, where the β-sheet content is higher than in any 
other sample.  
Table 4.1 - The amino acid sequences of rCPT1A TM2 G107 and G107G113 synthetic 
peptides used in this study. Non-native lysine residues are shown in bold. 
TM domain of 
interest 
Synthetic peptide sequence 
Molecular 
weight (Da) 
rCPT1A TM2 G107I COCH3-KKNIVSIVLFGTGLWVAVIMTMRK-CONH2 2745 
rCPT1A TM2 
G107G113I 
COCH3-KKNIVSIVLFGTILWVAVIMTMRK-CONH2 2804 
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Figure 4.3 - Analysis of purified rCPT1A TM2 G107I peptide by electrospray 
ionisation mass spectrometry (ESI-MS). The HPLC fractions containing the pure 
peptide were pooled and analyzed using ESI-MS (Bruker MicroTOF). In the deconvoluted 
spectrum, the major peak corresponds to the rCPT1A TM2 G107I peptide (2745 Da), and 
additional peaks correspond to sodium and solvent adducts. 
 
 
Figure 4.4 - Analysis of purified rCPT1A TM2 G107IG113I peptide by electrospray 
ionisation mass spectrometry (ESI-MS). The HPLC fractions containing the pure 
peptide were pooled and analyzed using ESI-MS (Bruker MicroTOF). In the deconvoluted 
spectrum, the major peak corresponds to the rCPT1A TM2 G107I G113I peptide (2802 Da), 
and additional peaks correspond to sodium and solvent adducts. 
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Figure 4.5 - The effect of DPC micelle concentration on the secondary structure of 
the rCPT1A TM2 G107I peptide. (a) CD spectra measured at different detergent micelle 
to peptide ratios, plotted in units of mean residue ellipticity (MRE). (b) High tension (HT) 
over the wavelength region specified in (a). (c) The secondary structure composition of 
the rCPT1A TM2 G107I peptide estimated from the CD spectra shown in (a) using the 
CDSSTR software (Johnson, 1999). 
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Figure 4.6 - The effect of DPC micelle concentration on the secondary structure of 
the rCPT1A TM2 G107IG113I peptide. (a) CD spectra measured at different detergent 
micelle to peptide ratios, plotted in units of mean residue ellipticity (MRE). (b) High 
tension (HT) over the wavelength region specified in (a). (c) The secondary structure 
composition of the rCPT1A TM2 G107I G113I peptide estimated from the CD spectra shown 
in (a) using the CDSSTR software (Johnson, 1999). 
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The CD spectra of the G107IG113I peptide at all concentrations of DPC displayed 
the negative minima at 208 and 222 nm characteristic of an α-helical secondary 
structure. These features can be seen in the spectrum collected in SDS. The data 
indicate that the peptide does have a largely α-helical secondary structure in 
DPC detergent micelles. Additionally, the signal was not very accurate below 195 
nm due to light scattering of the sample, therefore data were fit between 200 and 
240 nm to calculate secondary structure content. 
4.3.3 Oligomeric state of G107I mutant peptide 
To compare the oligomeric states achieved by the G107I and G107IG113I mutant 
peptides to that of the wild-type TM2 peptide, chemical cross-linking was initially 
used. Similar to our previous experiments (§ 3.4.4), the mutant peptides were 
dissolved in different concentrations of DPC micelles and subsequently cross-
linked with the amine-reactive cross-linker, BS3. The different oligomeric species 
were detected on SDS-PAGE and visualized by staining with silver nitrate. 
Cross-linking of the G107I peptide resulted in one main band migrating at 
approximately the molecular mass of the trimeric species (MW ~8.23 kDa; 
between the 6-14 kDa molecular weight markers). In addition, at low detergent 
concentrations a second band was observed migrating at the approximate 
molecular mass of the pentamer/hexamer (~13.73 kDa; between molecular 
marker 14-17 kDa). Increasing the M:P ratio did not destabilize the trimer, but it 
destabilized the formation of higher oligomeric species, while the concentration of 
monomeric species was only increased slightly (Figure 4.7 a). The above 
oligomerisation pattern is also in agreement with the G107I peptide secondary 
structure composition. In the light of the secondary structure calculated from CD 
spectra (Figure 4.5), lanes of M:P>5 contain more helical peptide, while lanes 
where M:P<10 the peptide also form β-sheet (aggregation typically at M:P=1/3-
2). As shown in Figure 4.7 b, the un-cross-linked peptide samples at all micelle 
concentrations migrate mainly as monomers. In addition, a weak band at the 
approximate molecular weight of the pentamer species was also detected at low 
detergent concentrations (M:P=1/3-5). 
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Figure 4.7 - SDS-PAGE analyses of chemically cross-linked rCPT1A TM2 G107I 
peptide oligomers. (a) The molecular weight marker is shown in the left-hand lane. The 
BS3-mediated cross-linking of peptides dissolved in DPC micelles. Cross-linking reactions 
were carried out in DPC (or SDS, last lane M:P=4) detergent micelles at various M:P 
concentration ratios as indicated below each lane. (b) rCPT1A TM2 G107I peptide in the 
absence of crosslinker migrates mainly as monomer. In figure, protein bands were 
visualized by staining with silver nitrate. Oligomeric states (e.g. trimer indicated by n=3) 
are indicated at the far right of the gels. 
 
To test the reproducibility of the above cross-linking experiment, and also to 
directly compare the oligomerisation of the single point mutant G107I peptide to 
the wt rCPT1A TM2 peptide, the cross-linked peptides were analysed on the 
same gel. The difference between the oligomeric species formed by the wt and 
G107I peptides at different DPC concentrations is clearly visible using SDS-PAGE 
(Figure 4.8). As previously discussed in § 3.4.4, wt rCPT1A TM2 forms 
predominantly hexamers and here the G107I peptide was observed to form 
predominantly trimeric species. 
This finding suggests that disrupting the first GxxxG motif results in 
destabilisation of the hexamer to form mostly trimers, but also a small proportion 
of pentamers. This result is in good agreement with our previously discussed 
model (§ 3.5.2), proposing that rCPT1A TM2 trimers could be stabilized by a 
single GxxxG(A) motif.  
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Figure 4.8 - SDS-PAGE visualisation of the cross-linked wt rCPT1A TM2 peptide 
side-by-side with the cross-linked G107I mutant peptide. A clear difference in the 
oligomerisation pattern is observed. 
 
To further study the oligomeric species formed by the G107I peptide, AUC 
experiments were carried out. AUC-SV data were collected at two different 
peptide concentrations, 49 and 98 µM (M:P ratio ~ 5 and 2.5), at 55,000 rpm and 
20°C (University of Oxford). Sedimentation profiles were fit using SEDFIT 
(Schuck, 2000) and the resulting sedimentation coefficient profile and fitting 
residuals are shown in Figure 4.9. Two species were detected in the fit data, with 
the major peak centered at S=0.46 and a minor peak centered at S=0.8. 
Conversion of the sedimentation coefficient to molecular mass, the peak at 
S=0.46 corresponds to a rCPT1A TM2 G107I peptide species with a molecular 
mass of 11.25 kDa (98 µM sample) and 9.8 kDa (49 µM sample), which most 
closely corresponds to tetramers. The calculated mass of a G107I tetramer is 
10.98 kDa, agreeing within 2.4% (98 µM) and 11% (49 µM) of the theoretical 
values. The minor peak at S=0.8 for both concentrations corresponds to octamer 
species with a molecular mass of ~ 22 kDa (probably dimer of tetramers). 
While from our cross-linking experiments we conclude the peptide forms mostly 
trimers, here we detected predominantly tetramer species during sedimentation 
of the sample. The discrepancy could be the result of the speed of the AUC-SV 
experiment, which resulted in error in the data analysis where smaller molecular 
species (monomer, trimer, pentamer) were not resolved.  
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Figure 4.9 - Analytical ultracentrifugation analysis of rCPT1A TM2 G107I synthetic 
peptide in DPC detergent solution. Sedimentation velocity data were obtained for TM2 
G107I peptide dissolved in buffer containing 15 mM DPC and 52.5% D2O. (a) Residuals of 
the fitting process for samples containing 49 and (b) 98 µM peptide. (c) Sedimentation 
coefficient distribution profiles for the peptide concentrations of 49 µM (open circles) and 
98 µM (closed circles) as calculated using the SEDFIT program.  
 
Taken together, both cross-linking and AUC experiments suggest the rCPT1A 
TM2 G107I peptide forms lower molecular weight oligomeric species than the wild-
type peptide in DPC micelles, and strongly support the possible role of the N-
terminal GxxxG motif in the previously observed TM2 oligomerisation. 
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4.3.4 Oligomeric state of the G107IG113I double mutant 
peptide 
To continue the examination a second point mutation was introduced within the 
peptide sequence in order to further investigate the role of both GxxxG(A) motifs 
in rCPT1A TM2 oligomerisation. This mutation created the sequence G107IG113I, 
where both motifs were disrupted by mutating their first glycine residues 
(G107xxxG and G113xxxA) to isoleucine. The oligomerisation of the resulting 
peptide (G107IG113I) was studied, in comparison with the wt rCPT1A TM2 peptide, 
using cross-linking and AUC analyses. 
The results for the double mutant (G107IG113I) peptide are shown in Figure 4.10 a, 
where a ladder of bands is observed after cross-linking. The strongest bands 
were initially assigned to monomer (n=1, MW=2.8 kDa), dimer (n=2, MW=5.6 
kDa), trimer (n=3, MW=8.4 kDa), and tetramer (n=4, MW=11.21 kDa) species. 
When the oligomerisation of the single G107I (lanes labelled s for single mutant) 
and double G107IG113I mutant (lanes labelled d for double mutant) peptides were 
directly compared with that of the wild-type TM2 (lanes labelled w) as shown in 
Figure 4.12, it is clear that the three peptides behave differently with respect to 
their oligomeric states. At low M:P ratios it is seen that, while the wild-type 
sequence forms primarily hexamers (as discussed previously in § 3.4.4 and in 
reference (Jenei et al., 2009)), the mutant peptides form smaller oligomers. At 
high M:P ratios, the wt peptide hexamer is destabilised and it exists mainly as 
monomer, with a small concentration of dimeric and trimeric species. In contrast, 
both mutant peptides still form stable trimers and the G107IG113I mutant also forms 
monomers and dimers whose populations increase at higher M:P ratios.  
These results reflect the possible role of GxxxG(A) motifs in stabilising the 
rCPT1A TM2 hexamer. When the G107xxxG111 or both the G107xxxG111 and 
G113xxxA117 motifs are absent, the sequence does not form hexamers at any of 
the M:P ratios studied. Furthermore, mutation of the G107xxxG111 motif in the G107I 
peptide resulted in formation of a very stable trimer at all detergent 
concentrations studied, suggesting that the G113xxxA motif is involved in 
stabilising the timer. Since the concentration of trimeric species for the double 
mutant peptide decreases at higher M:P ratios, we can say that trimers formed by 
the G107IG113I mutant peptide are not as stable as trimers formed by the single 
mutant sequence.  
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Figure 4.10 - SDS-PAGE analyses of chemically cross-linked rCPT1A TM2 G107IG113I 
peptide oligomerisation. (a) The molecular weight marker is shown in the left-hand 
lane. The BS3-mediated cross-linking of peptides dissolved in DPC micelles. 
Cross-linking reactions were carried out in DPC (or SDS, last lane M:P=4) detergent 
micelles at various M:P concentration ratios as indicated below each lane. (b) rCPT1A 
TM2 G107I peptide in the absence of crosslinker migrates mainly as monomer. In figure, 
protein bands were visualized by staining with silver nitrate. Oligomeric states (e.g. trimer 
indicated by n=3) are indicated at the far right of the gels. 
 
In addition, oligomerisation of G107IG113I peptide was also studied using AUC-SV. 
The experiment was carried out at 40,000 rpm, 25°C (Birmingham University), 
the peptide sample concentration was 112 µM (M:P ratio ~ 2.2). Fitting of the 
sedimentation velocity data resulted in a single peak at S=0.42 (Figure 4.11). 
Conversion of this sedimentation coefficient to molecular mass resulted in a 
G107IG113I peptide species with a mass of 7205 kDa. When compared with the 
calculated molecular weights for the dimer (5604 kDa) and trimer (8406 kDa), the 
experimental value agreed to within 12% and 14% of the theoretical values, 
respectively. This suggests that, in the AUC experiment, the peptide exists as a 
mixture of smaller molecular size oligomeric species (monomer, dimer, and 
trimer). This result agrees with the results of cross-linking Figure 4.12, where the 
monomer, dimer and trimer species of G107IG113I were detected in similar 
concentrations.  
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Figure 4.11 - Analytical ultracentrifugation analysis of a double mutant, rCPT1A 
TM2 G107I G113I synthetic peptide in DPC detergent solution. Sedimentation velocity 
data were obtained for TM2 G107I G113I peptide dissolved in buffer containing 15 mM DPC 
and 52.5% D2O. (a) Residuals of the fitting process for samples containing 112 µM 
peptide. (b) Sedimentation coefficient distribution profiles for the peptide as calculated 
using the SEDFIT program. 
 
These observations provide further evidence to support our hypothesis that 
formation of rCPT1A TM2 hexamers depends on the presence of GxxxG(A) 
motifs, and mutation of these motifs results in significant changes in the 
oligomeric states formed by the TM sequence. 
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Figure 4.12 - SDS-PAGE gel analyses of chemically cross-linked wild type rCPT1A 
TM2 (w) peptide and its point mutants G107I (s) and G107IG113I (d). BS
3-mediated 
cross-linking of peptides was carried out in DPC detergent micelles at various micelle to 
peptide concentration ratios as indicated below each lane. The molecular weight marker 
is shown in the far left-hand lane. Proteins were visualized by staining with silver nitrate. 
Oligomeric states (e.g. trimer indicated by n=3) are indicated at the far right of the gels. 
4.4 Modelling the sequence dependent oligomerisation  
As discussed above in sections § 4.3.3 and § 4.3.4, our experimental data 
(TOXCAT, cross-linking and AUC) suggest that mutation of GxxxG(A) interaction 
motifs within the rCPT1A TM2 peptide sequence changes its oligomerisation 
behaviour. Thus, molecular models of the primary oligomeric complexes formed 
by the mutant peptides (G107I trimers and G107IG113I dimers and trimers) were 
created using CHI (§ 2.6.4). 
In modelling the G107I trimer, symmetric trimer searches were performed for 
helices containing the rCPT1A TM2 G107I (K102-R123) sequence. The results were 
clustered into 7 structures with RMSD < 1.2 Å and a cluster size > 8. The 
interacting residues were analysed in all 7 structures, and typically two types of 
conformations were found. Similar to the previously (§ 3.5.2) discussed wt 
rCPT1A TM2 oligomerisation model (Figure 3.19), in the G107I trimer the 
interaction interfaces also contain either the mutated IxxxG motif (I107, G111) or a 
the GxxxA motif (G113, A117), respectively. The models shown in Figure 4.13 a-b 
provide further evidence that the G107I mutant TM2 sequence can form stable 
trimer complexes.  
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Figure 4.13 - Molecular models of rCPT1A TM2 mutants, G107I and G107IG113I 
oligomerisation. (a) Side and top view of G107I trimer model, when I107xxxG111 or (b) 
I113xxxA117 falls on the helical interface and form the helix interaction. (c) Side and top 
view of G107I G113I trimer model when I107xxxG111 motif or (d) I113xxxA117 falls on the 
helical interface. (e) Side view of G107I G113I dimer model, where T112 residues form 
interhelical hydrogen bond on the helical interface and form the helix interaction. (a)-(e) In 
all structures, sequence corresponds to rCPT1A TM2 (Lys102-Arg123) including the actual 
mutation(s). Individual helices are represented as grey ribbon cartoons and residues are 
labelled as follows: the mutated residues I107 and I113, highlighted as orange spheres, G111 
and A117 or G113 shown in yellow and blue spheres respectively. Thr112 residues are 
shown as sticks, coloured in red. 
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In modelling G107IG113I trimers, the same approach was used, with symmetric 
trimer searches carried out for helices containing the rCPT1A TM2 G107IG113I 
(K102-R123) sequence. Results were clustered into 10 clusters. From these 
structures, two typical structures were obtained as shown in Figure 4.13 c-d 
containing either the IxxxG motif (I107, G111) or the IxxxA motif (I113, A117), 
respectively, at the helix-helix interface. In addition, in the G107IG113I trimer model 
shown in Figure 4.13 d, the Val105-Leu109 residues (not highlighted) were also 
found at the interface. These residues together with Ile113 support the self 
association of the modelled helices by close packing at the N-terminus of the 
sequence.  
In the dimer model of the G107IG113I peptide, Thr112 residues were found on the 
helical interface (Figure 4.13 e). This model suggests that the dimer is stabilized 
by the interhelical hydrogen bonding (1.7 Å), which could also explain the above 
presented TOXCAT mutagenesis results, where the G107IG113IThr112A mutant 
sequence causes a decrease in self-association, as compared to the wild-type 
rCPT1A TM2 (Figure 4.2). 
4.5 Summary 
A region containing the second TM domain (residues 97-147) of the rCPT1A 
enzyme was previously found to have an important role in oligomerisation of the 
full-length protein (Faye et al., 2007). In the previous chapter, TM2 was studied in 
isolation (in vivo, in vitro and in silico), and was found to assemble into a 
hexamer-trimer oligomeric complex, mirroring the behaviour of the full length 
enzyme (§ 3.3.2). 
The research presented in this chapter sought to study the sequence specificity 
of the observed oligomerisation behaviour of rCPT1A TM2. To verify the role of 
well-known GxxxG(A) sequence motifs, the TOXCAT assay was initially used to 
analyse mutants of the TM2 domain. Building on these results, the 
oligomerisation of two mutant synthetic peptides (G107I and G107IG113I) was also 
studied. Finally, we constructed molecular models highlighting potential points of 
contact between TM helices and suggesting that oligomer formation is favoured 
by the relative positioning of tightly-packed GxxxG and GxxxA motifs within the 
predicted TM2 helix.  
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Figure 4.14 - Single and double mutation of GxxxG(A) motifs changes the size of 
the rCPT1A TM2 peptide complex. Molar mass distribution profiles of G107I (49 µM), 
G113I G107I (112 µM), and rCPT1A TM2 (62 µM) peptide samples calculated using 
SEDFIT. 
 
The systematic mutagenesis of sequence motifs G103xxxG111, G113xxxA117 and 
Thr112 within TM2 established potential residues involved in helix interaction, 
when mutant sequences showed weaker oligomerisation than the wt TM2 in 
TOXCAT chimera. Mutations of G107I and G107IG113I reduced the measured CAT 
activity by ~50%. Since these two mutants would provide critical information on 
the role of the two motifs, without making more than two mutations in the 
sequence, they were selected for further study in vitro (§ 4.2). 
Synthetic peptides of the G107I and G107IG113I mutants were studied using cross-
linking and AUC, and significant differences were found in peptide 
oligomerisation, compared to the wt rCPT1A TM2 (§ 4.3.3 and 4.3.4). Both 
mutant peptides were found to form oligomeric species smaller than hexamers. 
The G107I peptide (mutation of the N-terminal G107xxxG111 motif) forms a stable 
trimer, which we suggest is stabilised via the undisturbed G113xxxA117 motif. In 
addition, the G107IG113I peptide formed trimers in AUC experiments, but 
equivalent amounts of dimer and monomer species were detected by cross-
linking (Figure 4.10). According to our in silico models, the oligomers formed by 
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the mutant peptides are likely to be stabilized by interhelical hydrogen bonding of 
Thr112 residues or close packing of Val-Leu-Ile residues (Figure 4.13). 
Furthermore AUC experiments confirmed that mutation of GxxxG and GxxxA 
motifs changes rCPT1A TM2 oligomerisation. The mutant peptides found to 
sediment according to lower molecular weight species compared to the wild type 
peptide (Figure 4.14). 
The above presented results give rise to further questions, such as how important 
are these motifs in the full length protein complex formation, and how these 
mutations would influence the protein assembly and function. These questions 
will be investigated in the future by introducing these mutations in the full-length 
protein and studying its effect on the complex formation and the enzyme function. 
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CHAPTER 5 
 
 
 
5. HOMO-OLIGOMERISATION OF 
CPT1B TRANSMEMBRANE DOMAINS 
 
 
This chapter presents the results from biological assays and studies on 
synthetic peptides constituting the transmembrane domains of CPT1B. The 
homo-oligomerisaton of both studied TM domains is observed, together 
with the stoichiometry of assembly in detergent micelles in vitro, and 
possible interacting sites between these helical peptides are proposed from 
in silico models. 
 
5.1 Introduction 
The carnitine palmitoyltransferase I (CPT1) enzyme has another important 
catalytically active isoform, CPT1B. Also called the M-isoform (muscle isoform), 
CPT1B occurs in skeletal and cardiac muscle mitochondria and in other 
particularly high fatty acid oxidative capacity tissues (e.g. brown adipose tissue) 
(McGarry and Brown, 1997). The sequence of CPT1B is very similar (63%) to 
CPT1A, but there is an important kinetic difference between the two, namely their 
inhibitor sensitivity. In contrast to CPT1A (which has been discussed in detail 
previously in § 3.1 and § 4.1), the CPT1B isoform is much more sensitive to 
inhibition by malonyl-CoA, and has a permanently high malonyl-CoA sensitivity 
which is not modulated by physiological state, suggesting that this molecule 
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adopts a more “active” but “rigid” structure (Mynatt et al., 1992; Saggerson et al., 
1992). These observations suggest that there are molecular differences in the 
two isoforms which govern their inhibitor binding through different intramolecular 
interactions and could explain their different kinetic behaviour. 
The difference in the kinetic behaviour of the two isoforms can be investigated by 
focusing on molecular differences between CPT1A and CPT1B. If we consider 
their differences in molecular plasticity and kinetic response to changes in 
physiological state, both of which are governed by changes in the membrane 
such as lipid fluidity and lipid composition in the mitochondrial outer membrane, 
the study can be narrowed down to differences in the structure or interactions of 
the transmembrane (TM) domains. Differences in TM helix-helix interactions 
could explain why the two isoforms have different degrees of molecular flexibility 
and have such different kinetic behaviour, despite the large similarity in their 
sequences and topologies. 
The CPT1B isoform has no crystal structure or homology molecular model. There 
are no published data about the oligomerisation of the full length protein. 
However, the similarity in the protein sequence and topology indicates the 
possibility of complex formation similar to CPT1A. 
The work presented in this chapter was designed to explore the TM homo-
oligomerisation of the CPT1B TM domains, and compare it to that observed for 
CPT1A focusing on differences that might explain their different kinetic behaviour. 
For direct comparison, the same techniques were used as described for CPT1A 
in CHAPTERS 3 and 4. In vivo TOXCAT and GALLEX assays and in vitro peptide 
homo-oligomerisation and oligomeric state studies, together with molecular 
models, were used to determine important interaction motifs in CPT1B TM1 and 
TM2. 
5.2 Sequence conservation and helix-helix interaction 
motifs in CPT1B TM domains 
The two TM domains in CPT1B were defined using the UniProt database 
(www.expasy.org), highlighted in grey, with the sequence in white brackets, and 
using the TMHMM software (TM1 highlighted blue and TM2 highlighted in 
purple), as shown in Figure 5.1. 
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Figure 5.1 - Prediction of TM domain regions in CPT1B proteins from different 
species. TMs were predicted using the UniProt database and the TMHMM software. The 
sequence of CPT1B TM1 is highlighted in grey and blue, while that of TM2 is highlighted 
in grey and purple. TMs defined by UniProt are in brackets, residues highlighted with blue 
or purple were also predicted as part of TM by TMHMM (Sonnhammer et al., 1998). (The 
UniProt codes (from www.expasy.org) of the analysed CPT1B proteins are shown on the 
left hand side.) 
 
Using the TM domain sequences identified by TMHMM, the TM domains were 
further analysed to study the sequence conservation across different species, as 
well as the presence of known interaction motifs. TM domains of membrane 
proteins frequently contain sequence motifs that are known to stabilise the helix-
helix interactions (for more details, see § 1.2.2 and § 3.2.1). 
As shown in Figure 5.2, the sequence identities of CPT1B TM1 and CPT1B TM2 
were 73.1% and 50%, respectively, when comparing four different mammalian 
species. The sequence identity of TM1 is very similar to that found for CPT1A 
TM1, and it also has similar helix-helix interaction motifs such as GxxxG, GxxxS, 
and motifs of polar Thr and Ser residues. In contrast, CPT1B TM2 sequence is 
about 23% more variable than CPT1A TM2 (see in Figure 3.2), when compared 
across different species, but the largest difference observed for this TM domain is 
the absence of any “small-xxx-small” interaction motifs. This TM sequence, 
however, does contain aromatic Phe residues and polar Ser and Thr residues 
(both of which are potential sites of TM helix-helix interactions), as shown in 
Figure 5.2. 
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Figure 5.2 - Analysis of conserved residues and helix-helix interaction motifs in 
CPT1B TM1 and TM2. Sequence analyses of conserved residues were carried out using 
the Biology Workbench software (http://workbench.sdsc.edu). Completely conserved 
residues are labelled green, identical residues are labelled with yellow, similar residues 
with blue, and different residues with white. The sequence motifs are highlighted 
according to TMSTAT. 
 
This simple sequence analysis already suggests differences in the two isoforms, 
and we can see that the sequence of CPT1B TM2 contains no potential “GxxxG-
like” interaction motifs and is much less conserved than any other TMs 
investigated. 
 
5.3 In vivo oligomerisation of rCPT1B TM domains 
5.3.1 Self-association of transmembrane domain 1 (TM1) 
The TOXCAT assay was used to study the CPT1B TM1 domain self-association 
in the E. coli inner membrane. The TM domain sequences originally designed for 
the rCPT1B TM1 length optimization experiments were: Arg52-Lys76, Tyr55-Lys76 
and Tyr55-Tyr74, shown in Figure 5.3 a, and were 25, 22 and 20 amino acids in 
length. These chimeras all failed the malE complementation assay, Figure 5.3 c, 
suggesting that they were incorrectly inserted into the inner membrane. Chimeras 
containing TM1 sequences with lengths of 25 and 22 amino acids were tested 
with the CAT assay, but did not show oligomerisation Figure 5.3 b.  
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Figure 5.3 - Oligomerisation of TOXCAT chimeras containing rCPT1B TM1 domain 
sequences of varying length (25, 22, 24, 23, 22*, 20* residues) in E. coli membranes. 
(a) Transmembrane domain sequences of rCPT1B TM1 cloned and analyzed in TOXCAT 
assay. (b) The resulting CAT activities of rCPT1B TM1 length optimization study. CAT 
activities obtained for the different lengths of rCPT1B TM1 and expression level of 
chimeras detected by western blot analysis (using antibodies directed against MBP). All 
CAT activities are reported relative to the value obtained for wt GpA (positive control). 
Values are means (+/- standard deviation) for three or more independent measurements. 
(c) malE complementation to test for correct insertion of ToxR-TM1-MBP chimeras. 
 
Interestingly, rCPT1B TM1 sequences Asn48-Gly71 (24 residues in length), Arg52-
Tyr74 (23 residues), Arg52-Asn73 (22*) and Arg52-Gly71 (20*) were correctly inserted 
(Figure 5.3 c) across the membrane and yielded approximately 32-39% of CAT 
activities compared to the positive control wt GpA (Figure 5.3 b). 
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Figure 5.4 - Oligomerisation of rCPT1B TM1 (20) in GALLEX homo-oligomerisation 
assay. (a) The inverse sequences of rCPT1A TM1 were cloned into pBLM vector in wt 
LexA-TM-MBP chimera (Gly71-Arg52). Chimeras were expressed in SU101 using 0.01 mM 
IPTG when analyzed by GALLEX-homo assay. All activities are reported relative to the 
value obtained for GpAG83I (negative control). Values are means (+/- standard deviation) 
for three independent measurements. (b) Immunoblot of spheroplast proteolysis assay to 
test topology of rCPT1B LexA-TM1-MBP chimeras expressed in NT326 cells. 
Immunoblotting was carried out using antibodies directed against MBP. The correctly 
inserted chimeras were detected at 66kDa (full length chimeric protein) in whole cell 
fractions (W), and at 43 kDa (MBP molecular weight) in spheroplasts treated with 
proteinase K (S*) and lysed spheroplast treated with proteinase K (B*) fractions. 
 
In addition, the self-association of the rCPT1B TM1 domain sequence Arg52-Gly71 
was also studied using the GALLEX assay (Figure 5.4 a). This sequence was 
selected because it was the shortest (previous reports suggest that TM domain 
lengths of ≤ 19 amino acids are usually successful in this assay) of those which 
gave a positive CAT signal. The chimera wt LexA-TM1-MBP failed to grow in the 
malE complementation assay (data not shown), but the spheroplast proteolysis 
assay (Figure 5.4 b) again confirmed the correct insertion and orientation. In the 
GALLEX chimera rCPT1B TM1, oligomerisation was found to be similar to the wt 
GpA positive control (Figure 5.4 a). These results support the results obtained 
from TOXCAT (i.e. CPT1B TM1 has a propensity to self-associate), however the 
strength of this association relative to GpA appears to be much larger when 
measured in GALLEX.  
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5.3.2 Self-association of transmembrane domain 2 (TM2) 
The length optimisation of rCPT1B TM2 in the TOXCAT assay resulted in only 
one TM domain construct, containing residues Leu106-Arg125 (20 residues in 
length; see Figure 5.5 a), which showed both correct insertion and self-
association. Interestingly, the TOXCAT signal was similar to that obtained for 
rCPT1B TM1 20 (Arg52-Gly71) (Figure 5.3 b) yielding CAT activities 
approximately 31% of those observed for the positive control wt GpA (see in 
Figure 5.5 b). 
 
 
Figure 5.5 - Oligomerisation of rCPT1B TM2 (22, 20, 19, 17) TOXCAT chimeras in 
E. coli membranes. (a) Transmembrane domain sequences of rCPT1B TM1 cloned and 
analyzed in TOXCAT assay. (b) The resulting CAT activities of rCPT1B TM1 length 
optimization study. CAT activities obtained for the different length of rCPT1B TM1 and 
expression level of chimeras detected by western blot analysis (using antibodies directed 
against MBP). All CAT activities are reported relative to the value obtained for wt GpA 
(positive control). Values are means (+/- standard deviation) for three or more 
independent measurements. (c) malE complementation to test the ToxR-TM1-MBP 
chimeras correct insertion. 
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Figure 5.6 - Oligomerisation of rCPT1B TM2 (19) in GALLEX homo-oligomerisation 
assay. (a) The inverse sequences of rCPT1A TM1 were cloned into pBLM vector in wt 
LexA-TM-MBP chimera. Chimeras were expressed in SU101 using 0.01 mM IPTG when 
analyzed by GALLEX-homo assay. (b) The resulting β-galactosidase activities of GpA 
and rCPT1A TM1 chimeras. All activities are reported relative to the value obtained for 
GpAG83I (negative control). Values are means (+/- standard deviation) for three 
independent measurements. 
 
In the case of the 22 (Glu104-Arg125) and 19 (Leu106-Phe124) amino acid 
sequences, the very low signals detected (Figure 5.5 b) were most probably the 
result of incorrect insertion of the chimeras. Furthermore, the 17 (Leu106-Phe122) 
amino acid sequence which was correctly inserted according to the malE 
complementation assay (and membrane association with NaOH extraction) still 
yielded low signals despite numerous independent measurements. In 
comparison, both rCPT1A TM domains showed the strongest interaction at an 
optimal TM domain length of 16 residues (§ 3.3.1 and § 3.3.2), while here the 
rCPT1B TM2 length of 20 residues (Arg52-Gly71) was found to correctly span the 
E. coli membrane and oligomerise in the TOXCAT assay. To confirm rCPT1B 
TM2 homo-oligomerisation, GALLEX experiments were also designed.  
Based on our TOXCAT results, the rCPT1B TM2 20 residue (Leu106-Arg125) 
sequence was initially used for cloning, but ligation of this oligonucleotide into the 
pBLM plasmid failed after multiple attempts. However the 19 residue (Leu106-
Phe124) sequence was successfully cloned into pBLM. The resulting chimera was 
also correctly expressed and inserted into the membrane as tested with the 
spheroplast proteolysis assay (shown in Figure 5.4 b). The GALLEX chimera 
containing rCPT1B TM2 (19) yielded approximately 46% β-galactosidase activity 
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compared to the negative control GpA G83I, which suggests stronger 
oligomerisation than the 20 residue Leu106-Arg125 sequence analysed using the 
TOXCAT assay (Figure 5.5 b), but not as strong as the positive control GpA in 
Figure 5.6 b. 
5.4 In vitro oligomerisation of rCPT1B TM peptides 
The above presented oligomerisation studies of rCPT1B TM sequences 
suggested that these domains can self-associate in a natural membrane. In order 
to validate the results of in vivo assays and investigate the oligomeric state(s) 
formed by the rCPT1B TM domains, in vitro approaches were used. Synthetic 
peptides corresponding to rCPT1B TM domains were purified and their 
secondary structures were characterised in DPC detergent micelles using circular 
dichroism (CD) spectroscopy. To investigate the oligomeric state of rCPT1B TM 
peptides, chemical cross-linking and analytical ultracentrifugation sedimentation 
velocity (AUC-SV) experiments were carried out. (For peptide sequences and 
details see § 2.4-2.5, Table 2.6). 
5.4.1 Purification and structural analyses of synthetic TM 
peptides 
The crude synthetic peptides were purified by reversed-phase high performance 
liquid chromatography (RP-HPLC) as discussed in detail in § 2.4. To verify the 
peptides' purity and correct molecular weight, matrix-assisted laser desorption 
ionization-time of flight mass spectroscopy (MALDI-TOF-MS, Bruker) was used. 
The deconvoluted mass spectra of rCPT1B TM1 and TM2 peptides are shown in 
Figure 5.7 and Figure 5.8.  
Table 5.1 - The amino acid sequences of rCPT1B TM1 and TM2 synthetic peptides 
used in this study. Non-native lysine residues are shown in bold. 
TM domain of 
interest 
Synthetic peptide sequence 
Molecular 
weight (Da) 
rCPT1B TM1 COCH3-KILRGVYPGSPTSWLVVVMATVGSNYK-CONH2 2963 
rCPT1B TM2 COCH3-KETLLSMVIFSTGVWATGIFLFRK-CONH2 2785 
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Figure 5.7 - Analysis of purified rCPT1B TM1 peptide by matrix-assisted laser 
desorption ionization-time of light mass spectrometry (MALDI-TOF-MS). The HPLC 
fractions containing the pure peptide were pooled and analyzed using MALDI-TOF-MS. In 
the spectrum, the major peak corresponds to the rCPT1B TM1 peptide (2963 Da). 
 
 
Figure 5.8 - Analysis of purified rCPT1B TM2 peptide by MALDI-TOF-MS. The HPLC 
fractions containing the pure peptide were pooled and analyzed using MALDI-TOF-MS. In 
the spectrum, the major peak corresponds to the rCPT1B TM2 peptide (2785 Da), and 
additional peaks correspond to truncated peptides that co-purified with the major product. 
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Figure 5.9 - The effect of DPC micelle concentration on the secondary structure of 
rCPT1B TM1 peptide. (a) CD spectra measured at different detergent micelle to peptide 
ratios, plotted in units of mean residue ellipticity (MRE). (b) High tension (HT) over the 
wavelength region specified in (a). (c) The secondary structure composition of the 
rCPT1B TM1 peptide estimated from fitting of the CD spectra shown in (a) using the 
CDSSTR software (Johnson, 1999). Secondary structure composition was calculated by 
fitting of the CD data between 190-260 nm.  
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Figure 5.10 - The effect of DPC micelle concentration on the secondary structure of 
rCPT1B TM2 peptide. (a) CD spectra measured at different detergent micelle to peptide 
ratios, plotted in units of mean residue ellipticity (MRE). (b) High tension (HT) over the 
wavelength region specified in (a). (c) The secondary structure composition of the 
rCPT1B TM2 peptide estimated from fitting of the CD spectra shown in (a) using the 
CDSSTR software (Johnson, 1999). Secondary structure composition was calculated by 
fitting of the CD data between 190-260 nm.  
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CD spectra were then collected to determine whether the peptides were properly 
folded in DPC micelles. CD spectra collected at different micelle concentrations 
indicated that the rCPT1B TM1 peptide adopts mainly α-helical secondary 
structure (46-51%) at all different M:P ratios (Figure 5.9).  
In contrast, the rCPT1B TM2 peptide at lower peptide to micelle ratios (in SDS 
3:1 and in DPC 2:1) adopted a primarily β-sheet secondary structure (shown in 
Figure 5.10), which we suggest arises from insoluble aggregates. At higher, 4:1-
20:1 ratios the α-helical content of the peptide samples was 39%. One possible 
explanation of the observed differences between the secondary structure content 
of the rCPT1B peptides is that the TM2 sequence is more hydrophobic than TM1, 
making it more prone to aggregation (the TM2 sequence contains three 
phenylalanine residues and one tryptophan residue). The hydrophobicity values 
were calculated according to the relative hydrophobicity of the amino acid 
residues, as determined by the retention time in RP-HPLC (Liu and Deber, 1998).  
5.4.2 Determination of rCPT1B TM1 peptide oligomeric state 
To study the oligomeric state(s) achieved by the rCPT1B TM1 peptide in 
detergent micelles, chemical cross-linking and AUC experiments were carried 
out. The synthetic peptide derived from rCPT1B TM1 (mentioned above; 
MW=2963 kDa) was solubilised in DPC micelles and treated with the water-
soluble chemical cross-linker BS3. Cross-linked species were visualized by SDS-
PAGE analysis (Figure 5.11 a). The TM1 peptide produced a number of bands 
between the 6 and 17 kDa molecular weight markers, which corresponds to 
oligomeric states between trimer and pentamer. A broad band between 28-49 
kDa was observed at the lowest detergent concentrations (M:P=1/3–1), 
suggesting the presence of higher order aggregated states for very low detergent 
concentrations. As the detergent concentration was increased (M:P=2–5), only 
trimer and tetramer species were observed, which were destabilised by 
increasing the detergent concentrations to M:P=10–20, where only monomer 
species were detected. A double band migrating slightly above the expected 
monomer molecular weight could be seen at all M:P ratios, and may correspond 
to two different monomer conformations or to the monomer complexed with 
different numbers of cross-linker molecules. 
Also shown in Figure 5.11 a, is the result from cross-linking the TM1 peptide in 
SDS. The resulting single band corresponding to the molecular weight of the 
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monomer confirmed the specificity of the cross-linking reaction in DPC. The 
peptide was also analysed in the absence of cross-linker in SDS (M:P=3) and 
DPC micelles (M:P=2 and 5) on SDS-PAGE, as shown in Figure 5.11 b. Again, 
only monomeric species were observed, suggesting that this peptide cannot form 
SDS-stable oligomers. 
It is interesting to note that the results of the rCPT1B TM1 peptide cross-linking 
experiments closely mirror those obtained with the rCPT1A TM1 peptide in 
§ 3.3.1, Figure 3.13 which suggests strong similarities in the oligomerisation 
properties of this region of both enzymes. 
The rCPT1B TM1 peptide oligomerisation was also studied in the absence of a 
cross-linker by AUC-SV. Initially, data were collected at the speed of 40,000 rpm, 
25°C (Birmingham University), but when analysed, the sedimentation coefficient 
distribution indicated that the majority of the peptide forms mostly higher order 
species larger than 18-22 kDa, which was probably due to aggregation (data not 
shown).  
 
 
Figure 5.11 - SDS-PAGE analysis of chemically cross-linked rCPT1B TM1 peptide 
oligomerisation. The molecular weight marker is shown in the left-hand lane (Mr). (a) 
BS3-mediated cross-linking of peptides dissolved in DPC micelles. Cross-linking reactions 
were carried out in DPC detergent micelles at various micelle to peptide concentration 
ratios as indicated below each lane. Protein bands were visualized by staining with silver 
nitrate. Oligomeric states (e.g. trimer indicated by n=3 are indicated at the far right of the 
gels. (b) rCPT1B TM1 peptide in the absence of crosslinker migrates mainly as monomer 
in SDS micelles at M:P=4, and in DPC micelles at M:P=2 and 5. 
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With new sample preparation, and using 55,000 rpm, 20°C (Oxford University), 
we collected a better resolved data set (Figure 5.12). The sedimentation 
coefficient profile for the 83 µM concentration contained one species centered at 
S=0.71 (at RMSD value of 1.7×10-2), corresponding to a molecular mass of 
14.35 kDa, near the mass of the pentameric species. When compared with the 
calculated molecular weights for the TM1 pentamer (14.8 kDa), the experimental 
values agreed to within 4% of the theoretical values. 
Among all species observed by the previous cross-linking experiment (shown in 
Figure 5.11), only the pentameric species could be detected by AUC-SV at this 
speed. The smaller complexes were probably also present in the solution, but 
undetectable under the above mentioned experimental conditions with AUC. 
 
Figure 5.12 - Analytical ultracentrifugation analysis of rCPT1B TM1 derived peptide 
in DPC detergent solution. Sedimentation velocity data obtained for TM1 peptide 
dissolved in buffer containing 15 mM DPC and 52.5% D2O. (a) Residuals of the fitting 
process for samples containing 83 µM peptide (M:P ratio ~3). (b) Sedimentation 
coefficient distribution profiles for the peptide as calculated using the SEDFIT program. 
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5.4.3 The order of rCPT1B TM2 peptide oligomerisation  
To study oligomerisation of rCPT1B TM2, the peptide derived from this domain 
(MW=2785 kDa) was also cross-linked and analysed using SDS-PAGE, shown in 
Figure 5.13. The oligomeric species detected across all M:P ratios runs slightly 
above the 6 kDa molecular weight marker, suggesting the presence of a TM2 
trimer (8355 kDa) rather than a dimer (5570 kDa). As mentioned above, the 
oligomer appears as a closely spaced pair of bands, most clearly shown at 
M:P=10 and 20, that may represent two different trimer conformations or the 
trimer species complexed with different numbers of cross linker molecules. 
Increasing the micelle concentration resulted in a higher concentration of 
monomer and less aggregation, but the trimer band concentration did not 
change. This suggests that the rCPT1B TM2 peptide forms stable trimers in DPC 
micelles (Figure 5.13 a).  
The result from cross-linking the TM2 peptide in SDS is shown in Figure 5.13 a 
(lanes labelled SDS), and confirms the specificity of the cross-linking reaction in 
DPC. Analyses of the peptide in the absence of cross-linker in SDS and DPC 
micelles again yielded only monomer bands (Figure 5.13 b), demonstrating that 
this peptide also cannot form SDS-stable oligomers. 
 
Figure 5.13 - SDS-PAGE analysis of chemically cross-linked rCPT1B TM2 peptide 
oligomerisation. The molecular weight marker is shown in the left-hand lane (Mr). (a) 
BS3-mediated cross-linking of peptides dissolved in DPC micelles. Cross-linking reactions 
were carried out in DPC detergent micelles at various micelle to peptide concentration 
ratios as indicated below each lane. Protein bands were visualized by staining with silver 
nitrate. Oligomeric states are indicated at the far right of the gels. (b) rCPT1B TM2 
peptide in the absence of crosslinker migrates as monomer. 
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In order to more quantitatively determine the oligomeric state of the rCPT1B TM2 
domain, samples were also analysed by AUC-SV. The data were collected at a 
peptide concentration of 107 µM (M:P ratio ~ 2), at 55,000 rpm and 20°C 
(University of Oxford). The residuals of the fit and sedimentation coefficient profile 
are shown in Figure 5.14. The major peak of the resulting sedimentation 
coefficient profile was centered at S= 0.33, while a minor peak was also typically 
present at S=0.94 (Figure 5.14 b). Converting the sedimentation coefficient to 
molecular mass distribution indicated molecular weights for the peaks of 6.48 
kDa and 30.9 kDa, respectively. According to the molecular weight of the peaks, 
the majority of the peptides sedimented as dimers in the absence of cross-linker 
molecules (agreeing to within 15% of the theoretical value of 5.57kDa). The minor 
peak with higher molecular weight was probably due to aggregation in the sample 
caused by the high hydrophobicity of the peptide (as discussed in § 5.4.1). 
 
Figure 5.14 - Analytical ultracentrifugation analysis of rCPT1B TM2 derived peptide 
in DPC detergent solution. Sedimentation velocity data were obtained for TM2 peptide 
dissolved in buffer containing 15 mM DPC and 52.5% D2O. (a) Residuals of the fitting 
process for samples containing 107 µM peptide (M:P ratio ~2). (b) Sedimentation 
coefficient distribution profiles for the peptide as calculated using the SEDFIT program. 
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5.5 In silico models of rCPT1B TM oligomerisation  
The experimental data discussed above suggests that both TM domains of 
rCPT1B are able to form homo-oligomers in vivo and in vitro. The observed 
oligomerisation behaviour was further studied by in silico modelling of homo-
dimers and homo-trimers for each TM domain using CHI. The modelled 
sequences were identical to the peptide sequences (TM1: Ile50-Tyr74 and TM2: 
Glu104-Arg125). Modelling these structures enables us to determine possible 
interacting residues and motifs responsible for the observed oligomerisation.  
5.5.1 Modelling TM1 homo-oligomerisation 
The analysis of CPT1B TM1 domain already indicated several interaction motifs 
(GxxxG and Ser, Thr) within the sequence (§ 5.2). In the following models we 
examined their significance in rCPT1B TM1 homo-oligomerisation.  
First, for the simplest model of homo-interaction, a TM1 dimer was built and 
simulated. The results were clustered into 5 clusters with RMSD < 1.2 Å and a 
cluster size > 8 structures. The interacting residues within two symmetric clusters 
were assessed. Figure 5.15 a shows the cluster containing left handed helical 
dimer structures, while Figure 5.15 b illustrates the structure for the cluster 
containing right handed dimers. In the dimer model shown in Figure 5.15 a, four 
residue pairs (both R52-Y55, T69 -T69 and S72-N73) form interhelical H-bonds of 
lengths 1.7-1.9 Å. The right handed dimer model shown in Figure 5.15 b has the 
G53xxxG57 motif packed in the interface of the helices, bending them towards 
each other. In this model two pairs (S61-S61 and T69 -S72) of H-bonds also stabilise 
the helix-helix interaction. The donor and acceptor distances are within 1.8 Å of 
one another for these H-bonds. 
As trimer formation of rCPT1B TM1 was previously observed by cross-linking 
(Figure 5.11), we have also attempted to model the homo-trimer structure. 
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Figure 5.15 - Likely interaction motifs in rCPT1B TM1 (a-b) homo-dimer and (c-d) 
homo-trimer CHI models. (a) Left-handed, symmetrical dimer model. (b) Right-handed, 
symmetrical dimer model. (c)-(d) Left handed symmetrical trimer models. Individual 
helices are represented as blue ribbon cartoons and residues are labelled as follows: (a) 
R52 and Y55 shown as sticks, coloured by element (blue carbons), T69 (green carbons), S72 
and N73 (yellow carbons). (b) G53 and G57, highlighted as blue spheres, S61 shown as 
sticks coloured by elements (orange carbons), T69 and S72 (yellow carbons). (c) Y55 shown 
as sticks coloured by elements (blue carbons), T69 (green carbons) S72 and N73 (yellow 
carbons). (d) G53 and G57, highlighted as spheres coloured by element, T60 and S61 
residues are shown as sticks, coloured by element (green carbons). 
 
The structures found during the CHI search were arranged into 9 clusters, 
according to the criteria RMSD < 1.8 Å and cluster size > 4. All structures were 
analysed and typically two types of conformations were found. Interestingly, 
these were similar to that detailed for the dimer models: in Figure 5.15 c there 
are interhelical H-bonds (1.7-2 Å) between the Y55, T69 and S72-N73 residues, while 
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in the other model shown in Figure 5.15 d, the G53xxxG57 motif and a H-bond 
(1.8 Å) between S61-T60 residues is formed at the helix-helix interfaces to stabilise 
the trimer structure.  
Similarly to that observed for the rCPT1A TM1 domain (§ 3.5.1), in the rCPT1B 
TM1 models discussed here the same P56 and P59 residues (not highlighted) also 
disrupt the helical structure by forming proline kinks, but only for the 
conformations where the G53xxxG57 motifs are not at the interface.  
While chemical cross-linking and AUC (§ 5.4.2) experiments suggest that the 
TM1 peptide forms pentameric species, the CHI simulation using RMSD < 1.8 Å 
and a cluster size > 4 did not produce any pentameric structures. This may be 
due to the simulation software producing highly strained initial structures, making 
it impossible for the molecular dynamics to maintain a pentameric configuration. 
Using more sophisticated force fields and providing non-strained initial structures 
could be a way to investigate the stability of similar oligomers in the future. 
5.5.2 Modelling TM2 homo-oligomerisation 
The rCPT1B sequence is different from any previously modelled sequences, as it 
is the only one from the investigated TM domains containing no GxxxG like 
motifs, but it contains several aromatic and Thr, Ser residues. CHI searches were 
performed on either two or three parallel α-helices containing rCPT1B TM2 to 
study the structural features that may have a role in stabilizing both the trimeric 
(detected by cross-linking, § 5.4.3) and dimeric (observed by AUC, § 5.4.3) forms 
of the synthetic peptide. 
The dimer model was simulated using RMSD < 1.0 Å and a cluster size > 10. The 
simulation resulted in 3 clusters, from which the energy plot of the right handed 
cluster was sufficiently good to analyse further. L106 and V110 residues interact on 
the helix interface of the structure shown in Figure 5.16 a, constituting a possible 
heptad motif. We found no other known interaction motifs or any other interacting 
residues on the interface in the TM2 dimer model. 
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Figure 5.16 - Possible interhelical interactions in rCPT1B TM2 (a) homo-dimer and 
(b) homo-trimer CHI models. In (a)-(b), individual helices are represented as blue 
ribbon cartoons. (a) Model for the homo-dimer, we see packing of L106 and V110 which 
highlighted as yellow spheres. (b) Homo-trimer model, where we see packing of A118 
highlighted as blue spheres S108, F122 and R125 highlighted as stick coloured by elements. 
 
For the modelling of rCPT1B timers, symmetric trimer searches were carried out 
with helices containing the rCPT1B TM2 sequence. We clustered the structures 
according to RMSD < 1.5 Å and cluster size > 6. This resulted in one right 
handed coiled coil with the above parameters. In this cluster, the interface of the 
trimer model contains S108, and R125 residues forming interhelical H-bonds 
(1.7 Å), small A118 residues and F122 forming hydrophobic interactions (see in 
Figure 5.16 b). 
 
Molecular modelling of the TM homo-oligomerisation in CPT1B highlighted 
several sequence motifs, which are likely to play a role in stabilising self- 
association of these TM domains. In the future, these results could be used as a 
starting point for designing mutagenesis experiments, similar to what was already 
carried out for rCPT1A TM2 (CHAPTER 4). 
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5.6 Summary 
It is not known whether the full length CPT1B also exists as an oligomer in 
muscle mitochondria. In the previous chapter we found correlation between 
oligomerisation of full length CPT1A and the oligomerisation of its TM domains. 
This finding might be helpful in highlighting differences between the 
oligomerisation of the two isoforms by comparing the self-association behaviour 
of their TM domains. By studying the self-association of the TM domains, based 
on our previous results, we could compare the TM oligomerisation of the two 
isoforms directly. Biological assays and biophysics techniques were used to 
identify the oligomerisation properties of rCPT1B TM domains. Both of the 
rCPT1B TM domains showed self-association. 
Interestingly, we have found some similarity in the oligomerisation behaviour of 
rCPT1A and rCPT1B TM1 domains. When studying their corresponding synthetic 
peptides with chemical cross-linking, both form similarly sized species (n=3-5) 
with a very similar pattern according to SDS-PAGE analysis (see Figure 3.13 
and Figure 5.11). The observed similarity could be due to their sequence 
similarity (GxxxG like motifs, proline residues). However, the TM2 domain of 
rCPT1B behaved very differently from its counterpart in CPT1A, forming dimers 
and trimers as opposed to the hexamers formed by rCPT1A TM2. The sequence 
motifs in the TM2 domains are also significantly different in the two isoforms, and 
molecular modelling showed different interactions between their amino acids. 
The above observations do suggest that the CPT1B isoform is able to form 
oligomeric complexes. The oligomeric state of CPT1B could be different from that 
of CPT1A, as their TM2 domains have significantly different oligomerisation 
behaviour. In CPT1A oligomerisation the TM2 domain was found to have key role 
in forming hexamers (Faye et al., 2007). If the same applies to CPT1B, the 
oligomerisation of the full length CPT1B will be different. If for example, CPT1B 
would form trimer complexes, and the different sizes of the protein complexes for 
CPT1A and CPT1B would explain their different enzyme kinetics. However, the 
hypothesis needs more data to directly compare the complex and possible 
chanell formation for these proteins. 
The investigation of TM domain interaction in CPT1A and CPT1B still has one 
more aspect we need to consider, namely the hetero interaction of TM1-TM2 
domains, which is discussed in the following CHAPTER 6.  
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6. HETERO, TM1-TM2 INTERACTIONS 
IN CPT1 ISOFORMS 
 
 
In this chapter the possibility of hetero-oligomerisation between TM1 and 
TM2 domains is studied. Using the GALLEX assay, interactions of TM1-TM2 
were identified in both CPT1A and CPT1B, and by modelling the 
appropriate peptide sequences, interaction motifs playing a possible role in 
stabilising the oligomers are proposed.  
 
6.1 Introduction 
As previously discussed, intramolecular interactions in CPT1A (but not in CPT1B) 
are modulated by changes in the properties of the mitochondrial outer membrane 
(Kolodziej and Zammit, 1990; Zammit et al., 1998). The absence of a similar 
response by CPT1B to a change in physiological state suggests that TM1-TM2 
interactions may be fundamentally different in this isoform. When we studied the 
homo-oligomerisation of the TM domains of these isoforms, each TM helix was 
found to form higher order homo-oligomeric complexes. According to our 
molecular modelling results, the homo-oligomerisation in each TM domain 
occurred via different interaction interfaces and sequence motifs in the isoforms’ 
TM domains. The variety of interacting residues and motifs within one TM helix 
suggests the possibility that hetero-oligomerisation may also occur (Gerber et al., 
2004) between TM1 and TM2 in the isoforms. Therefore, the experiments 
described in this chapter were designed to investigate whether intramolecular 
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interactions involving known motifs within TM1 and TM2 of CPT1A and B are 
involved in hetero-association of the two TM domains. Furthermore, here 
differences in TM1-TM2 interactions in the two isoforms are examined which 
would explain their different kinetic characteristics. In order to examine the TM1-
TM2 hetero-interactions in both isoforms, the GALLEX biological assay was used 
in combination with molecular modelling. 
6.2 In vivo TM domain hetero-oligomerisation  
The GALLEX biological assay (for details see § 2.3) can be used to study hetero-
association between different TM domains (Schneider and Engelman, 2003). To 
investigate hetero-interaction of two different transmembrane helices, the assay 
uses two separately expressed chimeras (wt LexA-iTM1-MBP and mut LexA-
TM2-MBP). The TM domain sequences in the GALLEX chimera were designed 
according to the results of the TOXCAT and GALLEX assays presented in 
CHAPTER 3 and CHAPTER 5, respectively. Here we have inverted the sequences 
of the rCPT1A and rCPT1B TM1 domains in order to achieve an antiparallel 
orientation of the different TM domains (TM1 and TM2) in the membrane, as 
would be found in the native full length CPT1 proteins. 
To measure TM1-TM2 hetero-oligomerisation, TM2 domains of interest were 
cloned into the pALM148 vector used to transform the SU202 strain of E. coli. 
This was followed by a second transformation with the pBLM100 plasmid, which 
encoded the chimera containing the appropriate TM1 domain (inverted TM1 
sequences were used to gain antiparallel orientation). Both TM1 and TM2 
plasmids were previously used to perform the GALLEX homo-oligomerisation 
assays (see in CHAPTER 3 and CHAPTER 5). Here the two chimeras were 
expressed simultaneously in the SU202 strain of E. coli to perform β-
galactosidase assay. 
Initially, experiments were carried out to test different lengths of the TM1 and 
TM2 sequences, however as discussed CHAPTER 3 and CHAPTER 5, several of 
the chimera did not correctly insert into the E .coli membrane when studied with 
the control assays (malE complementation and proteolysis in spheroplasts). This 
length optimisation finally resulted in the transmembrane domain sequence pairs 
shown in Figure 6.1 a that were analysed using the GALLEX hetero-association 
assay. Before the quantitative measurement of β-galactosidase repression was 
carried out, the correct membrane insertion and topology of the chimeric proteins 
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was confirmed using the NaOH assay, the malE complementation assay, and the 
proteolysis in spheroplasts assay (all as described in § 2.2.2 and § 2.3.2). The 
NaOH assay confirmed that all chimeras were associating with the E. coli inner 
membrane (data not shown). According to the malE complementation assay, not 
all the constructs were inserted in the correct orientation into the E. coli inner 
membrane. While the rCPT1A TM2 (16) sequence and the positive and negative 
controls (GpA and G83I) did grow on the maltose minimal media plates, cells 
transformed with the rCPT1B TM2-containing plasmid did not grow (see in 
Figure 6.1 c). For this reason, further characterisation was performed using the 
spheroplast assay to confirm the correct orientation of the chimera mut LexA-
rCPT1B TM2 (19)-MBP (Figure 6.1 d). The correct orientation and insertion of 
wt LexA-TM1-MBP chimeras of rCPT1A TM1 or rCPT1B TM1 (with the inverted 
TM1 sequences) were previously discussed and illustrated in Figure 3.5 and 
Figure 5.4, respectively.  
Hetero-oligomerisation of the TM1-TM2 chimeras was measured at two different 
IPTG concentrations (0.1 and 0.01 mM) within the optimal range for induced 
chimeric protein expression (Finger et al., 2006). The measured β-galactosidase 
activities are shown in Figure 6.1 b. The TM1-TM2 hetero oligomerisation 
measurements produced β-galactosidase activities for rCPTA and rCPT1B of 
29% and 31%, respectively, relative to the G83I negative control when 0.1 mM 
IPTG was used in the growth medium. These results demonstrate, for the first 
time, that the TM domains of both isoforms can take part in TM1-TM2 hetero-
interactions. The relative β-galactosidase activity obtained using 0.01 mM IPTG 
resulted in less hetero-association, with rCPTA and rCPT1B displaying 45% and 
64% of the activity observed for G83I, respectively. This reduction of hetero-
association is expected at a reduced IPTG concentration, as less protein is 
expressed. However, working at this lower concentration still yields significant 
repression of β-galactosidase (and thus significant helix-helix interactions) and 
has the added benefit of revealing subtle differences between the two isoforms 
that were obscured at higher protein concentrations (i.e. 0.1 mM IPTG). The 
above results demonstrate that significant hetero-oligomerisation occurs between 
TM1 and TM2 domains in both rCPT1 isoforms. The results obtained upon 
moderate induction of the two protein chimeras (0.01 mM IPTG) also suggest that 
the TM1-TM2 interactions are stronger in the CPT 1A isoform, revealing a key 
difference in two isoforms that may be linked to their different kinetic behaviour. 
CHAPTER 6- HETERO, TM1-TM2 INTERACTIONS IN CPT1 ISOFORMS  
120 
 
 
Figure 6.1 - Hetero-oligomerisation of TM1-TM2 in rCPT1A and rCPT1B. (a) TM 
domain sequences cloned into the GALLEX plasmids. (b) The resulting β-galactosidase 
activities of GpA, G83I, and rCPT1A TM1 chimeras. The β-galactosidase activities 
obtained for the different lengths of rCPT1A TM1 and relative expression levels of 
chimeras were detected by western blot analysis. All activities are reported relative to the 
value obtained for GpA G83I (negative control). Values are means (+/- standard deviation) 
for three independent measurements. (c) Immunoblots of spheroplast proteolysis assay 
to test topology of LexA- rCPT1B TM2 (19)-MBP chimera. Chimeras were expressed in 
NT326 cells. The immunoblotting was carried out using antibodies directed against MBP. 
The correctly inserted chimeras were detected at 66 kDa (at the molecular weight of the 
full length chimeric protein) in whole cell fractions (W), and at 43 kDa (molecular weight of 
MBP) in spheroplasts treated with proteinase K (S*) and lysed spheroplasts treated with 
proteinase K (B*) fractions. (d) malE complementation assay to test for correct insertion 
and orientation of the mut LexA-rCPT1A TM2 (16)-MBP chimera. 
6.3 Molecular models of hetero interactions 
The primary aim of modelling the TM1-TM2 hetero-interactions in silico in CPT1 
proteins was to highlight potential residues or sequence motifs that could support 
the above observed oligomerisation behaviour, and design mutants for future 
experiments. As the experimental data shown in Fig. 6.1 demonstrate differences 
in the strength of TM1-TM2 hetero-oligomerisation in the two isoforms, modelling 
may also help to highlight differences in the interacting residues which could 
further our understanding of the CPT1 isoform’s different enzyme kinetics. 
Molecular modelling was performed using the CNS searching of helix interactions 
(CHI) software (described in detail in § 2.6.4). The CHI models were built to take 
it into account both the full length TM domains in CPT1A and B, and also the 
actual lengths of TM domains studied in the GALLEX hetero-assay. To estimate 
the hetero-interactions in all of the structures presented below, a full CHI search 
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was used and results were clustered into groups of structures with an RMSD of 
1.2 and a minimum cluster size of 8 members.  
The CHI search of hetero-interactions between rCPT1A TM1 (T52-V67) - iTM2 
(I119-I104) yielded 22 clusters, when these shortened sequences were modelled. 
One left-handed structure (cluster 9) was found to form a knobs into holes type 
interaction by closely packing residues (Lemmon and Engelman, 1994; Gurezka 
et al., 1999; Harrington and Ben-Tal, 2009), with L114 of TM2 packing against V54 - 
A57 of TM1 and I64 of TM1 packing between G111 – G107 of TM2 as shown in 
Figure 6.2 a. This interaction is one example of a hetero TM interaction that 
could explain the observed GALLEX results, formed through close packing 
interactions that bring the two helices into close contact. When the full length TM 
sequences of rCPT1A TM1 (K47-M73) – iTM2 (R123-K102) were used for modelling, 
a full CHI search was again carried out, and results were clustered into groups of 
structures with an RMSD of 1.2 and a minimum cluster size of 14 members.  
By modelling the hetero-association of full length TM domains, we find that one of 
the structures (left handed, cluster 2) again shows the helices packing through a 
knobs into holes type close packing of Ile/Val of TM1 to Ile residues (I51/V54 - 
I119) of TM2 and hydrogen bonding of Asn-Thr residues of TM1 and TM2, 
respectively (N58-T112: 1.9 Å) as shown in Figure 6.2 b. Interestingly, both 
G107xxxG111 and G113xxxA117 motifs in the rCPT1A TM2 sequence are present on 
the outside of the packing interface of the TM2 helix, motifs that have been 
previously found to drive TM2-TM2 homo-oligomerisation. This observation 
opens up the possibility that homo- and hetero-interactions could occur at the 
same time via different residues in CPT1A and could stabilise protein complex 
formation. 
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Figure 6.2 - CHI models of possible hetero interactions of TM1-TM2 within the 
rCPT1A protein. Amino acid sequences and CHI models of (a) rCPT1A TM1 (T52-V67) - 
iTM2 (I119-I104) (b) rCPT1A TM1 (K47-M73) – iTM2 (R123-K102) interaction. Individual helices 
are represented as grey ribbon cartoons and residues are labelled as follows: (a) 
interacting residues highlighted as spheres coloured by element (b) I119 highlighted as 
blue while I51 and V54 highlighted as yellow spheres, N58 and T112 hydrogen bonding 
residues are labelled as sticks and coloured by elements. 
 
The rCPT1B hetero-interaction was also studied, and the CHI search results 
were clustered into 18 clusters when the shorter iTM1 (G71-R52) - TM2 (L106-F124) 
(i.e. GALLEX assay equivalent) sequences were modelled. The models of these 
shorter sequences suggest that interhelical hydrogen bonds can be formed 
between Ser residues (S61 of TM1-S113 of TM2 within 2.1 Å of one another) and 
also small Gly residues can pack between TM1-TM2 helices (G57 -G53 to G120) as 
shown in Figure 6.3 a.  
When the full length TM sequences were used, the modelling resulted in 22 
structures for rCPT1B iTM1 (Y74-I50) –TM2 (E104-R125). In one of the left-handed 
clusters, as shown in Figure 6.3 b, the helices are associating via hydrogen 
bonding between Y74 of TM1 and T105 of TM2 (1.9 Å) and close packing of Ile/Val 
in TM1 to Ile residues in TM2 (V66 /L63 to I111). 
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Figure 6.3 - CHI models of possible hetero interactions of TM1-TM2 within the 
rCPT1B protein. Amino acid sequences and CHI models of (a) rCPT1B iTM1 (G71-R52) - 
TM2 (L106-F124), (b) rCPT1B iTM1 (Y74-I50) –TM2 (E104-R125) interactions. Individual helices 
are represented as blue ribbon cartoons and residues are labelled as follows: (a) 
interacting residues: G57, G53 and G120 highlighted as spheres coloured by element, 
hydrogen bonding residues S61 and S113 are labelled as sticks and coloured by elements. 
(b) I111 highlighted as blue while V66 and L63 highlighted as yellow spheres, Y74 and T105 
hydrogen bonding residues are labelled as sticks and coloured by elements. 
 
The above models present possible sites of TM1-TM2 interactions that will be 
investigated experimentally in the future via mutagenesis. These results should, 
of course, be interpreted with caution and must be investigated in vivo since the 
conformation of the TM domains in the full-length protein as inserted into the 
OMM, as well as the positions of TM1-TM2 relative to each other, could be 
different which could change the interacting residues and their position. 
Furthermore, several other combinations of well-known interaction motifs are 
present in the two sequences which could support the hetero interaction. 
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6.4 Summary 
To complement our homo-oligomerisation studies (CHAPTERS 3-5), in this chapter 
we investigated the possibility of TM1-TM2 interactions in CPT1 A and B for the 
first time. Using the GALLEX assay we studied the two different TM1-TM2 
interactions in isolation in E. coli membranes. The possible contacts between the 
TM domains were investigated by molecular modelling (CHI).  
It is known that changes in CPT1A enzyme kinetics, possibly due to changes in 
protein structure, occur in response to changes in composition and fluidity of the 
OMM, suggesting a larger flexibility of this protein, while CPT1B is believed to 
adopt a more rigid structure that is less sensitive to the membrane environment. 
This data could suggest that the TM1-TM2 interactions in CPT1B are stronger 
than those in CPT1A, and therefore more stable in a variety of membrane 
environments. Alternatively, if the TM1-TM2 interactions in CPT1B were weak, 
significant changes in these interactions may not be observed upon changing the 
membrane structure. While we found evidence for TM1-TM2 hetero-interactions 
in both isoforms using the GALLEX biological assay, the data reported in this 
chapter cannot prove that the interaction strengths are different in the two 
isoforms. Only at the lowest protein expression levels do we see a difference, 
where the TM1-TM2 interaction in CPT1B was slightly weaker than that for 
CPT1A. In this system, we also need to consider that while the enzyme is in the 
OMM, both homo and hetero interactions could occur at the same time through 
TM1 and TM2. Thus, to be able to accurately detect possible differences in 
hetero oligomerisation, the competition of the two types of interactions (homo, 
hetero) needs to be taken into account. Further in vitro analyses of the observed 
interactions have to be carried out along with their effects on the folding and 
enzyme kinetics of the full length protein and mutagenesis of the involved 
residues. 
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CHAPTER 7 
 
 
 
7. CONCLUSIONS 
 
Carnitine palmitoyltransferase 1 enzymes responsible for the regulation of 
mitochondrial fatty acid oxidation have a central role in many cellular 
mechanisms such as energy homeostasis (in heart and skeletal muscle (Eaton et 
al., 2001)) or insulin secretion (in pancreatic β-cells (Chen et al., 1994)), and thus 
are central in cell function (Zammit, 2008). The structural characterization of 
CPT1 is difficult because of its association with the mitochondrial membrane. 
Previous studies of the structure-function relationship in CPT1 proposed that the 
TM1-TM2 interactions affect the inter-cytosolic domain interactions, and hence 
the kinetics of the enzyme (Zammit et al., 2001). The lack of a detailed crystal 
structure for these proteins and the unknown but likely role of the TM domains in 
their observed kinetic characteristics has meant that this system provides an 
interesting problem to study. In addition, it has been reported that CPT1A forms 
protein complexes (Faye et al., 2007). At present one of the most significant 
problems in CPT1 research is the investigation of TM domain structure and 
oligomerisation and its role in the function of CPT1, which is fundamentally 
important in the design of pharmacological strategies aimed at the modulation of 
the activities of these enzymes in conditions such as diabetes (Giannessi et al., 
2001). 
The aim of this PhD research was to systematically investigate the homo- and 
hetero- transmembrane domain (TM) interactions, which are involved in 
modulating folding and driving oligomerisation of the carnitine 
palmitoyltransferase enzymes, CPT1A and CPT1B. The project involved using 
different biochemical and biophysical techniques (in vivo oligomerisation assays, 
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chemical cross-linking, circular dichroism and analytical ultracentrifugation) to 
characterise TM derived peptides.  
In the following sections the results presented, their significance and future 
directions are summarised. 
Self-association of CPT1A and CPT1B TM domains 
The initial question of the present research was whether the transmembrane 
spanning regions of CPT1A and CPT1B can form homo-oligomers. For this 
reason, we first studied the TM sequences using the in vivo TOXCAT and 
GALLEX assays. We observed homo-oligomerisation of these TM domains within 
natural, E. coli membranes. In addition, our experiments also indicated that the 
length of the TM spanning region greatly affected the results of these assays, 
which supports previous observations (Li et al., 2004). In light of these results, 
further investigations were carried out to quantify the oligomerisation propensities 
of the investigated TM domains. We used synthetic peptides and examined them 
by in vitro biophysical techniques. Cross-linking and AUC experiments both gave 
strong indications that the TM domains of both isoforms form oligomers, as 
summarised in Table 7.1. 
Our work demonstrates, for the first time, that the CPT1A and CPT1B TM 
spanning regions homo-oligomerise, and quantifies the oligomeric states they 
can achieve. Since the examined TM segments all contain well-known interaction 
motifs (§ 1.2.2), we used in silico modelling to highlight the interacting residues 
on the helix-helix interface of the resulting structures. The residues that are of 
potential importance in stabilizing the observed oligomers are indicated in Table 
7.1. 
In the case of the CPT1A isoform, our results not only quantified the order of its 
oligomerisation, but also indicated a strong link between the oligomerisation 
behaviour of TM2 and the in vivo oligomerisation of full length rCPT1A. The 
rCPT1A TM2 domain was found to have a key role in forming the native protein 
hexamer and trimer when studied in vivo (Faye et al., 2007). Here we observed 
that the synthetic CPT1A TM2 peptide also forms hexamers and trimers when the 
TM sequence was studied in isolation by cross-linking and AUC-SV. Such close 
correspondence between the oligomerisation behaviour of the full length rCPT1A 
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in vivo and those of TM2 segment in vitro provided further evidence that TM2 is a 
site of potentially important protein-protein interactions (Jenei et al., 2009). 
While there is a good indication that the oligomeric state formed by TM2 
correlates with the full length protein complex (Faye et al., 2007; Jenei et al., 
2009), it is not known whether the full length rCPT1B also exists as an oligomer 
in muscle mitochondria. This raises the question of whether the oligomerisation 
observed for the rCPT1B TM2 reflects the folding and assembly of full length 
rCPT1B in vivo. 
Table 7.1 - Summary of the observed transmembrane helix oligomerisation 
behaviour. 
 CPT1A CPT1B 
Oligomerisation observed by: TM1 TM2 TM1 TM2 
TOXCAT/GALLEX + + + + 
Cross-linking 3 - 5 3 , 6, 12 3 - 5 3 
AUC 5 6 ,12 5 2 
Interacting residues observed 
using CHI modelling: 
In homo-oligomeric structures: 
G49-G53, 
S60,  
L63-V67-I70 
G107-G111 
or 
G113-A117, 
 T112 
 
R52, Y55, 
T69, 
S72 - N73 
or 
G53-G57, 
T60 -S61 or 
T69 -S72 
 
L106, V110 
or  
A118, S108, 
F122, R125 
In hetero-oligomeric structures 
interfacial residues: 
 
TM1: V54 A57 I64 
TM2: L114 G111 G107 
or 
TM1: I51 V54 N58 
TM2: I119 T112 
 
 
TM1: G53 G57 S61 
TM2: G113 S120 
or 
TM1: L63 V66Y74 
TM2: I111 T105 
 
 
We have found strong similarities between the oligomerisation behaviour of 
rCPT1A and rCPT1B TM1 domains, when studying their corresponding synthetic 
peptides with chemical cross-linking or AUC-SV (see Table 7.1). However, the 
TM2 domain of rCPT1B behaved very differently from that of rCPT1A, forming 
dimers and trimers as opposed to the hexamers formed by rCPT1A TM2. The 
sequence motifs in the TM2 domains are also significantly different in the two 
isoforms, and molecular modelling showed different interactions between their 
amino acids. If TM helix-helix interactions are important in the folding and 
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enzyme kinetics of CPT1A and B, the above observations suggest that CPT1B 
would form different oligomers than CPT1A and may display different TM1-TM2 
interactions as well. For example, if CPT1B forms oligomeric complexes in the 
OMM, and its oligomerisation is driven by TM2-TM2 interactions (as suggested 
for CPT1A), then its oligomeric state would likely be different from that of CPT1A. 
However, confirming this hypothesis requires more data to directly compare the 
complex formation for these proteins (see Future directions). 
Sequence specificity of the self-association of rCPT1A TM2 
As CPT1A oligomerisation appears to be driven primarily by interactions between 
its TM2 domains, to further explore this effect we investigated the sequence 
motifs that drive TM2-TM2 interactions. In silico models presented in CHAPTER 3 
suggest that rCPT1A TM2 oligomerisation to trimers and hexamers is likely 
driven by the Gly107xxxGly111 and Gly113xxxAla117 motifs, while Thr112 could also 
have a stabilising effect. To verify the possible role of these sequence motifs we 
used mutagenesis strategies coupled with in vivo and in vitro biophysical 
methods. 
Systematic mutagenesis of sequence motifs G103xxxG111, G113xxxA117 and Thr112 
was performed using TOXCAT assay. The mutations of G107I and G107IG113I 
reduced helix interaction by ~50%, without making more than two mutations in 
the sequence, and these mutations were selected for further studies in vitro. 
Synthetic peptides of the G107I and G107IG113I mutants were both found to form 
oligomeric species smaller than the wt rCPT1A TM2 hexamers, with the most 
consistent oligomeric state observed for both mutants being the trimer species.  
In conclusion, the results presented in CHAPTER 4 propose that the GxxxG(A) 
motifs play a role in rCPT1A TM2 oligomerisation and also give rise to further 
questions about the role of these recognised motifs in full length protein assembly 
and function.  
Interaction of TM1-TM2 domains in CPT1A and CPT1B 
This work also reports the first direct measurements of TM1-TM2 oligomerisation 
in these proteins. The data presented in CHAPTER 6 provides evidence for the 
hetero-interactions of the TM domains in both isoforms. 
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The interaction between TM domains (both homo and hetero) is believed to be 
central to the function of CPT1 enzymes. In order to provide evidence for the TM 
domains hetero oligomerisation in CPT1A and CPT1B the in vivo GALLEX assay 
was used. We showed that TM1 and TM2 domains in both isoforms are capable 
of interacting in a natural (E. coli) membrane environment, and in silico models 
were built to find possible interacting residues supporting TM1-TM2 interactions 
(see Table 7.1). These results could be correlated with folding and enzyme 
kinetics of the full length CPT1A and CPT1B proteins. However, to verify the 
observed interactions, further analyses have to be carried out (see in Future 
directions). 
Future directions 
Based on our current experimental results strongly supporting interactions 
between TM domains, the exact role of such interactions in the tertiary structure 
of CPT1A and CPT1B proteins and in the previously proposed channel formation 
is still unclear. As shown in Figure 7.1, the observed TM helix-helix interactions 
can be described by several different models that summarize their potential role 
in driving oligomerisation of the native enzymes into both trimers (as observed for 
CPT1A and CPT1B TM2) and hexamers (as observed for CPT1A). 
For this reason, further in vitro analyses would help us to better understand 
whether these sequences are responsible for forming homo, hetero or both types 
of interactions, and the role of the suggested interaction motifs also needs to be 
verified by mutagenesis. The hetero interactions need further investigation as 
well, because at this point the data reported for TM1-TM2 hetero oligomerisation 
cannot prove that the interaction strengths are different in the two isoforms. 
Different interaction strengths would explain the difference in the kinetic 
behaviour of the isoforms. 
To translate our oligomerisation studies of isolated TM domains into biologically 
relevant data, mutations that resulted in significant disruption in the observed 
interactions need to be transferred into the full-length proteins. For example, in 
case of the CPT1A, mutations of G107I and G107IG113I need to be tested. For 
CPT1B, the oligomerisation of the full length protein needs to be clarified and the 
role of sequence motifs has to be investigated prior to carrying out mutagenesis 
of the full-length protein. Analysis of these full-length mutants will yield crucial 
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information on the functional consequences of altered TM homo- or hetero-
interactions. 
 
Figure 7.1 - Models of TM interactions in likely CPT1 complex formation. Hetero 
interactions of TM1-TM2 are indicated as red arrows, while homo-interactions of TM1-
TM1 as green and TM2-TM2 as yellow arrows. The trimer and hexamer models shown 
were preferred considering based on the already observed CPT1A oligomerisation by 
Faye and colleagues (Faye et al., 2007). 
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Appendix 1:  Oligonucleotide sequences were used to modify pCC-KAN plasmid vector. DNA letter coding: C=cytosine, G= guanine, A=adenine, 
T=thymine. Colour coding: Gly or Ala to Ile mutations are highlighted with yellow, Thr to Ala mutations are highlighted with green and Thr to Val mutations are 
highlighted with purple. The oligonucleotide sequences shown in capital letters were used as quick change primers, while sequences shown in lower case 
letters were used as primers for ligation reaction. Rows highlighted with blue correspond to rCPT1A TM1, with green to rCPT1A TM2, with purple to rCPT1B 
TM1, and with orange to rCPT1B TM2 primers. 
 
Primer Sequence 5’ to 3’ 
rCPT1A TM1(27)for 
ctagc aaa aac ggc att att acc ggc gtg ttt ccg gcg aac ccg agc agc 
tgg ctg att gtg gtg gtg ggc gtg att agc agc atg gg 
rCPT1A TM1(27)rev 
gatccc cat gct gct aat cac gcc cac cac cac aat cag cca gct gct 
cgg gtt cgc cgg aaa cac gcc ggt aat aat gcc gtt ttt g 
rCPT1A TM1(24)for GGGAATCGAGCTAGCATTATTACCGGCGTG   
rCPT1A TM1(24)rev CACGCCGGTAATAATGCTAGCTCGATTCCC 
rCPT1A TM1(21)for  GTGGTGGGCGTGATTGGGATCCTGATCAAC   
rCPT1A TM1(21)rev GTTGATCAGGATCCCAATCACGCCCACCAC 
rCPT1A TM1(18)for  
ctagc att att acc ggc gtg ttt ccg gcg aac ccg agc agc tgg ctg att 
gtg gtg gtg gg    
rCPT1A TM1(18)rev gatccc cac cac cac aat cag cca gct gct cgg gtt cgc cgg aaa cac 
gcc ggt aat aat g 
rCPT1A TM1(16)for  ctagc acc ggc gtg ttt ccg gcg aac ccg agc agc tgg ctg att gtg gtg 
gtg gg     
rCPT1A TM1(16)rev gatccc cac cac cac aat cag cca gct gct cgg gtt cgc cgg aaa cac 
gcc ggt g 
rCPT1A TM2(22)for  ctagc aaa aac att gtg agc ggc gtg ctg ttt ggc acc ggc ctg tgg 
gtg gcg gtg att atg acc atg cgc gg 
rCPT1A TM2(22)rev gatccc gcg cat ggt cat aat cac cgc cac cca cag gcc ggt gcc aaa 
cag cac gcc gct cac aat gtt ttt g 
rCPT1A TM2(20)for  GCGGTGATTATGACCGGGATCCTGATCAAC     
rCPT1A TM2(20)rev GTTGATCAGGATCCCGGTCATAATCACCGC     
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Primer Sequence 5’ to 3’ 
rCPT1A TM2(18)for  GGGAATCGAGCTAGCATTGTGAGCGGCGTG      
rCPT1A TM2(18)rev CACGCCGCTCACAATGCTAGCTCGATTCCC      
rCPT1A TM2(16)for  CTGTGGGTGGCGGTGATTGGGATCCTGATCAAC     
rCPT1A TM2(16)rev GTTGATCAGGATCCCAATCACCGCCACCCACAG     
rCPT1A TM2(16)_G107Ifor CTAGCATTGTGAGCATTGTGCTGTTTGGCAC 
rCPT1A TM2(16)_G107Irev 
GTGCCAAACAGCACAATGCTCACAATGCTAG 
rCPT1A TM2(16)_G111Ifor ctagc att gtg agc ggc gtg ctg ttt att acc ggc ctg tgg gtg gcg 
gtg att gg      
rCPT1A TM2(16)_G111Irev gatccc aat cac cgc cac cca cag gcc ggt aat aaa cag cac gcc gct 
cac aat g 
rCPT1A TM2(16)_G113Ifor 
CTGTTTGGCACCATTCTGTGGGTGGCG 
rCPT1A TM2(16)_G113Irev 
CGCCACCCACAGAATGGTGCCAAACAG 
rCPT1A TM2(16)_A117Ifor 
GGCCTGTGGGTGATTGTGATTGGGATC 
rCPT1A TM2(16)_A117Irev 
GATCCCAATCACAATCACCCACAGGCC 
rCPT1A TM2(16)_G107IG111Ifor 
 
ctagc att gtg agc att gtg ctg ttt att acc ggc ctg tgg gtg gcg 
gtg att gg 
rCPT1A TM2(16)_G107IG111Irev gatccc aat cac cgc cac cca cag gcc ggt aat aaa cag cac aat gct 
cac aat g 
 rCPT1A TM2(16) _G113IA117Ifor 
 
CCATTCTGTGGGTGATTGTGATTGGGATCC 
rCPT1A TM2(16) _G113IA117Irev 
GGATCCCAATCACAATCACCCACAGAATGG 
rCPT1A TM2(16)_G107IG113Ifor 
 
CTGTTTGGCACCATTCTGTGGGTGGCG 
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Primer Sequence 5’ to 3’ 
rCPT1A TM2(16)_G107IG113Irev 
 
CGCCACCCACAGAATGGTGCCAAACAG 
rCPT1A TM2(16)_G107IG111IG113IA117Ifor 
 
ctagc att gtg agc att gtg ctg ttt att acc att ctg tgg gtg att 
gtg att gg      
rCPT1A TM2(16)_G107IG111IG113IA117Irev gatccc aat cac aat cac cca cag aat ggt aat aaa cag cac aat gct 
cac aat g 
 rCPT1A TM2(16) _T112Afor 
 
GTGCTGTTTGGCGCCGGCCTGTGGGTG 
rCPT1A TM2(16) _T112Arev 
CACCCACAGGCCGGCGCCAAACAGCAC 
rCPT1A TM2(16)_G107IG113IT112Afor 
 
GCATTGTGCTGTTTGGCGCCATTCTGTGGGTGGCGG 
rCPT1A TM2(16)_G107IG113IT112Arev 
 
CCGCCACCCACAGAATGGCGCCAAACAGCACAATGC 
rCPT1A TM2(16)_G107IG113IT112Vfor 
 
GCATTGTGCTGTTTGGCGTGATTCTGTGGGTGGCGG 
rCPT1A TM2(16)_G107IG113IT112Vrev 
 
CCGCCACCCACAGAATCACGCCAAACAGCACAATGC 
rCPT1A TM2(16)_G107IG111IG113IA117IT112Afor 
 
GTGCTGTTTATTGCCATTCTGTGGGTG 
rCPT1A TM2(16)_G107IG111IG113IA117IT112Arev 
 
CACCCACAGAATGGCAATAAACAGCAC 
rCPT1A TM2(16)_G107IG111IG113IA117IT112Vfor 
 
GTGCTGTTTATTGTGATTCTGTGGGTG 
rCPT1A TM2(16)_G107IG111IG113IA117IT112Vrev 
 
CACCCACAGAATCACAATAAACAGCAC 
rCPT1B TM1(25)for ctagc cgc ggc gtg tat ccg ggc agc ccg acc agc tgg ctg gtg 
gtg gtg atg gcg acc gtg ggc agc aac tat tgc aaa  gg       
rCPT1B TM1(25)rev 
 
gatccc ttt gca ata gtt gct gcc cac cct cgc cat cac cac cac 
cag cca gct ggt cgg gct gcc cgg ata cac gcc gcg g 
rCPT1B TM1(22)for 
GGGAATCGAGCTAGCTATCCGGGCAGCCCG 
rCPT1B TM1(22)rev 
CGGGCTGCCCGGATAGCTAGCTCGATTCCC 
 
A
P
P
E
N
D
IX
 1
 
A
4
 
 
Primer Sequence 5’ to 3’ 
rCPT1B TM1(24)for 
 
GAATCGAGCTAGCAATGGCATCCTGCGCGGCGTGTATC 
rCPT1B TM1(24)rev 
GATACACGCCGCGCAGGATGCCATTGCTAGCTCGATTC 
rCPT1B TM1(23)for 
 
GTGGGCAGCAACTATGGGATCCTGATCAAC   
rCPT1B TM1(23)rev 
 
GTTGATCAGGATCCCATAGTTGCTGCCCAC   
rCPT1B TM1(22*)for 
 
CGTGGGCAGCAACGGGATCCTGATC 
rCPT1B TM1(22*)rev 
 
GATCAGGATCCCGTTGCTGCCCACG 
rCPT1B TM1(20*)for 
 
GGCGACCGTGGGCGGGATCCTGATC 
rCPT1B TM1(20*)rev 
 
GATCAGGATCCCGCCCACGGTCGCC 
rCPT1B TM2(22)for ctagc gaa acc ctg ctg agc atg gtg att ttt agc acc ggc gtg tgg 
gcg acc ggc att ttt ctg ttt cgc  gg      
rCPT1B TM2(22)rev 
 
gatccc gcg aaa cag aaa aat gcc ggt cgc cca cac gcc ggt gct aaa 
aat cac cat gct cag cag ggt ttc g 
 rCPT1B TM2(20)for 
 
GGGAATCGAGCTAGCCTGCTGAGCATGGTG 
rCPT1B TM2(20)rev 
 
CACCATGCTCAGCAGGCTAGCTCGATTCCC 
rCPT1B TM2(19)for 
 
CCGGCATTTTTCTGTTTGGGATCCTGATCAACCC   
rCPT1B TM2(19)rev 
 
GGGTTGATCAGGATCCCAAACAGAAAAATGCCGG   
rCPT1B TM2(17)for 
 
GCGACCGGCATTTTTGGGATCCTGATCAAC   
rCPT1B TM2(17)rev 
 
GTTGATCAGGATCCCAAAAATGCCGGTCGC 
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Appendix 2:  Oligonucleotide sequences were used to modify pALM148 or pBLM100 plasmid vectors.  
DNA letter coding: C=cytosine, G= guanine, =A=adenine, T=thymine.  
 
Primer Sequence 5’ to 3’ 
rCPT1A iTM1(21)for cg att gtg ggc gtg gtg gtg att ctg tgg agc agc ccg aac gcg ccg ttt 
gtg ggc acc att att a      
rCPT1A iTM1(21)for ctagt aat aat ggt gcc cac aaa cgg cgc gtt cgg gct gct cca cag aat cac 
cac cac gcc cac aat cgagct   
rCPT1A iTM1(18)for cg gtg gtg gtg att ctg tgg agc agc ccg aac gcg ccg ttt gtg ggc acc 
att att a      
rCPTA iTM1(18)rev ctagt aat aat ggt gcc cac aaa cgg cgc gtt cgg gct gct cca cag aat cac 
cac cac cgagct   
rCPT1A iTM1(16)for cg gtg gtg gtg att ctg tgg agc agc ccg aac gcg ccg ttt gtg ggc acc a    
rCPT1A iTM1(16)rev ctagt ggt gcc cac aaa cgg cgc gtt cgg gct gct cca cag aat cac cac cac 
cgagct 
rCPT1A TM2(16)for cg att gtg agc ggc gtg ctg ttt ggc acc ggc ctg tgg gtg gcg gtg att a 
rCPT1A TM2(16)rev ctagt aat cac cgc cac cca cag gcc ggt gcc aaa cag cac gcc gct cac aat 
cgagct 
rCPT1B iTM1(20)for cg ggc gtg acc gcg atg gtg gtg gtg  ctg  tgg  agc acc ccg agc  ggc  
ccg  tat gtg  ggc cgt a      
rCPT1B iTM1(20)rev ctagt acg gcc cac ata cgg gcc gct cgg ggt gct cca cag cac cac cac cat 
cgc ggt cac gcc cgagct 
rCPT1B TM2(19)for cg ctg ctg agc atg gtg att ttt agc acc ggc gtg tgg gcg acc ggc att 
ttt ctg ttt a       
rCPT1B TM2(19)rev ctagt aaa cag aaa aat gcc ggt cgc cca cac gcc ggt gct aaa aat cac cat 
gct cag cag cgagct 
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